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SUMMARY 
 
 
Work presented in this thesis is in two parts. 
Part one:  The X-ray crystal structures of potential antimicrobial drug targets. 
 
The protein IspF (2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase, EC: 4.6.1.12) 
from two pathogens (Burkholderia cenocepacia and Plasmodium falciparum) has been 
investigated.  IspF is an enzyme of isoprenoid-precursor biosynthesis and is considered 
to be a potential drug target.  The results of structural and fragment-screening efforts 
presented here inform early stage drug discovery efforts. 
 The structure of the PabC protein (4-amino-4-deoxychorismate lyase, EC: 
4.1.3.38) from the Gram-negative pathogen Pseudomonas aeruginosa was also 
determined.  PabC is involved in the production of para-aminobenzoic acid on the path 
to folate.  Comparisons with previously solved PabC structures identified a spatially 
conserved tyrosine residue in the active site and suggest that a re-evaluation of a 
published mechanism is warranted. 
 
Part two: Immunity proteins in the Gram-negative Type VI secretion system 
 
The X-ray crystal structures of the proteins Rap1a and Rap2a from Serratia 
marcescens, inhibitors of the peptidoglycan amidase toxins secreted by some Gram-
negative bacteria employing the Type VI secretion pathway, were determined by 
molecular replacement and analysed. 
 
 
Part one: 
Chapter 1: Introduces isoprenoid-precursor biosynthesis and its importance as a 
potential source of novel drug targets for infectious diseases.  The structure of IspF 
from the methyl-D-erythritol phosphate (MEP) pathway was sought, in complex with 
ligands, to inform early-stage drug discovery efforts.  The PabC protein is introduced.  
The significance of para-aminobenzoic acid for bacterial folate biosynthesis and the 
history of anti-folate drug discovery are discussed.  Some general background 
information is provided describing the processes of fragment based screening and 
structure-based drug discovery. 
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Chapter 2: Details of materials used and experimental procedures are given. 
 
Chapter 3: (Results and Discussion - IspF structures) High resolution structures of IspF 
from the pathogens B. cenocepacia and P. falciparum are presented.  The crystal 
structures of BcIspF with cytidine derivatives were determined by molecular 
replacement methods, refined and analysed.  The active site contained two molecules of 
cytidine monophosphate (CMP) and a structure was subsequently re-determined from a 
crystal grown in the presence of a lower CMP concentration.  A structure of BcIspF 
with citrate, a buffer component, bound at the active site is also reported.  Despite 
several concerted attempts, no co-crystal structures could be obtained with novel 
ligands.  The structure of PfIspF is described bound to cytidine diphosphate (CDP).  
This reproduced earlier studies on this protein in the Hunter lab by Dr. Kalinowska-
T!u"cik, demonstrating a robust protocol for production of PfIspF crystals.  
Additionally, holo-crystals of PfIspF without any cytidine derivatives present were 
obtained and the structure determined.  A chemical fragment screen was performed 
against biotinylated BcIspF and the E. coli IspF orthologue employing the bio-layer 
interferometry technique (BLI).  Fragments identified are described. 
 
Chapter 4: PaPabC structure 
The structure of PabC, an essential enzyme from P. aeruginosa, is described. This 
structure demonstrates the presence of a structurally conserved tyrosine residue in the 
active site that had been overlooked in previous studies. 
 
Part two: 
Chapter 5: Introduces the Type VI secretion system (T6SS) of Gram-negative bacteria 
and describes the structural determination of two proteins from Serratia marcescens, 
Rap1a and Rap2a, that confer immunity against certain peptidoglycan amidase effectors 
of the T6SS. 
 
Chapter 6: The structures of Rap1a and Rap2a are described and compared to 
previously reported immunity proteins from different bacteria.  Rap1a is shown to adopt 
a unique fold for an immunity protein, similar to that of other periplasmic proteins. 
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Abbreviations 
 
S.I. units are used throughout with the exception of Å representing 10-10 m; 
and temperatures values, which are given in degrees Celsius (°C). 
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PART ONE 
 
THE X-RAY CRYSTAL STRUCTURES OF 
POTENTIAL ANTIMICROBIAL DRUG 
TARGETS 
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CHAPTER 1 
INTRODUCTION 
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Introduction 
 
1.1  Structure-based drug discovery and fragment screening 
 
Modern drug discovery is often a long and costly process.  Target-based approaches to 
antimicrobial drug discovery involve careful selection of proteins demonstrated or 
predicted to be essential.  Crystallographic structural information about the target 
proteins, especially when structures in complex with ligands are available, can provide 
valuable information at the early stages of drug discovery; informing target assessment, 
rationalising structure-activity relationships between ligands and suggesting sites for 
potential improvements to the lead compounds (Hunter, 2009; Moynie et al., 2013; 
Verlinde & Hol, 1994; Whittle & Blundell, 1994).  In addition, high-quality structures 
can provide a template for virtual screening efforts (Mpamhanga et al., 2009).  The 
structure-based discovery of drugs in clinical use targeting human immunodeficiency 
virus (Kempf et al., 1995; Wlodawer & Erickson, 1993), influenza virus (von Itzstein et 
al., 1993) and kinases involved in cancer development (Bollag et al., 2010; Noble et al., 
2004; Tsai et al., 2008) are examples that illustrate the efficacy of this approach (Figure 
1.1). 
 Identifying ligands for target proteins during drug discovery can be challenging, 
as both high affinity and selective interactions are sought.  Libraries of chemical 
compounds with mass typically less than 300 Da, called 'fragments', can be screened in 
an attempt to identify starting points for such ligands (Congreve et al., 2008; Scott et 
al., 2012).  Structural studies complement this approach as once the relative binding 
location and orientation of fragments is elucidated, medicinal chemistry can often 
provide suggestions to link, fuse or otherwise elaborate on these starting points.  Such 
elaborated ligands often have much higher binding affinities than the original 
fragments, offering an attractive route to lead compounds; particularly for proteins 
! (!
where either no or only a limited number of ligands are known (de Kloe et al., 2009).  
Alternatively, fragments can be screened by attempting to co-crystallise with the target 
protein or by soaking into preformed crystals and determining the structure of 
complexes by high-throughput crystallography (Hartshorn et al., 2005).  Owing to the 
relatively small size and typically weak affinity of fragments, ranging from µM to mM, 
sensitive biophysical assays, such as surface plasmon resonance (SPR) or nuclear 
magnetic resonance spectroscopy (NMR), are usually required for screening 
(Navratilova & Hopkins, 2010; Shuker et al., 1996). 
 
Figure 1.1  An illustrative example of rational drug design informed by X-ray 
structural studies.  The development of zanamivir, a potent neuraminidase inhibitor for the 
treatment of influenza, is represented in schematic form.  Structural determination of the target protein in 
complex with ligands and lead compounds suggested routes for elaboration of the lead compounds by 
medicinal chemistry.  Iterative cycles of chemistry and structural determination support each other during 
the drug discovery process, leading to the identification of successively more potent compounds.  In this 
example the crystal structure of the target revealved the presence of two glutamate residues adjacent to 
the lead compound.  Addition of a guanidino group (present in the final inhibitor, zanamivir) to promote 
interaction with these glutamates increased potency.  (Smith et al., 2001; von Itzstein et al., 1993) 
 
 In the studies presented in this thesis, the structures of essential proteins from 
several human pathogens were determined.  Pseudomonas aeruginosa and Burkholderia 
cenocepacia are Gram-negative bacteria, implicated in hospital-acquired infections of 
immuno-compromised patients, and Plasmodium falciparum is a protozoan parasite - 
the causative agent of cerebral malaria. 
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1.2.1  The role of isoprenoids in microbial cells 
 
Isoprenoids, also known as terpenoids, are a large and structurally diverse class of 
natural products.  All isoprenoids derive from the five-carbon universal precursors 
isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), isomeric 
building blocks bearing an unsaturated carbon-carbon double bond that can be linked to 
together to form longer chains known as prenyl groups, such as geranyl- (C10), 
farnesyl- (C15) and geranylgeranyl (C20) pyrophosphate (Figure 1.2).  The attachment 
of prenyl groups to proteins is a common protein post-translational modification that 
results in anchoring to lipid membranes.  More complex isoprenoid structures, including 
membrane components such as cholesterol in eukaryotes and hopanoids in bacteria can 
be formed by cyclisation and further chemical modifications.  Certain compounds 
bearing isoprenoid-derived side chains, such as menaquinone and ubiquinone, are 
essential to respiratory redox chains for energy generation in cells, where they function 
as membrane associated mobile electron carriers.  Long-chain membrane associated 
isoprenoid compounds are employed as scaffolds during the assembly of glycan 
structures.  In eukaryotes dolichol pyrophosphate fulfills this role in N-glycosylation, 
and for many bacteria undecaprenyl pyrophosphate functions in the synthesis of 
peptidoglycan precursors during assembly of the cell wall (Bouhss et al., 2008; Ershov, 
2007). 
 
! *!
 
 
Figure 1.2  Isoprenoid compounds.  The chemical structures of selected isoprenoid compounds 
are shown.  1: isopentenyl pyrophosphate (IPP).  2: dimethylallyl pyrophosphate (DMAPP).  3: geranyl 
pyrophosphate (GPP).  4: farnesyl pyrophosphate (FPP).  5: dolichol phosphate.  6: ubiquinone.  7: 
hopane.  A double-headed arrow has been drawn to indicate that the isoprenoid-precursors, 1 and 2, are 
isomers.  (Adapted from Ershov, 2007) 
 
 
 
1.2.2  The methyl-D-erythritol phosphate (MEP) pathway of 
isoprenoid-precursor biosynthesis 
 
Two biosynthetic pathways have been discovered for the production of the universal 
isoprenoid-precursor molecules IPP and DMAPP.  The mevalonate pathway, which was 
discovered first (Bloch, 1964), starts with the condensation of two molecules of acetyl-
CoA to form acetoacetyl-CoA.  This is followed by conversion to 3-hydroxy-3-
methylglutaryl-CoA (HMG-CoA), which is in turn converted to mevalonic acid; an 
intermediate metabolite from which the pathway derives its name, by the action of the 
NADPH-dependent enzyme HMG-CoA reductase (EC: 1.1.1.34).  Mevalonic acid is 
subsequently phosphorylated twice and decarboxylated to form IPP.  IPP and DMAPP 
! +!
are interconverted by Mg2+ dependent IPP-isomerase (IDI) enzymes (EC: 5.3.3.2).  
HMG-CoA reductase is known to be a key regulatory enzyme on the mevalonate 
pathway (Brown & Goldstein, 1980).  Inhibitors of this enzyme such as the statin drugs, 
for example lovastatin (Alberts et al., 1980), are in clinical use for the treatment of 
hypercholesterolaemia (Figure 1.3). 
 
 
Figure 1.3  Lovastatin inhibits HMG-CoA reductase, a key regulatory enzyme on 
the mevalonate pathway of isoprenoid-precursor biosynthesis. 
 
 In 1993, Rohmer et al., provided evidence for the existence of a novel, non-
mevalonate pathway for isoprenoid-precursor biosynthesis (Figure 1.4).  Incorporation 
of 13C isotopes into isoprenoid species including hopanoids and ubiquinone was 
monitored by NMR using labelled test-substrates in several bacteria.  The labelling 
pattern was distinct from that established for the mevalonate pathway, and was 
consistent with the formation of IPP via a novel pathway starting from pyruvate and a 
triose phosphate, later shown to be glyceraldehyde-3-phosphate (Rohmer et al., 1996).  
This contention was tested and confirmed by investigating the isotope labelling pattern 
! ,!
observed in isoprenoids in the eukaryotic green-alga Scenedesmus obliquus following a 
similar procedure (Schwender et al., 1996).  Isoprenoid-precursor biosynthesis in plants 
was re-investigated in light of the work on green-algae (Lichtenthaler et al., 1997).  In 
that study, isoprenoids extracted from the cytoplasm, sitosterol and stigmasterol, were 
derived from the classical mevalonate pathway; whereas isoprenoids found exclusively 
in chloroplasts, phytol, #-carotene, lutein and the isoprenoid side chain of 
plastoquinone-9, exhibited the novel labelling pattern observed previously in bacteria 
(Rohmer et al., 1993) and algae (Schwender et al., 1996).  This suggested that in higher 
plants the mevalonate pathway operates in the cytoplasm and the non-mevalonate 
pathway operates in the chloroplasts (Lichtenthaler et al., 1997; reviewed in 
Lichtenthaler, 1999). 
 
 
Figure 1.4  The MEP pathway for isoprenoid-precursor biosynthesis.  The universal 
precursors for isoprenoid biosynthesis, IPP and DMAPP, are formed via the MEP pathway.  IspF, the 
fifth enzyme on this pathway, is the subject of studies reported in this thesis. 
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 The non-mevalonate pathway was subsequently re-named the 1-deoxy-D-
xylulose-5-phosphate (DOXP) pathway, when it was demonstrated that DOXP is the 
first metabolite on this pathway downstream of pyruvate and glyceraldehyde-5-
phosphate, and the enzyme responsible for its synthesis (DOXP synthase, DXS, EC: 
2.2.1.7) was characterised (Sprenger et al., 1997).  Since DOXP is also required for the 
synthesis of thiamine and pyridoxol, the non-mevalonate pathway in now referred to as 
the 2C-methyl-D-erythritol-4-phosphate (MEP) pathway, named after the first 
committed metabolite on the pathway to IPP/DMAPP.  DOXP is converted to MEP by 
the enzyme DOXP reductoisomerase (DXR, EC: 1.1.1.267; Takahasi et al., 1998).  
DXR was shown to require NADPH and divalent cations for activity (Takahasi et al., 
1998).  Fosmidomycin (Figure 1.5), a low-molecular weight natural product, inhibits 
DXR (Section 1.2.3).  Radiolabelled MEP was prepared (Rohdich et al., 1999) and, 
following incubation with E. coli cell extracts, thin layer chromatography (TLC) and 
NMR analyses showed that an enzyme activity transferred a cytidine 5’-phosphate 
moiety to the phosphate group of MEP, to form 4-diphosphocytidyl-2-C-
methylerythritol.  A database search for cytidylyltransferases turned up the N-terminal 
domain of the acs1 gene from Haemophilius influenzae, the enzyme product of which 
forms CDP-ribitol (Follens et al., 1999).  A bioinformatic analysis led to the 
identification of the gene ygbP, encoding 2-C-methyl-D-erythritol 4-phosphate 
cytidylyltransferase  (IspD, EC: 2.7.7.60).  Enzyme assays demonstrated that IspD 
indeed has MEP-cytidyltransferase activity; and when the cytidylated product (CDP-
ME) was incubated with chromoplasts of Capsicum annuum it became incorporated 
into plant isoprenoids (Rohdich et al., 1999).  Comparative genomic bioinfomatics 
identified a gene (ychB) that followed the same distribution as other genes involved in 
the MEP pathway.  The protein encoded by ychB, known as IspE (EC: 2.7.1.148), was 
shown by TLC and NMR analyses to transfer a phosphate group from ATP to the 2-
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hydroxy group of CDP-ME.  The product (CDP-MEP) was incorporated into the plant 
isoprenoids, phytoene and #-carotene (Lüttgen et al., 2000).  Previous work (Rohdich et 
al., 1999) had demonstrated the existence of gene fusions between ygbP and another 
gene, ygbB.  In 2000, Herz et al., sought to demonstrate that the YgbB protein, later re-
named IspF, was involved in the MEP pathway.  IspF from E. coli was recombinantly 
expressed, and purified protein was incubated with 13C-labelled CDP-MEP in vitro and 
demonstrated by TLC and NMR to catalyze the production of 2C-methyl-D-erythritol 
2,4-cyclodiphosphate (MEcPP), releasing cytidine 5’-monophosphate (CMP).  This 
reaction was shown to require Mg2+ or Mn2+ ions.  MEcPP was incorporated into 
carotenoids (Herz et al., 2000).  Thus, IspF displays 2C-methyl-D-erythritol-2,4-
cyclodiphosphate synthase (EC: 4.6.1.12) activity (Section 1.2.5).  MEcPP is converted 
to (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) by the iron-sulfur 
cluster dependent enzyme, HMBPP synthase (IspG, EC: 1.17.7.1), introducing the 
carbon-carbon double bond characteristic of isoprenoids (Kollas et al., 2002).  The last 
step on the MEP pathway is performed by HMBPP reductase (IspH, EC: 1.17.1.2), 
another iron-sulfur cluster dependent enzyme, which produces both IPP and DMAPP 
from HMBPP (Altincicek et al., 2002; Rodhich et al., 2002; Wolff et al., 2003).  While 
many organisms possess IDI enzymes that interconvert IPP and DMAPP, IDI may be 
dispensable since IspH produces both precursors (Rodhich et al., 2002) and genes 
encoding IDI are absent from the genomes of several organisms that use the MEP 
pathway (Cunningham et al., 2000).  In E. coli for example, the gene encoding the sole 
IDI enzyme is inessential (Hahn et al., 1999).  Structural studies have provided insight 
into the mechanisms of enzymes on the MEP pathway (Hunter, 2007; Zhao et al., 
2013). 
 The MEP pathway of isoprenoid-precursor biosynthesis is widely distributed in 
various bacteria, algae, and in the chloroplasts of higher plants.  Several apicomplexan 
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parasites, including Plasmodium species responsible for malaria, contain the MEP 
pathway in an organelle known as an apicoplast (Section 1.2.4).  Conversely, the MEP 
pathway is replaced with the classical mevalonate pathway in animals, fungi, archaea 
and the cytoplasm of plants (Rohdich et al., 2001).  Thus, the MEP pathway contains 
potential drug-target enzymes whose inhibition may provide broad-spectrum 
antimicrobial activity, and this is particularly attractive since this pathway is absent in 
humans. 
 
 
1.2.3  Fosmidomycin, a known drug targeting the MEP pathway 
 
Fosmidomycin, a phosphonic acid bearing an hydroxamate and an aldehyde (Figure 
1.5), was first isolated as a natural product from Streptomyces lavendulae in 1980 by 
researchers at Fujisawa Pharamceutical Co. Ltd., Osaka, (Okuhara et al., 1980a).  In 
1989 it was shown that fosmidomycin exerts its anti-bacterial effects by inhibiting 
isoprenoid biosynthesis (Shigi, 1989).  Fosmidomycin inhibited the production of 
menaquinones and ubiquinones in growing E. coli and inhibited the production of 
carotenoids and menaquinones in Micrococcus luteus (Shigi, 1989).  It was further 
noticed that the bacteria that were susceptible to fosmidomycin were unable to 
incorporate mevalonate, whereas those that could incorporate mevalonate were not 
susceptible, however the existence of the MEP pathway, or non-mevalonate pathway, 
was not known at the time. 
 Both fosmidomycin and a methylated derivative, FR-900098 (Okuhara et al., 
1980b), were shown to potently inhibit recombinant DXR from three different strains of 
P. falciparum, HB3, A2 and Dd2; with IC50 values ranging from 90 - 370 nM (Jomaa et 
al., 1999).  Mice infected with the closely-related P. vinckei species were cured 
following treatment with either compound.  Fosmidomycin inhibited the growth of 
blood-stage P. falciparum with an EC50 value of 0.98 µM (Yeh & DeRisi, 2011).  High 
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resolution crystal structures of DXR from P. falciparum in complex with fosmidomycin 
(1.9 Å), FR-900098 (1.9 Å) and inhibitor-free (2.2 Å) were solved by Umeda et al. in 
2011.  Clear electron density was observed for fosmidomycin and FR-900098 in the 
active site.  The hydroxamate group of the inhibitors binds to the active site magnesium 
cation, with the oxygen atoms in cis-configuration. 
 
 
 
 
Figure 1.5  Chemical structure of fosmidomycin.  Fosmidomycin, a phosphonic acid 
bearing an hydroxamate and aldehyde group, is a natural product with anti-microbial properties.  
Fosmidomycin inhibits DXR on the MEP pathway, binding to the active site Mg2+.  Fosmidomycin 
has been used clinically to manage urinary tract infections; and is now under investigation as a 
potential anti-malarial drug. (Cassera et al., 2004; Howe et al., 2012; Lell et al. 2003; Umeda et al., 
2011) 
 
 An open-label, uncontrolled trial evaluated fosmidomycin for the treatment of 
acute uncomplicated P. falciparum malaria in subjects aged 18-50 in Gabon and 
Thailand (Lell et al., 2003).  The drug was shown to be a safe and effective anti-
malarial, exhibiting rapid parasite and fever clearance - within 44 hours.  However, a 
high number of recrudescent infections were observed following treatment cessation, 
particularly in Thailand and the authors of the study cautioned against its use as a 
monotherapy.  A follow-up study evaluated the efficacy of a combination treatment of 
fosmidomycin with clindamycin in children aged 7-14 in Gabon (Borrmann et al., 
2004).  In contrast to the previous trial, combination therapy with clindamycin resulted 
in complete parasite elimination and absence of clinical signs of infection, provided 
treatment lasted more than three days on a 12 hour dosing schedule.  Fosmidomycin is 
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thus an example of an effective anti-malarial and its use in clinical trials chemically 
validates the MEP pathway as a source of targets for drug discovery (Rohdich et al. 
2005; Hunter, 2011). 
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1.2.4  Targeting the MEP pathway in P. falciparum 
 
P. falciparum contains an organelle known as an apicoplast which resembles a 
cyanobacterium and is thought to have arisen from an ancestral secondary 
endosymbiosis with an alga (Ralph et al., 2004).  In 1999, Jomaa et al., reported that 
DXR localises to the apicoplast in P. falciparum.  Indeed, all MEP pathway enzymes in 
P. falciparum bear an apicoplast localisation sequence (Ralph et al., 2004) and chemical 
disruption of apicoplast replication results in parasites that are IPP auxotrophs (Yeh & 
DeRisi, 2011).  The presence of an active MEP pathway in all intra-erythrocytic stages 
has been experimentally confirmed, and treatment with fosmidomycin depletes 
intermediates downstream of DXR as well as ubiquinone and dolichol compounds 
(Cassera et al., 2004).  Treatment with fosmidomycin also leads to a loss of protein 
prenylation, causing various small GTPases such as Rab5 to mislocalise which results 
in defects in both vesicular trafficking and the integrity of vacuolar membranes (Howe 
et al., 2013).  In 2012 No et al. published an example of successful targeting of an 
isoprenoid-utilising protein downstream of the MEP pathway.  A library of 
bisphosphonates was screened against the intraerythrocytic form of P. falciparum and 
lipophilic derivatives of the drugs risedronate and zoledronate were identified as leads.  
X-ray crystal structures of the likely target, geranylgeranyl diphosphate synthase (EC: 
2.5.1.29), were determined from the P. vivax orthologue in complex with these 
compounds.  Such inhibitors suppressed parasitaemia in a murine model infected with 
P. chabaudi (No et al., 2012).  P. falciparum also synthesises carotenoids that have a 
likely role in anti-oxidant defense, and inhibition of synthesis by norflurazon suppresses 
parasite growth in a dose-dependent manner (Tonhosolo et al., 2009).  The prospect of 
developing novel antimalarial agents that exploit the MEP pathway dependence of P. 
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falciparum, following the example of fosmidomycin, is particularly attractive (Hunter, 
2011; van der Meer & Hirsch, 2012). 
 
1.2.5  IspF – Known structures, catalytic mechanism and essentiality 
 
The structure of IspF is known from twelve different species in addition to the two 
disclosed in this thesis, and thus the overall fold is well established.  IspF forms a 
homotrimer and active sites are located at interfaces between adjacent subunits.  
Subunits form a fluted "-prism consisting of four "-stands that are oriented 
approximately parallel to the three-fold axis of symmetry that runs through the center of 
the molecule; flanked by three $-helices (Kemp et al., 2002).  A hydrophobic cavity is 
present along the axis in most species, but is absent in the IspF from Thermus 
thermophilus (TtIspF, Kishida et al., 2003).  The genes encoding IspF and IspD are 
fused in numerous organisms, an unusual arrangement since these enzymes catalyse 
non-consecutive steps of the MEP pathway; IspE must first phosphorylate the product 
of IspD to form the substrate for IspF.  Bifunctional IspD-IspF from Campylobacter 
jejuni has been biochemically characterised (Gabrielsen et al., 2004a) and the crystal 
structure has been determined (Gabrielsen et al., 2004b).  The overall structure of IspF 
is unchanged in the fusion protein.  Although IspE associates with the IspD-IspF protein 
in solution (Gabrielsen et al., 2004b), no rate-enhancement is observed upon 
complexation (Lherbet et al., 2006), and thus the physiological significance of such an 
association remains to be clarified. 
 In 2002, structural studies were published on IspF from E. coli (EcIspF) by three 
groups (Kemp et al., Richard et al., Steinbacher et al., 2002) that provided insight into 
the catalytic mechanism (Table 1.1).  A metal, identified as Zn2+ (Kemp et al., 2002), 
binds at the active site coordinated by the side chains of two histidines and an aspartate.  
IspF catalyses the production of MEcPP by facilitating an intramolecular nucleophilic 
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attack on the substrate, CDP-MEP, bridging #-phosphate by the 2-phosphate (Figure 
1.6).  Zn2+ aligns and polarises the "-phosphate for nucleophilic attack and is 
indispensible for catalysis.  The cytidine portion of the substrate is held in a rigid 
binding pocket, whereas the predominantly apolar binding pocket for the 
methylerythritol phosphate portion is more flexible. 
Table 1.1  IspF proteins of known structure 
Organism name Representative Protein Data Bank (PDB) code 
Arabidopsis thaliana 2PMP (Calisto et al., 2007) 
Burkholderia cenocepacia (this thesis) 4C8G (O'Rourke et al., 2013; to be published) 
Burkholderia pseudomallei 3IEQ (Begley et al., 2011) 
Campylobacter jejuni (bifunctional IspDF) 1W55 (Gabrielsen et al., 2004b) 
Escherichia coli 1U3L (Steinbacher et al., 2002) 
Francisella tularensis 3RE2 (No associated publication) 
Haemophilus influenzae 1JN1 (Lehmann et al., 2002) 
Mycobacterium smegmatis 2UZH (Buetow et al., 2007) 
Plasmodium falciparum (this thesis) 4C81 (O'Rourke et al., 2013; to be published) 
Plasmodium vivax 3B6N (No associated publication) 
Salmonella enterica serovar Typhimurium 3GHZ (No associated publication) 
Shewanella oneidensis 1T0A (Ni et al., 2004) 
Thermus thermophilus 1IV2 (Kishida et al., 2003) 
Yersinia pestis 3FPI (No associated publication) 
 
 
 In EcIspF structures Mg2+, positioned by Glu135, fixes the !- and "-phosphate 
groups of the CDP moiety (Kemp et al., 2002; Steinbacher et al., 2002).  Mg2+ is 
essential for catalysis (Herz et al., 2000) and is thought to stabilise the negative charge 
on the !-phosphate of the CMP leaving group and may help stabilise the transition state 
complex.  The !-phosphate is further positioned by Thr133.  Residues in proximity to 
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the Zn2+ site conserved in sequence and structure are expected to contribute to catalysis; 
these include His34 and Ser35 which form a phosphate binding site for the attacking 2-
phosphate group (Steinbacher et al., 2002).  Additionally, the His34 side chain positions 
a loop of ten residues, Pro62 - Ala71, that surround the methylerythritol phosphate 
moiety.  The 2C methyl group makes a favourable hydrophobic contact with highly 
conserved Ile57 in a structure of EcIspF in complex with CDP-ME, which is a substrate 
analogue lacking the attacking phosphate.  Orientation of the methyl-D-erythritol 
moiety is achieved by hydrogen bonds from the 3-hydroxy group to main chain 
carbonyl groups of Phe61 and Ile57 and the product, MEcPP, binds to His34, Ser35, 
Ile57, Phe61 and Asp63 (Steinbacher et al., 2002).  In TtIspF a lysine side chain, 
Lys132, binds to the bridging "-phosphate further polarising the substrate, however this 
interaction is not conserved in EcIspF, but is replaced by a water positioned by Thr132. 
Some of the interactions described here are presented in the corresponding results 
section (Chapter 3, Figure 3.3 and 3.4). 
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Figure 1.6  Reaction catalysed by IspF.  IspF catalyses the production of 2C-methyl-D-
erythritol-2,4-cyclodiphosphate (MEcPP) from 4-diphosphocytidyl-2C-methyl-D-erythritol-2-phosphate 
(CDP-MEP), with the loss of cytidine 5'-monophosphate (CMP).  Curly-arrows indicate the flow of 
electrons.  This reaction is an example of electrophilic catlysis, with Zn2+ acting as a Lewis acid. 
 
 The essentiality of IspF for growth and survival of E. coli has been established 
(Campbell & Brown, 2002; Campos et al., 2001; Freiberg et al., 2001; Sauret-Güeto et 
al., 2003).  Deletion of the ispF gene, formerly referred to as ygbB, does not support 
growth and is fatal (Freiberg et al., 2001).  When IspF expression was impaired by 
deletion of ispF and replacement with a copy at a distant and conditionally expressed 
locus, thereby depleting isoprenoid-precursors, E. coli exhibited an aberrant filamentous 
phenotype indicative of disrupted peptidoglycan synthesis (Section 1.2.1).  
Additionally, heightened sensitivity to the cidal effect of fosmidomycin and various 
inhibitors of cell wall biosynthesis was observed (Campbell & Brown, 2002).  The 
essentiality of IspF has been demonstrated in other organisms including, Bacillus 
subtilis (Campbell & Brown, 2002) and Mycobacterium tuberculosis (Buetow et al., 
2007).
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1.3.1  para-Aminobenzoic acid biosynthesis 
 
para-Aminobenzoic acid (also known as 4-aminobenzoic acid, PABA) is synthesised 
by many microogranisms and plants since it is required to form folate (Figure 1.7).  
Folate, also known as vitamin B9, is a generic name for a family of structurally related 
compounds; essential cofactors in several enzymes.  Folates typically function as single 
carbon unit donors in catalysed reactions (Reviewed, for example, by Benkovic, 1980; 
Gisondi et al., 2007; Lucock, 2000).  Folate is required for the formation of thymidylate 
and methionine and as such is essential for nucleic acid synthesis, cell growth and 
division.  Unlike plants and most microorganisms, humans do not synthesise their own 
folate and so it must be obtained in the diet.  Folate deficiency can have several 
injurious effects including certain forms of anaemia and, during pregnancy, it is 
associated with a range of complications and adverse outcomes including a higher risk 
of neural tube defects in children (Kirke et al., 1993; Lucock, 2000; Varela-Moreiras et 
al., 2009). 
 
Figure 1.7  Chemical structure of a) para-aminobenzoic acid (PABA). 
b) folic acid (mono-L-glutamyl), also known as vitamin B9.  The para-aminobenzoic acid 
derived moiety, highlighted in red, links a pterin moiety to L-glutamic acid. 
 
 The enzyme dihydropteroate synthase (DHPS, EC: 2.5.1.15) links PABA to a 
GTP-derived pterin moiety, 7,8-dihydro-6-hydroxymethylpterin-pyrophosphate.  The 
product of this reaction, 7,8-dihydropteroate, is subsequently glutamylated and reduced 
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to form the intracellular pool of available folate  (Lucock, 2000; Richey and Brown, 
1969).  Thus, a PABA-derived moiety has a structural role in the folate molecule 
(Figure 1.7).  In E. coli and many other bacteria, PABA is synthesised in two steps 
starting from chorismate (Nichols et al., 1989).  The first step produces 4-amino-4-
deoxychorismate (Anderson et al., 1991) by transferring ammonia, derived from 
glutamine, to chorismate.  This reaction is performed by aminodeoxychorismate 
synthase (EC: 2.6.1.85), a heterodimer of proteins encoded by the pabA and pabB genes 
(Parsons et al., 2002).  4-amino-4-deoxychorismate is then converted to PABA with the 
loss of pyruvic acid (Figure 1.10).  4-amino-4-deoxychorismate lyase (PabC, EC: 
4.1.3.38), a pyridoxyl 5%-phosphate (PLP) - dependent enzyme (Figure 1.8), catalyzes 
this second step (Green & Nichols, 1991; Nichols et al., 1989).  In the Gram-positive 
bacterium Bacillus subtilis a third chemical step is required for PABA biosynthesis.  
Chorismate is first converted to 2-amino-2-deoxyisochorismate before production of 4-
amino-4-deoxychorismate, which is then converted to PABA and pyruvate by PabC 
(Schadt et al., 2009). 
 
 
Figure 1.8  PLP forms a covalent link with the amino group of lysine sidechains.  
The &-amino group of a lysine sidechain, typically in the enzyme active-site acts as a nucleophile, 
attacking PLP to form an enzyme-PLP adduct (Schiff base); with water as a leaving group.  This lysine-
linked PLP is referred to as the internal aldimine form.  Curly arrows indicate the flow of electrons. 
! &%!
 
1.3.2  Anti-folate drug discovery and sulphonamides as antimicrobial 
agents 
 
Since PABA is required for folate production and by extension a range of physiological 
processes in many microorganisms, PABA biosynthesis presents itself as a potential 
target for antimicrobial drug development.  Targeting PABA biosynthesis directly has 
been chemically validated as a viable approach to identifying antimicrobial compounds, 
as exemplified by the natural products atrop-abyssomicin C (Keller et al., 2007; 
Riedlinger et al., 2004) and rubreserine (Camara et al., 2012) that both inhibit 
aminodeoxychorismate synthase and show potent activity.  In 2004, Bulloch et al. 
demonstrated the mechanism though which the known anti-bacterial agent (6S)-6-
fluoroshikimate targets PABA biosynthesis; it is converted to 2-fluorochorismate in 
vivo by chorismate synthase (EC: 4.2.3.5), which proceeds to irreversibly inhibit 
aminodeoxychorismate synthase. 
 Several anti-infective medicines in both current clinical use and historically have 
achieved their salutary effect through inhibition of folate metabolism in microbes.  A 
large number of sulphonamide drugs were discovered during the 1930s, starting with 
prontosil - shown to be a pro-drug of the active agent, sulfanilamide (Domagk, 1947).  
Sulphonamide antimicrobials inhibit DHPS, thereby depleting folate levels (Brown, 
1962; Woods, 1940).  This is due to their structural similarity to the PABA molecule 
(Figure 1.9).  Prior to the introduction of penicillin, 'sulfa drugs' and their derivatives 
were highly sucessful; for example the sulfone drug dapsone was widely used to treat 
leprosy (Barr, 2010; Shepard, 1969). 
 Dihydrofolate reductase (DHFR, EC: 1.5.1.3) is another enzyme of folate 
metabolism that has been targeted for therapeutic benefit.  Several DHFR inhibitors, 
such as trimethoprim and pyrimethamine are used clinically to manage a range of 
conditions including urinary tract infections, bacterial pneumonia and protozoal 
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infections.  Indeed, DHFR inhibitors are often given in combination with sulphonamide 
drugs for synergistic effect (Bushby & Hitchings, 1968; Masters et al., 2003); well-
established drug combinations include co-trimoxazole (a combination of trimethoprim 
with sulfamethoxazole) and pyrimethamine with sulfadiazine or sulfadoxine (World 
Health Organization, List of Essential Medicines, 2011). 
 
 
 sulfanilamide    sulfamethoxazole  sulfadiazine 
 
Figure 1.9  Chemical structures of sulphonamide antimicrobials that inhibit folate 
biosynthesis.  
 
 Structural studies of the enzymes involved in PABA and folate metabolism can 
provide significant insight into the mechanism of the reaction catalysed (Nakai et al., 
2000, Parsons et al., 2002, Schnell et al., 2004), the molecular nature of drug-resistance 
(Vanichtanankul et al., 2011; Yun et al., 2012) and can guide early-stage drug discovery 
initiatives (Chhabra et al., 2012; Eadsforth et al., 2012; Morgan et al., 2011). 
 
1.3.3  PabC 
 
4-Amino-4-deoxychorismate lyase, encoded by the pabC gene, catalyzes the formation 
of PABA from 4-amino-4-deoxychorismate (Figure1.10) as part of the biosynthetic 
route to folate (Green & Nichols, 1991; Ye et al., 1990). 
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Figure 1.10  PabC catalyzes the conversion of 4-amino-4-deoxychorismate to 
PABA and pyruvate. 
 
 Inhibitors of microbial PabC would reduce PABA levels and so deplete the 
supply of folic acid available to the microorganism.  Provided that the microbe cannot 
obtain sufficient PABA or folate from the cellular environment or by other means these 
cells would be expected to cease growth and die.  This is what is observed in pabC 
knockouts in E. coli (Green et al., 1992), Pseudomonas aeruginosa (Hoang et al., 1998) 
and Acinetobacter baylyi (de Berardinis et al., 2008).  Combining novel PabC inhibitors 
with sulphonamides or with other anti-folates such as the dihydrofolate reductase 
inhibitor trimethoprim, could produce a synergistic antimicrobial effect.  New inhibitors 
of PabC would allow such a hypothesis to be tested. 
 X-ray crystal structures of PabC from E. coli (PDB code: 1ETO; Nakai et al., 
2000), Thermus thermophilus (2ZGI; Padmanabhan et al., 2009) and Legionella 
pneumophila (3LUL) have been determined.  PabC displays a similar overall fold to 
branched-chain amino acid transferases and D-amino acid transferases (Eliot & Kirsch, 
2004; Jhee et al., 2000; Nakai et al., 2000).  These aminotransferases have been 
investigated to identify potential inhibitors in support of research for treatments of 
neurodegenerative disease (Castell et al., 2010; Hu et al., 2006; Lepore et al., 2010; 
Soper & Manning, 1981).  Moreover, since PLP-dependent enzymes provide 
opportunities for the design of mechanism-based suicide inhibitors (Eliot & Kirsch, 
2004) this enzyme family appears an attractive one from the perspective of structure and 
mechanism-based drug discovery.  For example, the anti-trypanosomal medicine 
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eflornithine ($-difluoromethylornithine) used in the treatment of African sleeping 
sickness is a suicide inhibitor of the PLP-dependant enzyme ornithine decarboxylase 
(EC: 4.1.1.17), forming an adduct with the active site cofactor (Grishin et al., 1999).  
 The absence of the PabC enzyme in humans and its essentiality in various 
microbes suggests that its inhibition offers the possibility of new therapies targeting a 
range of microbial infections and structural studies provide useful data to assess the 
potential of this protein for such early stage drug discovery (Hunter, 2009; O'Rourke et 
al., 2011). 
 
 
1.4  Biophysical screening techniques 
 
Bio-layer interferometry (BLI) is an optical technique that can be used to perform label-
free fragment screening against an immobilised protein target.  The sensors used in the 
assay are fiber optic tips with a streptavidin-coated protein binding surface and protein 
target can be biotinylated to facilitate binding to the sensor (Figure 1.11).  Following 
protein loading and capture by the streptavidin surface, the sensors are immersed in 
wells containing analytes, typically chemical fragments and control compounds, and a 
binding response is recorded in real-time.  A sensor records the interference pattern 
produced by white light reflected from two layers in the sensor, an internal reference 
layer and the protein binding surface, or 'bio-layer'.  Binding of ligand to the bio-layer 
increases the optical thickness and shifts the interference pattern, resulting in an 
apparent shift in wavelength of the reflected light (Wartchow et al., 2011). 
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Figure 1.11  Principles of BLI.  A protein target is immobilised on the biolayer and subjected to 
incident white light.  An optical interference pattern is recorded from light returning from the biolayer 
and compared to that returning from an internal reference layer.  An increase in mass at the biolayer, due 
to the binding of a chemical fragment for example, will increase the optical thickness, shifting the 
interference pattern, which results in an apparent shift in wavelength ('() of the reflected light 
(Wartchow et al., 2011).  The OctetRed BLI system is shown inset. 
Images taken from the ForteBio website:  http://www.fortebio.com/bli_technology.html 
 
 
 In differential scanning fluorimetry (DSF), protein unfolding in response to 
increasing temperature can be measured by monitoring the fluorescence signal of a dye 
with an affinity for hydrophobic residues (Pantoliano et al., 2001).  The dye will be 
excluded from the hydrophobic interior of the protein and will not fluoresce until the 
protein exposes hydrophobic residues as it unfolds.  The assay is typically performed 
using an RT-PCR machine to incrementally raise the temperature.  Melt curves can be 
fit to the fluorescence data and the temperature corresponding to the transition mid-
point (Tm) during unfolding can be calculated.  The stabilisation of a protein by ligand 
or buffer can be inferred from a positive shift in Tm (Ericsson et al., 2006; Niesen et al., 
2007).  Screening of buffers using differential scanning fluorimetery can also identify 
conditions to pursue or avoid during crystallisation (Ericsson et al., 2006; Reinhard et 
al., 2013). 
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 Both of these methods were used in these studies; buffer screening with 
differential scanning fluorimetry (Section 2.1.4) and screening of fragment libraries 
with BLI (Section 2.1.5). 
 
1.5  Aims - Part one 
 
This study sought to determine the crystal structures of potential drug targets from 
human pathogens to inform early stage drug discovery.  Studies of recombinant IspF, an 
essential enzyme on the MEP pathway; from B. cenocepacia and P. falciparum were 
pursued.  Fragment screening was carried out to identify novel ligands.  The suitability 
of the enzyme from these organisms as a platform for ligand co-crystallisation studies 
was assessed.  Additionally, the structure of PabC from P. aeruginosa, an essential 
enzyme required for the synthesis of PABA, was determined to provide insight into 
catalytic mechanism and to facilitate studies of this enzyme in antimicrobial drug 
discovery. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
! &,!
Materials and methods 
 
2.1.1  Reagents, bacterial strains, growth media and equipment 
 
All chemical reagents used were of the highest possible purity available and were 
sourced from VWR and Sigma-Aldrich unless otherwise stated.  E. coli strains were 
sourced from Life Technologies, Promega and Stratagene.  PCR amplifications of DNA 
were performed using a programmable thermal cycler (GeneAmp 2700, Applied 
Biosystems).  Oligonucleotide primers for PCR were sourced from Life Technologies.  
DNA ligase and restriction enzymes were sourced from Fermentas, New England 
Biolabs and Promega.  All sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) was performed using NuPAGE Bis-Tris pre-cast gels sourced from Life 
Technologies. 
 Plasmid preparations and DNA gel-extractions were performed using Qiagen 
kits (QIAprep spin miniprep, QIAquick gel extraction).  DNA electrophoresis was 
performed in gels prepared to contain 10% w/v agarose (VWR) and 0.0002% w/v 
ethidium bromide (10 mg mL-1 stock, Electran, VWR BDH Prolabo).  DNA sequencing 
was performed by DNA Sequencing & Services (University of Dundee) using Applied 
Biosystems Big-Dye Ver 3.1 chemistry on an Applied Biosystems model 3730 
automated capillary DNA sequencer.  All LB bacterial growth media used in these 
studies were prepared and autoclaved by the Media Services staff (University of 
Dundee).  Shake-flask bacterial culture was performed using either an incubation shaker 
(Multitron, Infors-HT) or a room temperature orbital shaker (KS501 Digital, IKA).  
Both electrospray ionisation mass spectrometry (ESI-MS), and matrix-assisted laser 
desorption/ionisation - time-of-flight mass spectrometry (MALDI-TOF MS) were 
performed by the Proteomics and Mass Spectrometry Facility (FingerPrints, University 
of Dundee).  In particular, MALDI-TOF MS analyses were performed by Samantha 
Kosto on an AB Sciex Voyager DE-STR system using a sinapinic acid matrix.  Samples 
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for MALDI-TOF MS were diluted in de-ionised water and loaded onto the matrix in a 
concentration range between 2-5 pmol. 
 
Table 2.1  List of key details for the proteins reported in this thesis (Part 1) 
! BcIspF PfIspF PaPabC 
UniProt code! B4EC22! P62368! Q9HZN6!
Enzyme 
nomenclature!
2C-methyl-D-erythritol 
2,4-cyclodiphosphate 
synthase!
2C-methyl-D-erythritol 
2,4-cyclodiphosphate 
synthase!
4-amino-4-
deoxychorismate lyase!
E.C. number! 4.6.1.12! 4.6.1.12! 4.1.3.38!
Source 
organism!
Burkholderia cenocepacia, 
strain J2315!
Plasmodium falciparum, 
isolate 3D7!
Pseudomonas 
aeruginosa, strain PAO1!
Number of 
amino acids!
182! 184! 292!
Molecular 
mass (Da)!
19328.8! 20545.5! 32291.9!
Theoretical 
isoelectric 
point!
!
6.4!
!
9.0!
!
6.0!
Theoretical 
extinction 
coefficent (!)!
5960!
(Bradford assay was used 
to estimate concentration)!
!
11920!
!
33710!
!
PDB codes!
4C8G (CMP complex), 
4C8E (2 x CMP complex),!
4C8I (citrate complex)!
4C81 (CDP complex),!
4C82 (holo-structure)!
2Y4R (PLP complex)!
 
 
2.1.2  Gene cloning and plasmid preparation 
 
The genes encoding the proteins described in this thesis were amplified from genomic 
DNA by PCR (Table 2.2), with the exception of EcIspF which was provided by Dr. 
Thomas Eadsforth and PfIspF which was purchased as a synthetic gene (below).  PCR 
products were blunt-end ligated into a TOPO cloning vector (Life Technologies), then 
ligated into an expression vector, pET15b-TEV, that encoded the protein-of-interest 
bearing an N-terminal hexahistidine purification tag (His-tag) linked via a tobacco-etch 
virus (TEV) protease cleavage site. 
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Table 2.2  Oligonucleotide primers for PCR 
 
BcIspF 
Forward 
Reverse 
 
5'- CAT ATG GAC TTC AGA ATC GGA CAA GG -3' 
5'- GGA CCT CAG CCG CCC TGC TTC ACC -3' 
 
Strain 
J2315 
PaPabC 
Forward 
Reverse 
 
5’- CAT ATG CTG GAC TGG GTC GAC -3’ 
5’- GGA TCC TCA GAA ATC CAG GTC G -3’ 
 
Strain 
PAO1 
 
 The gene encoding IspF from P. falciparum isolate 3D7, GenBank accession 
number: XP_001349603, was synthesised (Genscript, Boston) with codons optimised 
for recombinant expression in E. coli.  NdeI and BamHI restriction sites were included 
at the 5' and 3' ends of the gene.  The sequence encoding residues 1-59, a predicted 
apicoplast targeting sequence, was excluded and the codon for Cys60 was replaced with 
one for serine.  The synthetic gene was provided by Dr. Scott Cameron in a pUC57 
shuttle vector and was subcloned into the pET15b-TEV vector. 
 The genes encoding BcIspF and EcIspF were also ligated into a pET15b-TEV 
vector that had been further modified to append an N-terminal biotin acceptor peptide to 
the protein in addition to the protease-cleavable His-tag.  These vectors were used in the 
production of biotinylated IspF proteins for fragment screening. 
 
 
2.1.3  Protein production 
 
Recombinant production was performed in E. coli BL-21 (DE3) Gold for all proteins.  
Strains were transformed with expression plasmids by heat-shock.  Transformants were 
selected following outgrowth at 37 °C, on LB agar plates supplemented with the 
antibiotics chloramphenicol and/or carbenicillin.  1 L shake-flask cultures were grown 
in LB at 37 °C and monitored by UV spectrophotometry (BioPhotometer, Eppendorf).  
When the optical density at 600 nm (OD600) reached 0.6, expression was induced with 
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0.1 mM IPTG - with the exception of EcIspF, which was induced at an OD600 of 1.0.  
Culturing was continued for a further 16 hours at 18 °C, or 22 °C in the case of BcIspF, 
before cells were harvested. 
 
 
2.1.4  Differential scanning fluorimetry and buffer screening 
 
All assays reported here were performed in 96-well plates (Thermo-Fast, Thermo 
Scientific) on a Stratagene-Mx30005P RT-PCR machine.  SYPRO Orange (Life 
Technologies) was used as the fluorescent dye.  Buffer screening was carried out for all 
proteins reported here; with the exception of the IspF samples, which were found to 
give either irreproducible (PfIspF) or uninterpretable (BcIspF) responses during 
assessment. 
 
 
2.1.5  Fragment screening by bio-layer interferometry 
 
A fragment screen using the Drug Discovery Unit (DDU, University of Dundee) 
fragment library was performed by BLI (Octet Red system, ForteBio) on two enzymes; 
BcIspF and EcIspF.  BcIspF was screened first against the original fragment set (652 
commercially available compounds).  EcIspF was screened later against a revised 
version of the fragment library that had been changed to remove non-specific binders 
and to add novel fragments with different scaffolds (Table 2.3; Dr. David Robinson, 
personal communication). 
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Table 2.3  BLI fragment screen assay conditions 
 
 
Biotinylated-BcIspF 
 
Original DDU 
fragment library 
(652 fragments at 
200 µM in 100% 
DMSO) 
 
Buffer:  20 mM NaCl, 100 µM MgCl2, 
100 µg ZnCl2, 20 mM Tris-HCl, 
pH 7.5 
 
Biotinylated-EcIspF 
 
Revised DDU 
fragment library 
(658 fragments at 
200 µM in 100% 
DMSO) 
 
Buffer:  50 mM NaCl, 100 µM MgCl2, 
100 µM ZnCl2, 50 mM Tris-HCl, 
pH 7.7 
 
 Both BcIspF and EcIspF were loaded onto biosensors (SuperStreptavidin, 
ForteBio) at 1 µM and screened at 25 °C, alongside double-referenced biosensors (one 
set referenced with assay buffer, and one set with blocked streptavidin).  Known IspF 
ligands, CMP and CDP, were used as positive controls.  Fragment screens were 
conducted after immobilising target proteins for ten minutes, blocking unoccupied 
binding sites with the biotin analogue biocytin at 10 µg mL-1 for one minute, followed 
by surface washing and equilibration of the biosensors in assay buffer for five minutes.  
Coefficient-of-determination (R2) values were calculated for sensorgram fitting curves 
and used as a measure of reliablity throughout the screens. 
 
 
2.1.6  Screening for crystallisation conditions 
 
An automated liquid-handling system (Phoenix, Art Robbins) was used in screening for 
crystallisation conditions in combination with commercially available screens (JCSG-
plus, Molecular Dimensions; AmSO4 suite, PEGs suite, Classics suite, Qiagen).  All 
samples were filtered through a 0.1 µm PVDF filter (Ultrafree, Millipore) immediately 
prior to screening.  The protein samples were dispensed (100 nL drops) into 96-well 
sitting-drop plates (MRC-2, Molecular Dimensions).  Reservoirs were dispensed in a 
1:1 or 1:2 ratio with the protein sample (100 nL protein + 100 nL reservoir, or, 100 nL 
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protein + 200 nL reservoir).  Plates were then sealed and stored at room temperature in 
a benchtop protein crystal drop imager (Minstrel DT system, Rigaku). 
 Crystallisation plates were inspected at regular intervals for up to one month.  
Productive conditions identified in initial screens were optimised by scaling-up to larger 
volumes (1-2 µl) in hanging-drop vapour diffusion trays (24-well Linbro plates, 
Hampton Research).  The crystallisation landscape around identified conditions was 
investigated by varying the concentrations of various reservoir components and/or the 
protein concentration, pH and temperature (20 °C or 4 °C). 
 
 
2.2.1  Purification of PfIspF 
 
Cells were harvested by centrifugation at 3000 g for 30 minutes at 18 °C and re-
suspended in 100 mM KCl, 100 mM L-arginine, 50 mM CHES, pH 9.5 (buffer A).  
DNAseI and a protease inhibitor tablet (EDTA-free, Roche) were added prior to cell 
lysis by passage through a French pressure cell.  The cell lysate was clarified by 
ultracentrifugation at 40000 g for 30 minutes at 18 °C (Avanti centrifuge, Beckmann) 
and supernatant was syringe-filtered through a pre-filter followed by a 0.2 )m filter 
(Sartorius). 
 PfIspF precipitates during purification at temperatures below 18 °C (Dr. 
Kalinowska-T!u"cik, personal communication).  Therefore all procedures described 
were performed at room temperature unless otherwise stated.  The cell lysate was 
loaded onto a nickel ion affinity chromatography column (5 mL HisTrap HP, GE 
Healthcare) with the assistance of an FPLC system (Äkta Explorer, GE Healthcare).  A 
linear concentration gradient of imidazole, from 0 - 1M, was applied to elute PfIspF 
(which eluted at 200 mM imidazole).  Protein sample was then dialysed against fresh 
buffer A.  The purification tag (His-tag) was cleaved with His-tagged TEV protease at 
20 °C for 16 hours.  The protease-treated sample was re-applied to a nickel ion affinity 
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chromatography column, which eluted the cleaved protein while removing the TEV 
protease and remaining uncleaved PfIspF.  Fractions were analysed by SDS-PAGE and 
those containing PfIspF were pooled.  The protein was further purified on a size-
exclusion chromatography column (Superdex 200 26/60, GE Healthcare) equilibrated 
with buffer A.  This column had previously been calibrated (by Sharon Shepherd) with 
molecular weight standards; thyroglobulin (670 kDa), *-globulin (158 kDa), ovalbumin 
(44 kDa), myoglobin (17 kDa), and vitamin B12 (1.35 kDa); (Bio-Rad).  The high level 
of PfIspF purity was confirmed by SDS-PAGE and MALDI-TOF MS. The sample was 
concentrated to 6 mg mL-1 using a centrifugal filter (Vivaspin 20, Sartorius) to provide a 
stock solution for crystallisation.  Protein concentration was estimated 
spectrophotometrically; a theoretical extinction coefficient, &: 11920 M-1 cm-1 at 280 
nm, was calculated by the ProtParam server (Gasteiger et al., 2005). 
 
 
2.2.2  Purification of BcIspF 
 
BcIspF was purified in the manner described for PfIspF, except that buffer B (100 mM 
NaCl, 100 mM Tris-HCl, pH 7.5) was used throughout the process and the His-tag was 
not cleaved off the protein.  Further, the marked temperature sensitivity observed for 
PfIspF was not seen for BcIspF and samples were kept either on ice or at 4 °C 
throughout. 
 
 
2.2.3  Purification of biotinylated BcIspF and EcIspF for BLI 
 
Cultures containing BcIspF were harvested by centrifugation and re-suspended in buffer 
D (150 mM NaCl, 50 mM Tris-HCl, pH 8.0).  To this was added one protease inhibitor 
tablet (EDTA-free, Roche) and DNAse I.  The re-suspended cells were lysed and the 
high-speed supernatant was recovered as described for PfIspF.  The supernatant was 
syringe-filtered and loaded on to a nickel ion affinity chromatography column.  The 
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protein was eluted from the column with a linear gradient of imidazole.  Protein sample 
was dialysed into fresh buffer D then treated with TEV protease (16 hours at 4 °C).  A 
sample was taken for MALDI-TOF MS before and after treatment with protease. 
 Protease-treated protein was passed through a second nickel ion affinity 
chromatography column and protein cleaved from its purification tag, was collected in 
the flow-through.  This cleaved protein was dialysed into biotinylatyion buffer (10 mM 
Tris-HCl, 200 mM KCl, 5 mM MgCl2).  Following dialysis, the protein was prepared 
for biotinylation by being diluted to <10 µM in biotinylation buffer.  D-biotin was 
added to a final concentration of 100 µM, and the biotinylation reaction was started 
with the addition of 500 µM ATP and 1 µM of the biotin ligase, BirA (His-tagged, 
provided by Dr. Vincent Rao).  The reaction was carried out for four hours at 20 °C.  
The protein eluted in the flow-through of a third nickel ion affinity chromatography 
column, removing the BirA enzyme.  Biotinylated-BcIspF was concentrated and 
exchanged into a buffer for size-exclusion chromatography (20 mM NaCl, 20 mM Tris-
HCl, pH 7.5) by centrifugal filtration, to remove residual biotin and ATP.  Sample was 
loaded on to a size-exclusion chromatography column (Superdex 200 26/60, GE 
Healthcare).  The peak was collected and a sample was sent for MALDI-TOF MS 
analysis.  Protein, diluted to 5 mg mL-1 in size-exclusion chromatography buffer and 
supplemented with 10% glycerol, was flash-cooled in liquid nitrogen and stored at -80 
°C for later use on the Octet Red BLI system.  EcIspF was purified and biotinylated as 
described above for BcIspF, except that the buffer condition used throughout 
purification was different (50 mM NaCl, 50 mM Tris-HCl, pH 7.7), and that the His-tag 
was kept. 
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2.2.4  Purification of PaPabC 
 
PaPabC was purified in the manner described for PfIspF, except that a different buffer 
was used throughout the process (500 mM NaCl, 100 mM HEPES, pH 7.5) and that the 
His-tag was kept.  Samples were kept either on ice or at 4 °C throughout.  Sample purity 
and mass were confirmed by electrospray ionisation mass spectrometry. 
 
 
2.3.1  Crystallisation of PfIspF in complex with CDP 
 
A stock solution of PfIspF was prepared at 6 mg mL-1 in buffer A supplemented with 2 
mM MgCl2.  CDP disodium salt was added to a final concentration of 2 mM.  Crystals 
were obtained by mixing protein (2 µl) with reservoir solution (2 µl) at 20 °C.  The 
reservoir solution consisted of 1.8-2.5 M (NH4)2SO4, 5 mM ZnCl2 and 100 mM Bis-
Tris, pH 5.5.  Prisms (0.15 x 0.15 x 0.15 mm) appeared within 2-4 days.  Crystals were 
cryo-protected with a saturated sucrose solution and data were collected at the European 
Synchrotron Radiation Facility (ESRF, Grenoble). 
 
 
2.3.2  Crystallisation of holo-PfIspF 
 
PfIspF was prepared as before except that fosmidomycin, an hydroxamate compound 
(Figure 1.5), was added to the protein sample (20 mM) prior to crystallisation.  Crystals 
of similar morphology were obtained as described above and a dataset was collected 
under a gaseous nitrogen cryostream at +173 °C on an in-house rotating-anode X-ray 
source (MicroMax 007 HF, Rigaku) with an image plate detector (RAXIS IV++). 
 Despite the presence of fosmidomycin, a putative ligand, no interpretable 
electron density was observed in the resulting maps (Results, Chapter 3), producing a 
holo-PfIspF structure. 
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2.3.3  Crystallisation of BcIspF in complex with CMP 
 
BcIspF was prepared at 5 mg mL-1 in buffer B supplemented with 2 mM MgCl2, to 
which was added CMP disodium salt to a final concentration of 20 mM.  A second 
sample was prepared at 10 mg mL-1 in buffer C (100 mM NaCl, 2 mM MgCl2, 100 mM 
sodium formate, pH 5.0) to which CMP was also added (2 mM final concentration). 
 The BcIspF sample in buffer B was crystallised by mixing (2 )L) with reservoir 
(2 )L) containing 25% w/v PEG 3350, 2.2 M (NH4)2SO4, 0.1 M sodium formate, pH 
5.0, and 1% v/v dioxane.  Orthorhombic blocks reached maximum size within ten days.  
A crystal of approximate dimensions 0.15 x 0.10 x 0.10 mm was used for data 
collection.  Buffer B supplemented with 20% v/v glycerol was used as a cryoprotectant. 
 The second BcIspF sample, in buffer C, was crystallised by mixing (2 )L) with 
reservoir (4 )L) containing 5% w/v PEG 1000, 33% v/v ethanol, 0.1 M Na2HPO4, pH 
4.0, and 2% v/v dioxane.  Prisms grew within six days.  A crystal of approximate 
dimensions 0.25 x 0.10 x 0.10 mm was used for data collection.  A mixture of buffer C 
with reservoir (1:2), replacing PEG 1000 with PEG 4000 at 25% w/v, was used as a 
cryoprotectant. 
 
 
2.3.4  Crystallisation of BcIspF in complex with citrate 
 
BcIspF at 10mg mL-1 in buffer C without MgCl2 present was crystallised by mixing (1.5 
)L) with reservoir (3 )L) containing 5% w/v PEG 1000, 36% v/v ethanol, 0.1 M 
Na2HPO4 and 0.1 M citric acid, pH 4.2.  Prisms grew within 4 days, belonging to a 
different crystal form.  A crystal of approximate dimensions 0.4 x 0.10 x 0.10 mm was 
used for data collection.  A mixture of sample buffer with reservoir (1:2), replacing 
PEG 1000 with PEG 4000 at 25% w/v, was used as a cryoprotectant.  Datasets for 
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BcIspF crystals were collected on the in-house X-ray system as described for PfIspF 
(Section 2.3.2). 
 
 
2.3.5  Crystallisation of PaPabC 
 
To PaPabC at 33 mg mL+1 in sample buffer (100 mM HEPES, 500 mM NaCl pH 7.5), 
PLP and PABA were added (final concentration: 0.1 mM and 10 mM respectively).  
PLP increased the thermal stability of PaPabC in a dose-dependent manner; the 
optimum concentration was determined by DSF.  PaPabC was crystallised by mixing 
sample (1 )L) with reservoir (1 )L) containing 10% w/v PEG 400, 1.8 M (NH4)2SO4 
and 100 mM MES, pH 6.5.  Clumps of pale yellow, orthorhombic blocks grew over one 
week.  Mother liquor supplemented with 25% v/v glycerol was used as a cryo-
protectant.  A crystal fragment (0.3 , 0.2 , 0.1 mm) was flash-cooled in liquid nitrogen 
and sent for data collection at a synchrotron-radiation source (ESRF). 
 
 
2.4  Data processing, structure solution and refinement 
 
Data were indexed and integrated using either MOSFLM (Leslie, 2006; Battye et al., 
2011) or XDS (Kabsch, 2010) and scaled using SCALA (Evans, 2006) with 5% of data 
kept for Rfree calculations.  All structures were solved by molecular replacement.  Search 
models for molecular replacement used coordinates from orthologues in E. coli (PDB 
code: 1GX1; ~33% identity, Kemp et al., 2002) and B. pseudomallei (PDB code: 3F0G; 
63%, Begley et al., 2011) for PfIspF and BcIspF respectively, edited to remove all non-
protein atoms.  The search model for PaPabC was prepared by generating a poly-
alanine model of the E. coli PabC structure (35% identity, Nakai et al., 2000) in 
CHAINSAW (Stein, 2008).  Molecular replacement calculations were performed using 
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either PHASER (McCoy et al., 2007; Collaborative Computational Project, Number 4, 
1994) or MOLREP (Vagin and Teplyakov, 1997). 
 Refinements were performed in REFMAC5 (Murshudov et al., 2011) and 
models were inspected and manipulated in COOT (Emsley et al., 2010).  Strict non-
crystallographic symmetry (NCS) restraints were employed in the early stages of 
refinement and then removed towards the end.  Greater weighting was given to 
geometric parameters than default values during refinement of medium resolution 
structures of BcIspF.  The validation tools in COOT and the MolProbity server (Chen et 
al., 2010) were used to assess model geometry.  Comparisons with structures in the 
PDB were performed using the DALI server (Holm & Rosenström, 2010).  AREAIMOL 
(Collaborative Computational Project, Number 4, 1994) and the Protein Interfaces, 
Surfaces & Assemblies server, (Krissinel & Henrick, 2007) were used to calculate 
surface and interface areas.  Figures of proteins were prepared using PyMOL molecular 
graphics software (DeLano, 2002). 
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CHAPTER 3 
IspF; STRUCTURAL ANALYSIS and 
FRAGMENT SCREENING 
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3.1  PfIspF and BcIspF results 
 
3.1.1  Structure of IspF 
 
Structures were determined of BcIspF in complex with either CMP or citrate, and of 
PfIspF in complex with CDP, as well as a holo-PfIspF structure (where holo- refers to 
the protein in complex with the Zn2+ cofactor, without any other ligands present in the 
active site).  All structures are at a resolution of 2.0 Å or better.  Crystallographic 
statistics are presented in Tables 3.1 and 3.2.  Sequence alignments and structural 
overlays of IspF from P. falciparum, B. cenocepacia, B. pseudomallei and E. coli were 
inspected to inform on conservation of residues and interactions, and an alignment of 
BcIspF with PfIspF is shown in Figure 3.1. 
!!
Figure 3.1  Sequence alignment of BcIspF and PfIspF.  The alignment has been annotated 
with elements of secondary structure.  Only the BcIspF sequence has been numbered.  Strictly conserved 
residues between the two species are highlighted in black.  Residues that bind Zn2+ are marked with a 
yellow star, those that bind at position 1 with a grey disk and those at position 2 with an orange triangle.  
Residues that bind MEcPP in EcIspF (Steinbacher et al., 2002) are marked with a magenta triangle.  A 
conserved glutamate that binds either Mg2+ or Mn2+ in EcIspF structures is highlighted with a blue star.   
This figure was prepared using ALINE (Bond & Schüttelkopf, 2009). 
! (&!
 
 The calculated masses of monomeric BcIspF and PfIspF are 19.3 kDa and 20.5 
kDa respectively.  IspF forms a homotrimer, both in the crystal structures and in 
solution; size-exclusion chromatography returns an estimate of 57 kDa for each.  IspF 
from both species adopts the established fold reported from other organisms; a core 
region containing four #-strands, flanked by !-helices (Section 1.2.5, Figure 3.2).  The 
accessible surface area (ASA) of an IspF subunit averages out as approximately 8130 
Å2 for BcIspF and 8680 Å2 for PfIspF; for comparsion the value for EcIspF is 7900 Å2. 
 A search for structurally-related proteins in the PDB using the DALI server 
(Holm & Rosenström, 2010) showed that PfIspF aligns 143 residues with an RMSD of 
0.8 Å, and 151 residues with an RMSD of 1.2 Å with IspF from P. vivax and A. 
thaliana respectively.  BcIspF aligns 151 residues with an RMSD of 0.4 Å to IspF from 
B. pseudomallei.  In BcIspF structures the asymmetric unit consists of three subunits, 
chain A, B, C; related by a three-fold non-crystallographic axis of symmetry.  NCS is 
high with least squares overlays of C! positions in the range 0.2 - 0.3 Å; nonetheless 
some differences are present and these are described below.  One subunit is present in 
the asymmetric unit of PfIspF and the trimer is generated by the symmetry operations (-
x+y, -x, z) and (y, y-x, z).  A least squares superimposition of C! positions from both 
PfIspF structures matches all 156 residues with an RMSD of 0.3 Å.  Since there are no 
pronounced differences between the CDP bound and holo- PfIspF structures, only the 
former is discussed.  In 2007, a holo-structure of IspF to a resolution of 2.3 Å from P. 
vivax, a closely related species to P. falciparum, was deposited with the PDB without an 
associated publication (code: 3B6N).  Although Zn2+ has been modelled at the active 
site, a water molecule most likely occupies the metal binding site instead, or the site is 
only partially occupied, since the corresponding B-value is 2.6 times greater than the 
average B-value of the protein atoms and the side chain of one of the two histidines that 
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coordinate the metal in other structures is in an unsuitable orientation.  In contrast, in 
PfIspF the B-value for Zn2+ is within 30% of the average B.  Further, PfIspF provides a 
higher resolution structure from a Plasmodium species. 
    
 a)      b) 
 
 
 c)      d) 
 
Figure 3.2  Overall structure of IspF.  IspF forms a homotrimer.  a)  Axial view.  b)  Side view.  
The figure has been drawn using the coordinates for PfIspF in complex with CDP; a trimer has been 
generated from symmetry-related subunits.  Subunits (displayed as ribbons) are coloured blue, orange and 
green respectively.  Zn2+ cations are displayed as grey spheres, sulfate and CDP are displayed as sticks.).  
The secondary structure of PfIspF and BcIspF subunits is shown in c) and d) respectively, similarly 
orientated.  The location of unmodelled loops is highlighted with arrows. 
 
 Electron density is absent for a loop between !2 and !3 that covers the active 
site in both PfIspF structures and the BcIspF complex with a single CMP in the active 
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site, spanning Asp144 - Asn151 and Phe63 - Ala73 respectively.  In contrast, these loop 
residues could be modelled in the BcIspF structure where two molecules of CMP are 
present.  The loop residues have elevated B-factors, 2.4 times greater than the average 
B-value for the entire the protein.  The same loop could only be modelled for chain A in 
the BcIspF-citrate complex.  These observations are consistent with the inference that 
the loop that covers the active site is flexible (Kemp et al., 2002; Steinbacher et al., 
2002).  Such flexibility has been speculated to have a role in catalysis (Lehmann et al., 
2002).  PfIspF contains a 19 residue sequence at the N-terminus, Lys76 - Glu94, that 
does not align with sequences from other organisms (Figure 3.1).  Residues Tyr82 - 
Phe97, which overlap with this region, are unmodelled in PfIspF because corresponding 
electron density is absent.  The highly conserved His115 and Ser116 that are located on 
a six residue loop above the Zn2+ binding site (Figure 3.1) are also flexible and have 
elevated B-factors in all structures except in one chain of a BcIspF-CMP structure where 
they are unmodelled. 
 The active site is located in a cleft formed by adjacent subunits (Section 1.2.5).  
Zn2+, which plays a functional role in catalysis is present in all structures and 
coordinated by the side chains of Asp10, His12 and His44 in BcIspF.  In EcIspF a 
highly conserved glutamate, Glu135, helps coordinate either a Mg2+ or Mn2+ together 
with the bridging phosphates of the substrate or CDP (Kemp et al., 2002; Steinbacher et 
al., 2002).  However, no metal is seen at this site in any structure reported here. 
 A hydrophobic cavity is present at the trimeric core of IspF.  In BcIspF the 
cavity is lined by the side chains of Tyr9, Val11, Ile101 and Tyr141, and the floor of the 
cavity is formed by a ring of hydrophobic residues; Val3 and Leu155 from all three 
subunits.  In PfIspF the side chains of Phe230 form the floor of the cavity.  Anions such 
as sulfate, phosphate or pyrophosphate bind at the entrance to this cavity in several IspF 
structures, for example phosphate is observed in IspF from Arabidopsis thaliana (PDB 
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code: 2PMP; Calisto et al., 2007).  In the structure of BcIspF crystallised with 
(NH4)2SO4 as a precipitant, a sulfate is coordinated by Arg144.  In PfIspF, a sulfate at a 
similar site is coordinated by the main chain amides of Val220 from all three subunits.  
In structures of BcIspF in which Na2HPO4 was the precipitant, Tyr141 amide groups 
bind a phosphate in a similar fashion.  Isoprenoid-species such as geranyl- or farnesyl-
pyrophosphate have been observed in the cavity that is present in IspF structures from 
other species, and a possible role in feedback regulation has been suggested (Kemp et 
al., 2005; Ni et al., 2004; Sgraja et al., 2005).  A molecule of di(hydroxyethyl)ether; a 
likely decomposition product or impurity of PEG 3350 used in crystallisation, occupies 
the cavity in one of the BcIspF structures (Table 3.2), possibly mimicking a prenyl 
chain.  A solvated Mg2+ is present further down the cavity in one of the BcIspF 
structures, forming interactions similar to IspF from B. pseudomallei (Begley et al., 
2011).  A shell of water molecules surround Mg2+ in an octahedral coordination 
geometry.  These waters are bound by Glu149, and waters in the second shell bind to 
the hydroxyl groups of Tyr9 and Tyr141.  A Mg2+ at a similar position is coordinated 
directly by the side chains of the conserved Glu149 from all three subunits in IspF from 
Salmonella enterica serovar Typhimurium (PDB code: 3GHZ) and E. coli (Ramsden et 
al., 2009). 
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Table 3.1  Crystallographic statistics for PfIspF 
 
Structure PfIspF - CDP complex holo - PfIspF 
Space group H3 H3 
Unit cell dimensions 
a, b, c (Å) 
 
 
84.9, 84.9, 101.0 
 
84.2, 84.2, 102.5 
Resolution rangea (Å) 41.63-1.60 (1.69-1.60) 29.71-2.00 (2.11-2.00) 
No. reflections 181781 (16968) 41802 (5780) 
Unique reflections 35607 (5194) 18068 (2622) 
Completeness (%) 99.4 (99.3) 98.6 (97.0) 
Rmergeb (%) 9.3 (42.0) 9.4 (48.2) 
Multiplicity 5.1 (3.3) 2.3 (2.2) 
< I/#(I)> 11.1 (2.6) 5.3 (2.0) 
Wilson B (Å2) 24.4 32.0 
Rworkc/Rfreed (%) 14.4, 16.5 19.4, 22.6 
Number of residues 
/ waters / ligands 
156 residues, 
85 waters, 1 CDP, 
2 Zn2+, 3 Cl-, 1 SO42- 
156 residues, 
94 waters, 
2 Zn2+, 1 SO42- 
RMSD bond lengths (Å) /  
bond anglese (º) 
0.005 
1.000 
0.019 
2.087 
Mean B-factors (Å2) 
Main chain, side chain 
Waters 
Ligands 
 
25.1, 33.8 
35.2  
31.5 (CDP) 
35.8 (Zn2+, Cl-, SO42-) 
 
34.2, 39.5 
47.8  
44.5 (Zn2+, SO42-) 
Ramachandran plot 
Favoured regions (%) 
Allowed regions (%) 
Outliers 
 
98.6 
0.7 
1 outlier: Asp79 
 
95.3 
4.0 
1 outlier: Asp79 
 
a. Values in parentheses refer to the highest resolution shell. b. Rmerge = -hkl-i|Ii(hkl) - <I(hkl)>|/ 
-hkl-i Ii(hkl); where Ii(hkl) is the intensity of the ith measurement of reflection hkl and <I(hkl)> 
is the mean value of Ii(hkl) for all i measurements. c. Rwork = -hkl||Fo|-|Fc||/-|Fo|, where Fo is the 
observed structure factor and Fc is the calculated structure factor.  d. Rfree is the same as Rwork 
except calculated with a subset, 5%, of data that are excluded from the refinement calculations. 
e. (Engh & Huber, 1991).  These considerations apply to all tables of crystallographic statistics 
presented in this thesis. 
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Table 3.2  Crystallographic statistics for BcIspF 
 
Structure BcIspF - 1 x CMP 
complex 
BcIspF - 2 x CMP 
complex 
BcIspF - citrate 
complex 
Space group C2 C2 C2 
Unit cell dimensions 
a, b, c (Å), 
# 
 
97.2, 88.6, 72.4, 
103.9° 
 
97.9, 89.3, 73.0, 
104.2° 
 
131.7, 52.5, 72.1, 
94.6° 
Resolution range (Å) 29.84-2.00 (2.10-2.00) 19.32-1.90 (2.00-1.90) 40.90-2.00 (2.10-2.00) 
No. reflections 98451 (13335) 164120 (24760) 119715 (15957) 
Unique reflections 38409 (5579) 47918 (6972) 33460 (4696) 
Completeness (%) 96.0 (95.4) 99.9 (100.0) 99.4 (96.1) 
Rmerge (%) 11.0 (32.2) 13.8 (32.3) 3.2 (7.8) 
Multiplicity 2.6 (2.4) 3.4 (3.6) 3.6 (3.4) 
< I/#(I)> 5.9 (2.7) 6.2 (3.1) 23.9 (12.8) 
Wilson B (Å2) 16.5 16.3 18.7 
Rwork/Rfree (%) 23.7, 28.0 20.4, 25.1 15.6, 19.8 
Number of residues 
/ waters / ligands 
458 residues, 
173 waters, 3 CMP, 
3 Zn2+, 1 Mg2+, 1 PO43- 
483 residues, 
420 waters, 6 CMP, 
3 Zn2+, 1 SO42-, 
1 di(hydroxyethyl)ether 
460 residue, 
320 waters, 3 citrate, 
3 Zn2+, 1 PO43- 
RMSD bond lengths (Å) /  
bond angles (º) 
0.020 
2.198 
0.011 
1.526 
0.020 
2.101 
Mean B-factors (Å2) 
Main chain, side chain 
Waters 
Ligands 
 
13.6, 15.3 
16.5 
15.1 (CMP) 
24.8 (Zn2+, Mg2+, PO43-) 
 
18.7, 20.4 
29.9 
18.2 (CMP, # 1) 
28.7 (CMP, # 2) 
25.0 (other ligands) 
 
16.2, 20.1 
26.7 
34.4 (citrate) 
26.1 (Zn2+, PO43-) 
Ramachandran plot 
Favoured regions (%) 
Allowed regions (%) 
Outliers 
 
96.9 
2.2 
4 outliers: Ser37A/C, 
Tyr29B, Gly17C 
 
97.8 
2.2 
No outliers 
 
97.7 
2.3 
No outliers 
 
 
3.1.2 Complexes with CMP and CDP 
 
Residues from both subunits that form the active site position cytidine nucleotides 
though hydrogen bonding (Figures 3.1 and 3.3).  In BcIspF, carbonyl groups from 
Ala102 and cis-Pro105 bind to the N4 base amine, and the amide groups of Leu107 and 
Ala108 bind to the N3 and O2 atoms of the cytosine respectively.  Ribose hydroxyl O2' 
is held by Asp58 from the adjacent subunit.  Gly60 amide, also from the adjacent 
subunit, binds the O3' hydroxyl, however this interaction is not conserved in PfIspF.  
Thr135 amide and side chain hydroxyl bind to an oxygen on the !-phosphate.  
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Lys134NZ binds the CMP !-phosphate and may play a role in catalysis by helping to 
position the transition-state intermediate or, in conjunction with Zn2+, align the substrate 
for nucleophilic attack; but this interaction is not observed in PfIspF.  This interaction in 
BcIspF is reminiscent of that previously reported for the active site Lys132 in TtIspF 
(Kishida et al., 2003), and an overlay (not shown) confirms this, except that in TtIspF 
Lys132NZ binds the "-phosphate.  Lys106 side chain is situated above the cytosine and 
provides van der Waals contacts. 
 
 
Figure 3.3  Superimpostion of position 1 residues in BcIspF and PfIspF.  Structurally 
conserved residues that bind CMP or CDP at position 1 in IspF are displayed as sticks.  Sequence 
numbers for BcIspF are followed by those for PfIspF; and residues contributed from the adjacent subunit 
are marked with a prime (').  BcIspF and PfIspF are coloured cyan and green respectively.  Interactions 
are detailed in the text. 
 
 Unexpectedly, a second molecule of CMP was observed in the active site in a 
structure of BcIspF co-crystallised in the presence of 10 mM ligand (Section 2.3.3).  
The previously described cytidine-binding site is referred as position 1, and this new 
site as position 2 (Figure 3.4).  Residues that bind CMP at position 2 (CMP #2) are from 
the same subunit that binds the active site Zn2+.  The CMP #2 phosphate associates 
directly with the active site Zn2+.  Ser64 carbonyl binds cytosine O2 thorough a water 
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molecule.  Phe70 and Ala73 carbonyl groups position a water molecule that binds 
cytosine N3.  Ala73 carbonyl also binds directly to cytosine N4, together with Ser37 
side chain OG.  Asp65 binds to ribose O2'.  His36 main chain amide and carbonyl 
position waters that each bind to the phosphate.  Overlay with the EcIspF-product 
complex shows that CMP #2 binds in the same location as MEcPP (Figure 3.5; 
Steinbacher et al., 2002).  Additionally, citrate may mimic the MEcPP product, or 
transition state since it binds directly, and indirectly through solvent, to residues 
conserved with EcIspF that are known to bind MEcPP (Section 3.1.3). Residues that 
bind MEcPP are conserved in PfIspF as His115, Ser116, Ile138, Phe142 and Asp144 
(Figures 3.1 and 3.5). 
 
 
Figure 3.4  CMP binding interactions at the enzyme active site in BcIspF.  
Interactions between BcIspF and CMP, and the coordination of Zn2+ are highlighted with black and red 
dashed lines respectively.  The established nucleotide binding site is labelled CMP "1"; the novel CMP-
binding site is labelled CMP "2".  Solvent molecules are depicted as red spheres.  There are some minor 
differences in the residues involved in binding interactions with CMP #2 in active sites related by NCS 
(not shown).  Adjacent subunits are coloured yellow and cyan respectively.  Electron density is displayed 
as green chicken-wire corresponding to an |Fo-Fc| map (omit map) for CMP #2 contoured at 2.5 .. 
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a)  Product binding site in EcIspF  b)  Overlay of MEcPP and CMP #2 
 
Figure 3.5  CMP #2 occupies the same site as MEcPP. a)  The binding interactions between 
EcIspF (PDB code: 1JY8) and the reaction products CMP and MEcPP.  Relevant residues are discussed 
in the text and marked in Figure 3.1.  b)  An overlay of EcIspF product complex and BcIspF.  CMP #2 
binds in a similar site as MEcPP and also associates with Zn2+.  Further, the loop surrounding the ligands 
(EcIspF: Phe61-Ser73; BcIspF: Phe63-Ser75) adopts a strikingly different conformation. 
 
 
3.1.3  BcIspF-citrate complex 
 
Attempts to produce holo-BcIspF crystals for ligand soaking experiments identified 
conditions with citrate in the crystallisation reservoir (Section 2.3.4).  However holo-
BcIspF crystals had not been formed, instead electron density consistent with citrate was 
present, blocking the three active sites.  Citrate was well defined in one site and 
modelled at full-occupancy, but poorly defined in the remaining two sites.  The well-
defined citrate binds to the active site Zn2+ via both a carboxylate and hydroxyl.  In 
contrast, citrate is present at lower occupancy, 0.75, in the remaining sites and adopts a 
different pose, with only a carboxylate binding to Zn2+.  The carboxylates of the well-
defined citrate also interact with the main chain amides of His36 and Ser37, and side 
chains of Asp65 and Lys134 (Figure 3.6).  An additional solvent mediated interaction is 
formed with the side chain of Glu137 (not shown).  This well resolved citrate helped to 
order the loop covering the active site in this subunit and an overlay (not shown) 
demonstrated that these residues adopt the conformation observed in the EcIspF-MEcPP 
complex (Steinbacher et al., 2002). 
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Figure 3.6  Citrate binding to Zn2+ in BcIspF.  A well resolved citrate binds to Zn2+ and 
makes interactions in the active site through carboxyl groups.  An omit map is displayed for citrate in 
green chicken wire contoured at 3#.  Residues are shown as sticks and a grey sphere represents Zn2+.  
Interactions are marked with dashed lines.  Solvent mediated interactions are not shown. 
 
3.1.4  Co-crystallisation with potential ligands 
 
Crystallisation of PfIspF and BcIspF in the presence of fosmidomycin, 
benzohydroxamic acid, acetohydroxamic acid or pyrithione was attempted.  A dataset 
was collected to resolution of 2.0 Å from a crystal of BcIspF that formed in the presence 
of 10 mM pyrithione.  The structure demonstrated that pyrithione leaches Zn2+ from the 
active site (not shown) and once both Zn2+ and pyrithione were known to be absent the 
structure was not refined further.  Crystals of BcIspF were prepared in the presence of 
both 2 mM CMP and stoichiometric amounts (0.5 µM) of pyrithione.  Nine such 
crystals were screened for diffraction quality and a data set was collected from one to a 
resolution of 2.1 Å and refined (Rwork 20.8%, Rfree 24.6%).  Electron density was present 
for both CMP and Zn2+, however no pyrithione was visible in the resulting maps.  
Similarly, structures of IspF determined in the presence the other compounds, showed 
no density for the putative ligands and were not subsequently refined. 
 A fragment screen against BcIspF, described in Section 3.3.1., identified six 
compounds that gave a reliable binding response.  Co-crystallisation and ligand soaking 
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experiments were performed with three of the fragments identified (fragments a-c, 
Figure 3.8).  When fragments were present at 1 mM, crystals were only observed to 
form in the presence of 1 mM CMP.  Higher concentrations of fragments resulted in 
precipitation; fragment c undergoing phase-separation.  A crystal of BcIspF that formed 
in the presence of 1 mM CMP and 1 mM of fragment a was collected and the structure 
determined (not shown).  Electron density maps indicated that CMP was present but no 
density for fragment a was identifiable.  Another dataset was collected from a crystal 
that had been co-crystallised with 1 mM CMP present and subsequently soaked for 
three hours with a cocktail of fragments a-c.  Fragments were dissolved in DMSO and 
reached a final concentration of 5 mM in the crystallisation drop.  In this crystal 
structure also, CMP was present but no ligand density was identified.  Longer soaking 
times resulted in crystal damage or poor diffraction. 
 
 
3.2 Structural studies on IspF - Conclusions 
 
The structures of IspF from two pathogens have been determined, demonstrating 
similarity to known structures from other species.  These proteins have been assessed for 
suitability as platforms for structure-based drug discovery.  However, since numerous 
attempts to obtain the structure of protein-ligand complexes failed, it is concluded that 
neither BcIspF nor PfIspF are promising candidates for such studies; at least using the 
crystallisation conditions reported here, all of which are at high ionic strength.  Future 
studies may employ EcIspF or BpIspF, for which successful co-crystallisation with small 
molecule ligands have been reported (Crane et al., 2006; Ramsden et al., 2009; Begley et 
al., 2011), in concert with efforts to co-crystallise with the fragments identified in this 
thesis (Section 3.3).  As observed previously, the cytidine-binding pocket is rigid in both 
structures, whereas the pocket that binds the methylerythritol-phosphate portion of the 
substrate is relatively flexible. 
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 The unexpected observation of a second molecule of CMP in the active site of 
BcIspF, as well as the presence of citrate in a related structure may inform on ligand 
design.  Novel ligands addressing the MEcPP pocket could conceivably be designed to 
recapitulate the binding interactions observed for CMP #2, although loop flexibility and 
the requirement to select out a single conformation from an ensemble may introduce 
unfavourable entropic costs to binding (Zürcher & Diederich, 2008).  Potential ligands 
could be generated, for example, by extending out from a core cyclohexa-1,5-dien-1-
amine fragment, replacing the water molecules in Figure 3.4 that bind to Ala73, Phe70 
and Ser64 with hydrogen bonding groups, and strengthening the interaction with Asp65 
by replacing the ribose O2' hydroxyl with a positively charged group such as a primary 
amine.  A screen of six generic Zn2+-binding compounds identified L-tryptophan 
hydroxamate as one of the compounds with the highest affinity for IspF known to date 
(Kd: 2 µM), suggesting that addition of a hydroxamate group may anchor ligands in the 
active site (Ramsden et al., 2009).  Additionally, any compounds targeting position 2 that 
might be developed could be linked with CMP analogues that target position 1 to 
produce compounds that may block both sites, mimicking the substrate or transition 
state. 
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3.3  IspF fragment screening 
 
3.3.1  BcIspF screening results 
 
Dissociation constant values (Kd) recorded for CMP and CDP were 18 µM and 3.7 µM 
respectively using the BLI technique (Figure 3.7).  These measurements provided a 
positive control for the fragment screen. 
 
 
                     CMP  (Kd: 18 µM, R2: 0.93)                 CDP  (Kd: 3.7 µM, R2: 0.99) 
  
Figure 3.7  Measuring the binding affinities of cytidine nucleotides for BcIspF.  The 
response of BcIspF to CMP and CDP was recorded by BLI, acting as a positive control for fragment 
screening (CMP was measured in duplicate).  The dose-dependent binding curves were generated using 
statistically smoothed data derived from the raw sensorgram traces with interpolation.  Kd values were 
calculated using this smoothed data.  R2-values indicate the goodness-of-fit and reliability of the data. 
 
 Seven compounds (a-g) were identified in the screen against BcIspF (Figure 
3.8).  One of the fragments (g) is now considered to be a non-specific binder since it has 
been flagged in several unrelated screens (Dr. David Robinson).  Fragments a-c were 
selected for purchase.  However co-crystal structures with BcIspF could not be 
determined despite several efforts (Section 3.1.4). 
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    a       b 
  DDD00074968     DDD00100705 
 
 
       
    c       d 
  DDD00100355     DDD00100398 
 
 
       
    e       f 
  DDD00100354     DDD00100425 
 
 
       
    g 
  DDD00100710 
 
Figure 3.8  Fragments identified in the screen against BcIspF.  The chemical structures 
and identification codes of seven compounds (a-g) that were identified as potential IspF binders are 
shown. 
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3.3.2  EcIspF screening results 
 
CMP gave a positive control signal (Kd: 40 µM, R2: 0.96).  In 2009, Ramsden et al. 
reported a Kd value of 900 µM, however experimental differences complicate direct 
comparison.  The previously reported Kd value was arrived at using an SPR assay with 
EcIspF bound to sensors via amine-coupling.  Additionally, a different buffer was used; 
2 mM MgCl, 50 mM Na2HPO4, pH 7 (Ramsden et al., 2009).  Nonetheless, the R2 value 
reported in the current study provides reliability.  The content of the DDU fragment 
library changed between the screen on BcIspF and subsequently on EcIspF (Section 
2.1.5).  31 compounds from the revised library were identified that gave a double-
referenced binding response to EcIspF, corresponding to 4.7 % of all the compounds in 
the fragment library.  28 of these fragments were taken forward to generate dose-
response curves (Figure 3.9).  The three excluded compounds, DDD00100335, 
DDD00100377 and DDD00100546, were not considered reliable since they produced 
the large binding responses characteristic of non-specific aggregation.  Consideration of 
the reliability and goodness-of-fit statistical scores, including R2-values as well as direct 
inspection of the raw sensorgrams produced for each of the 28 fragments allowed the 
identification of the most reliable hits (Figure 3.10).  These fragments have Kd values 
ranging from approximately 30 - 700 µM. 
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a) 
BLI Sensorgram for EcIspF dose-dependent response to fragment j 
!
 
b) 
Dose-dependent binding curve for j generated from sensorgram 
!
 
Figure 3.9  An example of BLI data from fragment screening of EcIspF.  a) The 
binding response to the fragment (inset) is shown.  Vertical displacement represents binding response in 
nm at increasing concentrations (2, 6.2, 18.5, 55.5, 166.7 & 500 µM).  b) A dose-dependent binding curve 
generated for the fragment using statistically smoothed data derived from the raw sensorgram traces with 
interpolation.  The maximum shift in wavelength (after 60 seconds) is plotted for each concentration.  
Readings from the two lowest concentration points were discarded owing to weak and noisy signal.  Kd 
values were calculated using this smoothed data. 
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    h       i 
 DDD00100744, R2: 0.78      DDD00100759, R2: 0.96 
 Kd: 30 µM        Kd: 670 µM 
 
   
    j       k 
 DDD00100596, R2: 0.86      DDD00100638, R2: 0.95 
 Kd: 200 µM        Kd: 500 µM 
 
   
    l       m 
 DDD00100615, R2: 0.80      DDD00060900, R2: 0.79 
 Kd: 380 µM        Kd: 720 µM 
 
   
    n 
 DDD00100669, R2: 0.93 
 Kd: 100 µM 
 
Figure 3.10  Fragments identified in the screen against EcIspF.  The chemical structures 
of the compounds (h-n) identified in the screen against EcIspF with the highest reliability scores and best 
quality sensorgrams are shown.  In addition to the compounds displayed, fragment e (Figure 3.8) was re-
identified in this screen (Kd: 75 µM, R2: 0.82).  Kd values have been calculated from a global fit of the 
BLI sensorgram data and R2-values represent the reliability of the fit. 
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3.3.3  IspF fragment screening - Discussion 
 
A total of 13 unique chemical fragments were identified that gave reliable binding 
responses in the two BLI fragment screens reported here.  Of the fragments identified 
for BcIspF from the original DDU fragment library, only fragment c and fragment e 
(Figure 3.8) were present in the revised library that was screened against EcIspF.  
Fragment e, was re-identified in the later screen against EcIspF.  Curiously, while 
fragment c was not re-identified in the later screen, fragment h (Figure 3.10) differs 
from fragment c by a single chlorine atom. 
 Computational docking and modelling of the identified fragments was 
considered unsuitable owing to their small size, limited number of hydrogen bonding 
groups and the relatively large, open active site of IspF.  For example, EcIspF has an 
active site volume of 1530 Å3, according to the CASTp volume calculation server set to 
a probe radius of 1.4 Å (Dundas et al., 2006). 
 Six of the fragments contain either a thiazole or an oxazole (fragment c in Figure 
3.8; fragments h, j, k, l and n in Figure 3.10).  Thiazole-bearing fragments have been 
reported to bind IspF previously (Begley et al., 2011).  Such a fragment was observed to 
bind in a pocket outside the active site in a co-crystal structure with IspF from the 
related Burkholderia species, B. pseudomallei (Begley et al., 2011).  In that crystal 
structure an arginine residue, Arg69, forms a cation-/ interaction with the thiazole ring, 
however Arg69 is not conserved in BcIspF and EcIspF - replaced by Ala69 and Ala67 
respectively.  The thiazole- and oxazole-bearing fragments reported here may bind to 
the active site Zn2+ cation.  Most of the fragments identified contain metal binding 
groups, planar groups and can make hydrophobic contacts, similar to CDP-MEP, the 
substrate of IspF. 
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 In fragment screening it is considered good practice to validate initial hits by 
counter-screening with a complementary biophysical technique (Scott et al., 2012).  
Assessment and counter-screening of fragment hits using either isothermal titration 
calorimetry or NMR, accompanied by attempts at co-crystallisation with EcIspF for 
structural determination would be ideal, but this has not been pursued due to time-
constraints.  Future work could build from the results of the initial fragment screens 
reported here. 
A convenient enzyme kinetics assay for IspF is unavailable; however unambiguous 
demonstration of enzyme activity and determination of inhibition constants will require 
such an assay.  Fluorescent IspF substrate-analogues have been designed, which may 
facilitate a fluorescence-displacement approach (Crane et al., 2006).  Alternatively, 
Narayanasamy et al. described a novel IspF kinetics assay in 2010; which involves 
coupling CMP release to four enzymes (nucleotide monophosphate kinase, pyruvate 
kinase, pyruvate oxidase and horseradish peroxidase); which alter the emission 
wavelength of a fluorescent dye.  Future work could also direct effort to developing a 
simpler kinetics assay (Narayanasamy et al., 2010). 
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CHAPTER 4 
PaPabC; STRUCTURAL ANALYSIS 
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4.1  PaPabC - Overall structure 
A single species, ~50 kDa, commensurate with a PaPabC homodimer was observed 
during size-exclusion chromatography.  A dimer was also observed in the X-ray crystal 
structure.  Two polypeptide chains, labelled A and B, constitute the asymmetric unit 
(Figure 4.1), and crystallographic statistics are presented in Table 4.1. 
 
Figure 4.1  The PaPabC dimer.  Each subunit is depicted as a C$ trace (yellow and magenta) 
with PLP shown as a stick model. The N- and C- terminal residue positions are labelled. 
 
 The subunits display a high degree of NCS, with an RMSD of 0.4 Å following 
least squares fitting of 270 C$ positions.  It is therefore only necessary to detail one 
subunit and one active site.  The subunit is constructed from two domains (Figure 4.2).  
The N-terminal domain (domain I) is smaller than the C-terminal domain (domain II).  
Domain I comprises residues 1–107, which contains three $-helices, $1-$3, and a four-
stranded anti-parallel #-sheet in order #1-#4-#3-#2.  Domain II comprises residues 112–
271 that form five $-helices, $4–$8, one short two-stranded parallel #-sheet, #5–#6, and 
one short two-stranded anti-parallel #-sheet, #7–#8.  Residues 108–111 link the two 
domains.  The PLP cofactor is covalently bound to Lys140 in domain II and the active 
site is found in a cleft formed between the two domains (Figures 4.1, 4.2, 4.3).
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 Table 4.1  Crystallographic statistics for PaPabC 
PDB code 2Y4R 
Space group P212121 
Unit cell dimensions 
a, b, c (Å) 
 
40.8, 66.8, 202.7 
Resolution range (Å) 30.00 - 1.75 (1.84 - 1.75) 
No. reflections 209336 (26399) 
Unique reflections 56255 (8090) 
Completeness (%) 98.9 (98.5) 
Rmerge 7.8 (45.1) 
Multiplicity 3.7 (3.3) 
< I/#(I)> 10.7 (2.5) 
Wilson B (Å2) 18.4 
Rwork/Rfree 16.7, 21.5 
Number of residues 
/ waters / ligands 
538 residues, 
474 waters, 2 PLP, 
3 Cl-, 2 SO42-, 2 glycerol, 3 
di(hydroxyethyl)ether, 5 tetraethylene 
glycol, 3 1,2-ethanediol 
RMSD bond lengths (Å) /  
bond angles (º) 
0.025 
2.100 
Mean B-factors (Å2) 
Main chain, side chain 
 
Waters 
Ligands 
 
Chain A: 15.1, 18.2 
Chain B: 18.5, 20.7 
30.8 
(PLP) Chain A: 15.8, Chain B: 21.5 
36.3 (other ligands) 
Ramachandran plot 
Favoured regions (%) 
Allowed regions (%) 
Outliers 
 
93.7 
5.7 
3 outliers: Arg90A & B, Leu89B 
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Figure 4.2  Ribbon diagram of the PaPabC monomer.  Secondary structural elements have 
been numbered and the position of PLP is indicated.  #-strands are shown in purple, $-helix in yellow. 
 
 Sixty residues from each subunit, provided by both domains, contribute to dimer 
formation.  These residues participate in around 30 hydrogen-bonding associations and 
eight salt bridge interactions to stabilise the quaternary structure.  Most of the residues 
that contribute to the dimer interface are found in two patches; residues Ala10 - Gly25 
centred on $1 and residues Arg127 - Ala152 centered on $5.  The approximate 
dimensions of the dimer are 80 , 40 , 40 Å and this displays a solvent accessible 
surface area of approximately 21000 Å2.  The contact area between the two subunits 
covers approximately 2050 Å2, about 15% of the surface of a subunit.  These values are 
similar to those observed for other PabC proteins; for example the interface of the E. 
coli protein (Nakai et al., 2000) covers an area of 2130 Å2. 
 The structures of PabC from three organisms, E. coli, L. pneumophila and T. 
thermophilus, display a high degree of structural conservation with PaPabC.  Least 
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squares fitting of the C$ positions of single subunits results in RMSD values between 
1.3 - 2.0 Å, with a coverage in the range of 81 - 92% of the structures.  The sequence 
identity shared with PaPabC, falls in the range 26 - 35%. 
 
4.2  PLP cofactor binding site and interactions 
 
The active site of PaPabC is positioned between the two domains of the monomer close 
to the dimer interface (Figure 4.1).  Here, the PLP cofactor is covalently linked to 
Lys140 and oriented by interactions with key residues, a selection of which are depicted 
in Figure 4.3.  The PLP phosphate accepts hydrogen bonds donated by a cluster of main 
chain amide groups from Val200, Met201 and Ser237, and the side chain of Arg46.  
The side chain of Arg46 is positioned by interactions with the side chain of Glu28, 
which in turn accepts a hydrogen bond from His43 ND1.  Two well ordered water 
molecules mediate hydrogen bonding networks linking the phosphate group to Asn178 
OD1 and Arg202 N on one side, and the main chain O and N groups of Thr29 on the 
other.  The cofactor ring is sandwiched between Val197 and the main chain of a 
tripeptide segment comprising Val175-Phe176-Ser177.  A hydrogen bond between 
Asn236 ND2 and the carbonyl of Phe176, in conjunction with bonds formed between 
the amide groups and side chain of Glu161, determine the conformation of the 
tripeptide that forms a tight turn between #9 and #10 covering part of the cofactor.  The 
PLP methyl group makes van der Waals interactions with Gln147 CG and is positioned 
3.2 Å distant from the carbonyl oxygen of Val175.  The geometry of this latter contact 
is compatible with the presence of a C-H•••O hydrogen bond (Leonard et al., 1995).  
The side chain of Gln147 is held in place by a hydrogen bond with Arg144 NE.  Bonds 
formed with the carbonyl groups of Leu139 and His141 position the side chain of 
Arg144.  There are also three water molecules, which form a network of hydrogen 
bonds linking the side chain of Arg144 to other sections of the enzyme (not shown).  In 
! **!
addition the positive dipole from $6 - the closest residue on this helix is Gly199 - 
provides an attractive force to interact with the PLP phosphate.  The side chain of 
Glu173 displays a degree of conformational freedom with two rotamers being observed.  
One rotamer places the side chain to accept a hydrogen bond donated from PLP N1 
(Figure 4.3).  The alternative rotamer places the carboxylate at a distance of 3.7 Å from 
N1.  Tyr92 from the partner subunit forms a hydrogen bond to PLP O3.  The cofactor is 
also likely to posses an intra-molecular hydrogen bond involving O3 and NZ of Lys140.  
The side chain of Phe27, Val197 and aliphatic components of Arg46 and Arg144 
surround the side chain of Lys140 (not shown). 
 
Figure 4.3  Omit map for PLP and Lys140 from subunit A of PaPabC.  |(Fo)-(Fc)| 
difference density contoured at 3 . (green chicken wire).  Selected hydrogen bonding associations 
between the protein, two water molecules (red spheres) and PLP are depicted as dashed lines.  An asterisk 
marks Tyr92 contributed from subunit B.  The side chain of Glu173 displays two rotamers with only one 
shown. 
 
 No structures of PabC-ternary complexes have yet been published to inform on 
aspects of substrate recognition and enzyme activity.  It was considered important to 
attempt structural determination of PaPabC in complex with a number of compounds 
including PABA, pyruvate, phenylpyruvate, thiomersal and sulfanilamide.  For 
example, the structure reported here was crystallised in the presence of 10 mM PABA.  
However, no electron density compatible with binding of any such ligand in the 
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substrate-binding pocket has been identified.  Therefore, the position of PLP and 
Lys140 NZ, together with the conservation of amino acid sequence and structures was 
judged to give an indication of where substrate binds; as well as which residues are 
important for substrate recognition and catalytic function.  Consideration of an amino 
acid sequence alignment and structural overlay of PaPabC with three other structures in 
the PDB proved particularly informative (Discussion) when combined with molecular 
modelling and docking of the covalent intermediate formed during catalysis. 
 
 
4.3  PaPabC active site – Comparision with orthologues 
 
Overlays of PaPabC with the structures of three orthologues were generated, together 
with sequence alignments, for comparison of active site residues.  The contributions of 
24 residues within 5 Å of PLP to binding the cofactor (Section 4.2) and organising the 
active site are summarised in Figure 4.4.  Seven of these residues are strictly conserved 
in PabC from P. aeruginosa, E. coli, L. pneumophila and T. thermophilus (Phe27, 
Thr29, His43, Arg46, Gly199, Lys140 and Arg202 in PaPabC).  With one exception 
these residues contribute to the active site using the chemical properties of their side 
chains.  The exception is Gly199 where any alteration on C$ would result in a steric 
clash with the phosphate group of PLP.  Another seven residues contribute to the active 
site primarily through the hydrogen bonding capacity of the main chain (Val175, 
Phe176, Ser177, Leu139, His141, Val200 and Met201).  Phe176 is not conserved in any 
of the three other sequences but the remainders are conserved in at least one other 
orthologue.  Ser237 interacts with the PLP phosphate using main chain and side chain 
groups.  This residue is only different in the E. coli sequence where it is replaced by an 
alanine and an additional water molecule binds nearby helping to satisfy hydrogen-
bonding capacity.  A similar observation is made when considering PaPabC Asn236.  
This residue is conserved in EcPabC and LpPabC but is changed to glycine in TtPabC 
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where a water molecule is observed to replace the side chain.  Asn178 is strictly 
conserved in EcPabC and LpPabC but changed to serine in TtPabC.  The side chain here 
helps to form one side of the cofactor-binding site.  Val197 is conserved in EcPabC and 
conservatively substituted as leucine in the other two sequences.  The residue at this 
position in the active site forms van der Waals interactions with the cofactor.  In 
PaPabC Arg144 NE donates hydrogen bonds to Gln147 OE1 and the carbonyl of 
His141; interactions that help to create one side of the cofactor-binding site and to fix 
the position of Val197.  These residues and the interactions they form are conserved in 
EcPabC but not in LpPabC or TtPabC.  Sequence and structure alignments indicate that 
PaPabC Arg144 is replaced by tyrosine in both LpPabC and TtPabC, and PaPabC 
Gln147 replaced by an alanine in LpPabC and a tyrosine in TtPabC (Discussion). 
 
 
Figure 4.4  Alignment of PaPabC and LpPabC.  Residues encased in black are strictly 
conserved.  Red stars indicate the tyrosine residues at position I (PaPabC Y92), and position II (LpPabC 
Y144).  Triangles mark residues that are discussed in the text.  Red triangles identify Lys140 and residues 
that interact directly with the Lys140-PLP adduct; yellow triangles mark residues that contribute to the 
organisation of the active site or that participate in solvent mediated interactions between the protein and 
the cofactor. 
 
 
 There are three glutamates among the 24 residues discussed above (Glu28, 
Glu161 and Glu173).  Glu28 helps to position Arg46 to bind the cofactor phosphate.  
Both residues are strictly conserved in LpPabC.  A conservative substitution of the 
glutamate to threonine occurs in both EcPabc and TtPabC, and the interactions to 
support the binding of arginine to the cofactor are preserved.  Glu161 helps to configure 
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a tripeptide segment to cover part of the cofactor (not shown) and this feature is 
conserved since a glutamate is present in the other structures (an aspartate occupies this 
position in LpPabC).  The carboxylate side chain of Glu173 can interact directly with 
the cofactor by accepting a hydrogen bond donated from N1.  In a similar fashion to 
what is observed for Glu161, such interactions occur in the orthologues with the residue 
either strictly conserved, or as in TtPabC, replaced by aspartate. 
 
4.4  PaPabC - Discussion 
 
A catalytic mechanism, based on previous studies of PLP-dependent enzymes, was 
proposed for PabC prior to any structural data being available (Green et al., 1992).  
Following structure determination of EcPabC, a model of substrate binding was 
prepared to inform an assessment of the mechanism (Nakai et al., 2000).  The 
contribution of PLP was considered the same, that is, following covalent linkage the 
enzyme-cofactor adduct undergoes a nucleophilic attack by the substrate amino group to 
produce an external aldimine.  PLP, which contains a conjugated electronic structure 
linked to the pyridine-ring nitrogen N1, acts as an electron sink; weaking the bond 
between the $-proton and C4 of the substrate (Figure 1.10).   The PLP-substrate species 
then undergoes $-proton elimination, to the &-amino group of a lysine to yield a 
quinonoid intermediate.  In EcPabC Lys159 forms the covalent link to the cofactor and 
is likely responsible for $-proton abstraction.  Nakai et al., further suggested that Thr28 
of EcPabC supplies a proton, converting the methylene group of the substrate to a 
methyl group as pyruvate is released.  PABA is released and the Schiff-base form of the 
enzyme is recovered as PLP reacts with Lys159 (Figure 4.5). 
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Figure 4.5  Proposed catalytic mechanism of PabC.  Curly arrows indicate the flow of 
electrons.  The amino group of the substrate, 4-amino-4-deoxychorismate, attacks the Schiff-base to form 
an external aldimine.  The displaced lysine is proposed to abstract the $-proton from the substrate at C4, 
producing a quinonoid intermediate.  Aromatisation of the substrate ring leads to the loss of pyruvate.  
Concomitant with the loss of pyruvate a suitably placed threonine is proposed to act as a proton donor to 
facilitate conversion of methylene to methyl.  Regeneration of the internal aldimine following 
nucleophilic attack of lysine displaces PABA (highlighted in a yellow box). 
(Mechanism described in Nakai et al., 2000) 
 
 Three residues described as contributing to the mechanism of action in EcPabC, 
Thr28, Lys97 and Lys159 (Nakai et al., 2000), are strictly conserved in PaPabC as 
Thr29, Lys80 and Lys140.  They are also conserved in LpPabC and TtPabC with the 
conservative change of Lys80 to arginine in the thermophilic orthologue (Figure 4.4).  
Lys140 of PaPabC is suitably placed to support $-proton abstraction and although 
Thr29 may engage in the proposed proton shuffling with both the olefin moiety of the 
substrate and Lys80, an alternative residue (Tyr90) might fulfil this role.  Tyr90 may 
have been overlooked because Nakai et al., had access to only a single structure of 
PabC.  Alignments based on sequences alone would not identify a tyrosine that is 
conserved in the three-dimensional structure. 
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 In EcPabC and PaPabC tyrosine hydroxyl groups (Tyr109 and Tyr92 
respectively), from the partner subunit, donate a hydrogen bond to PLP O3 (Figures 4.3, 
4.5) in an interaction that influences the electronic structure of the cofactor (Nakai et al., 
2000).  The sequence alignment of PabC orthologues suggests a degree of variation in 
the identity of the amino acid that occupies the position of this tyrosine (Figure 4.4).  In 
contrast, the structural overlays are striking since they clearly identify a spatially 
conserved tyrosine in relation to the cofactor (Figure 4.6).  In EcPabC and PaPabC, 
Tyr109 and Tyr92 respectively, are contributed from the partner subunit (position I).  
However, in LpPabC and TtPabC, Tyr144 and Tyr130 respectively, are contributed 
from the same subunit (position II). 
 
  a)    b)    c) 
Figure 4.6  Structural conservation of tyrosine in the PabC active site.  PLP is shown 
in the same manner as Figure 4.3.  a)  A structural overlay of PaPabC (green C atoms) and EcPabC (blue 
C atoms).  Here, Tyr92 and Tyr109, which represent position I, are contributed from the partner subunit.  
b)  LpPabC.  c)  TtPabC.  Thr27 displays two rotamers.  In the LpPabC and TtPabC structures, Tyr144 
and Tyr130 respectively represent position II and belong to the same subunit that forms the PLP-binding 
site. 
 A conservative group of 129 putative PabC sequences were retrieved from the 
UniProt database, aligned using MUSCLE (Edgar, 2004) and then inspected following 
pairwise alignment with PaPabC.  This was done to investigate the distribution of 
tyrosine at these two positions (I & II); seeking to address the hypothesis that if tyrosine 
is present at position I then it is likely absent from position II and vice versa.  This 
hypothesis holds true for 125 out of the 129 sequences.  Two sequences, which share 
less than 30% sequence identity, have a tyrosine at both positions.  Analyses of the 
sequences suggests that PabC can be classified into two groups depending on whether 
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this active site tyrosine is provided by the same subunit which primarily forms the 
active site or from a partner subunit. 
 The high degree of conservation of an active site tyrosine in three-dimensional 
structures of PabC suggests a functional role.  One possibility is that this residue could 
act as a proton donor for the conversion of methylene to methyl that completes the 
reaction.  Such a conversion would have little influence on the cleavage of the C-O 
bond of the substrate since the driving force for that reaction would be production of an 
aromatic six-carbon ring system.  A model of the catalytic intermediate (4-amino-4-
deoxychorismate linked to PLP, Figures 4.5, 4.7) was specifically prepared to 
investigate the potential role of this active site tyrosine and to re-evaluate the olefin 
conversion process that completes the reaction (calculations were performed by Dr. 
Thomas Eadsforth). 
 
 
Figure 4.7  A stereoview of the catalytic intermediate docked into the active site of 
PaPabC.  Protein components are coloured as in Figure 4.3.  The C atoms of the modelled intermediate 
(1) are in black.  Black dashed lines represent potential hydrogen bonding interactions, with a separation 
of 3.5 Å or less, and the red dashed line between Thr29 OG1 and the sp2 hybridised C indicates the 
proximity of functional groups likely involved in catalysis. 
 
 The model was prepared using the PRODRG server (Schüttelkopf & van Aalten, 
2004) and placed in the active site with COOT using the position of PLP as a guide. 
Docking in the active site was performed using ICM pro (MolSoft L.L.C.) with the 
centre of the ligand-binding site defined by a cavity that contained the residues within 5 
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Å of the ligand.  The top ten docking poses, as scored by ICM pro gave similar 
orientations in the active site and one was selected for display. 
 The model suggests that Tyr112 donates a hydrogen bond to the C1 carboxylate 
while, with contributions from the partner subunit, the main chain amide of Tyr92 and 
hydroxyl group of Tyr22 donate hydrogen bonds to the other carboxylate of the 
intermediate (Figure 4.7).  Tyr92 contributes to the positioning and electronic structure 
of the cofactor by virtue of the hydrogen bond involving the hydroxyl group with the 
PLP carbonyl (Figure 4.3).  For example, it has been suggested that a tyrosine at a 
similar position in the PLP-depedent enzyme aspartate aminotransferase affects the pKa 
of the Schiff base; and this has been investigated by generating Tyr-Phe mutants 
(Goldberg et al., 1991; Inoue et al., 1991).  The bulk of the tyrosine side chain serves to 
create a hydrophobic wall on one side of the active site.  Although placed to interact 
with the catalytic intermediate this residue does not appear to be involved in donating a 
proton to convert methylene to methyl (Figure 4.7).  Rather, Thr29, as first postulated 
by Nakai et al., appears to fulfil such a role with the hydroxyl group placed about 3.5 Å 
from the olefin (Figure 4.7).  Lys80 NZ is around 4.3 Å distant from the sp2 hybridised 
C and it is possible that an alternative rotamer could bring this functional group into 
proximity; providing a proton itself or activating the Thr29 hydroxyl for proton 
donation.  Thr29 is strictly conserved in 123 out of the 129 PabC sequences and 
conservatively substituted by serine in another five sequences. 
 To further investigate the structure-activity relationship of PabC, and to assess 
the potential of this enzyme as a target for structure-based drug discovery will require 
the powerful combination of steady-state kinetic analysis with site-directed mutagenesis 
studies, alongside screening of chemical libraries.  In particular, the construction of 
Tyr92-Phe, Thr29-Ala, Lys80-Met and Glu173-Gln mutants will permit assessment of 
the contribution of these residues to catalysis (Goldberg et al., 1991; Inoue et al., 1991).  
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Following production of the substrate from commercially available chorismate and 
glutamine by recombinant PabA-PabB, the kinetics of PabC can be assayed by 
determining the production of PABA upon addition of the enzyme.  This would involve 
taking aliquots at various time-points, incubating in 1 M HCl to inactivate the enzymes, 
and then quantifying PABA concentrations using HPLC (He et al., 2004; and references 
therein).  UV-visible spectroscopy could be performed in parallel to gain insight into the 
electronic structure of the PLP cofactor (Fasella, 1967).  Substrate-analogues containing 
Michael acceptors or halogens could also be considered during inhibitor design and 
testing, since these may potentially form covalent adducts with the cofactor (Eliot & 
Kirsch, 2004).  It will be imperative to extend from this work and to elucidate a means 
whereby structural data on enzyme-ligand complexes can be obtained. 
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PART TWO 
 
IMMUNITY PROTEINS IN THE GRAM-
NEGATIVE TYPE VI SECRETION SYSTEM 
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CHAPTER 5 
Rap1a and Rap2a - 
INTRODUCTION AND METHODS 
! ++!
Introduction 
 
Preamble:  Dr. Vincent Rao and Dr. Velupillai Srikannathasan performed the 
purification, crystallisation and X-ray data collection of Rap1a and Rap2a respectively.  
My contribution to this project involved the processing of datasets, determining the 
structures by molecular replacement and analysing the results.  This work, performed as 
part of a team, has been accepted for publication and this thesis draws on this source 
extensively.  The relevant publication is referred to throughout as (Srikannathasan et al., 
2013). 
 
 
5.1 Type VI secretion systems (T6SS) 
 
Specialised secretion systems are key to bacterial fitness, survival and pathogenesis.  
They contribute a myriad of roles in the processes that influence growth, colonisation, 
attack and defense as bacteria interact with each other and with eukaryotic organisms 
(Filloux, 2011; Gerlach & Hensel, 2007).  The recently identified Type VI secretion 
system  (T6SS), present in about 25% of Gram-negative bacteria for which genome 
sequences are available (Boyer et al., 2009; Pukatzki et al., 2006), can be used to target 
bacterial and eukaryotic cells, and is thus important for both inter-bacterial competition 
and pathogenesis (Burtnick et al., 2011; de Pace et al., 2010; Jani & Cotter, 2010).  
Anti-bacterial T6SSs mediate efficient killing of competitors by direct injection of 
toxic, antagonistic effector proteins into target cells (Hood et al., 2010; MacIntyre et al., 
2010; Murdoch et al., 2011; Schwarz et al., 2010). 
 T6SS gene clusters encode the core components of a secretion machine capable 
of membrane perforation (Table 5.1).  This is a multi-protein needle-like assembly 
(Figure 5.1) -resembling the contractile tail of a bacteriophage - that delivers effectors 
across three envelope layers in a single step (Basler et al., 2012; Bönemann et al., 2010; 
Cascales & Cambillau, 2012; Silverman et al., 2012).  The clusters also encode 
accessory and post-translational regulatory components.  Some T6SS-secreted effector 
proteins are also encoded within these large gene clusters.  In the case of anti-bacterial 
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T6SSs, effectors are always encoded adjacent to specific, cognate immunity proteins.  
Immunity proteins bear appropriate signals to direct their localisation to the 
compartment in which the toxic effectors act; for example, a Sec-signal sequence guides 
localisation to the periplasm.  The provision of a cognate immunity protein provides 
protection against attack from sister cells (Coulthurst, 2013). 
 
 
Figure 5.1  Schematic model of the Type VI secretion apparatus.  The components of 
the T6SS assemble to form a cell-puncturing needle that resembles an inverted bacteriophage tail.  Hcp 
protein forms a membrane-spanning tube with an internal diameter of ~40 Å (Mougous et al., 2006), and 
VgrG protein punctures membranes of target cells.  Inner and outer membranes are shown as green 
rectangles, and a grey palisade represents the peptidoglycan layer.  Certain immunity proteins such as 
Rap, shown as a light pink disk, localise to the periplasm via the Sec transporter, coloured cyan.  Effector 
proteins of the T6SS (T6 effectors, red disk), such as the peptidoglycan amidase Ssp1 are thought to be 
secreted into target cells by transit through the Hcp tube. 
 
 Different catalytic activities are associated with T6SS effectors.  These include 
actin cross-linking and ADP-ribosylation that disrupt the cytoskeleton of mammalian 
and amoebal cells (Pukatzki et al., 2007; Rosales-Reyes et al., 2012; Suarez et al., 
2010), and phospholipases that degrade phosphatidylethanolamine, the major 
component of the bacterial membrane (Russell et al., 2013).  The best-characterised 
effectors are peptidoglycan hydrolases, which exhibit potent anti-bacterial activity 
(Russell et al., 2012; Russell et al., 2011).  These enzymes degrade peptidoglycan, the 
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heteropolymer that occupies the periplasmic space imparting mechanical strength to the 
cell wall and helping to maintain the shape of Gram-negative bacteria. 
 
Table 5.1  Components of the T6SS apparatus  
(Cascales and Cambillau, 2012; and references therein) 
 
 
 
 
 
 
 
 
 
 Peptidoglycan hydrolases constitute a large enzyme family, which displays a 
rich diversity in terms of structure, mechanism and specificity (Vollmer et al., 2008).  
There are enzymes specific for every glycosidic and amide bond in peptidoglycan.  
Such diversity is exploited to regulate bacterial cell growth, division and daughter cell 
separation, and of particular interest here, to provide bactericidal properties that can be 
exploited in niche competition.  Several classes of peptidoglycan hydrolase have been 
identified as T6SS effector proteins.  These are termed Tse proteins.  Tse3 of P. 
aeruginosa is a muramidase, cleaving the glycan backbone (Russell et al., 2011), and 
the C-terminal domain of Vibrio cholerae VgrG-3, a component at the tip of the 
secretion apparatus (Figure 5.1), is suggested to have lysozyme-like muramidase 
activity (Brooks et al., 2013).  A diverse group of T6SS-secreted peptidoglycan 
amidases, which cleave the peptide cross-links, has been described (Russell et al., 
2012).  Within this superfamily, four distantly-related families with distinct cleavage 
specificities were defined.  Family 1 (‘Tae1’), which includes Tse1 of P. aeruginosa, 
Components 
of the T6SS 
Localisation of component Homologous proteins 
TssA cytosol (putative) n/a 
TssB associates with outer membrane bacteriophage sheath 
TssC associates with outer membrane bacteriophage sheath 
TssD/Hcp forms a hexameric ring, secretion 
tube 
bacteriophage tail gp19 
TssE not known bacteriophage wedge gp25 
TssF not known n/a 
TssG not known n/a 
TssH/ClpV cytosol, AAA+ ATPase Hsp100/Clp AAA+ ATPase 
TssI/VgrG forms trimers, cell puncturing device bacteriophage tail spike gp27-
gp5 
TssJ/SciN outer membrane lipoprotein transthyretin 
TssK cytosol (putative) n/a 
TssL inner membrane T4bSS IcmH/DotU protein 
TssM inner membrane T4bSS IcmF protein 
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hydrolyse peptide crosslinks at the *-D-glutamyl-meso-diaminopimelate DL-bond; 
representatives of Families 2 and 3 (‘Tae2’ and ‘Tae3’) hydrolyse DD-crosslinks 
between D-mA2pm (meso-diaminopimelate) and D-alanine, and a representative of 
Family 4, Tae4 from Salmonella enterica serovar Typhimurium, also hydrolyses the *-
D-glutamyl- mA2pm DL-bond.  Structures of Tse1 from P. aeruginosa, and Tae4 from 
S. Typhimurium and Enterobacter cloacae (Benz et al., 2012; Chou et al., 2012; Ding 
et al., 2012; Zhang et al., 2013) place these T6-secreted effectors in the NlpC/P60 
family of endopeptidases, amidases and acyltransferases; named after the New 
lipoprotein C from Escherichia coli and a 60 kDa extracellular protein from Listeria 
monocytogenes (Anantharaman & Aravind, 2003).  The opportunistic pathogen Serratia 
marcescens has recently been shown to utilise T6-dependent secretion of two Family 4 
amidases, Ssp1 and Ssp2, to mediate anti-bacterial activity (English et al., 2012). 
 
 
 a)    b) 
 
Figure 5.2  The T6SS delivers toxic effectors to target cells.  A schematic close-up is 
depicted of two adjacent bacteria during an attack by one (dark green) using the T6SS.  a) T6 effectors 
are translocated from the attacking bacterium into a susceptible target cell, inflicting damage in the 
periplasmic space or in the cytoplasm.  b)  A resistant cell, such as a sibling of the attacking strain, 
neutralises T6 effectors through the action of specific immunity proteins.  In the example shown, the 
peptidoglycan amidase 'Tse1' is bound and inhibited by the immunity protein 'Tsi1' (crystal structures 
inset; Ding et al., 2012).  This figure has been adapted with permission from Coulthurst, 2013. 
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Table 5.2  List of key details for the proteins reported in this thesis (Part 2) 
 Rap1a Rap2a 
Source organism Serratia marcescens, strain Db10 
Number of residues! 101 (mature protein)! 100 (mature protein)!
Signal sequence omitted! Yes; 26 residues at N-terminus! Yes; 24 residues at N-terminus!
Molecular mass (Da) 11486.0  11106.4 
Theoretical isoelectric point 6.2 5.1 
PDB codes 3ZFI  (1.98 Å resolution) 3ZIB  (1.90 Å resolution) 
Position of disulfide bonds Cys78-Cys122 Cys42-Cys102 
 
 
 Bacteria that secrete potent peptidoglycan hydrolase effectors, using the T6SS to 
attack competitors, could generate a deleterious effect on their own population.  To cope 
with this potential for 'friendly fire' damage, such bacteria also possess cognate 
immunity or resistance proteins located in the periplasm (Figure 5.2).  These immunity 
proteins bind their cognate effectors with low nanomolar affinity to neutralise them in a 
highly specific manner, (English et al., 2012).  Four distinct families of putative 
immunity proteins are associated with four Tae amidase families (Tai1-Tai4; Russell et 
al., 2012).  In S. marcescens, the resistance associated proteins, Rap1a and Rap2a, 
neutralise Ssp1 and Ssp2, respectively (English et al., 2012).  The crystal structures of 
Rap1a and Rap2a are reported in this thesis (Table 5.2).  Rap1a and Rap2a have only 
marginal sequence identity and are scarcely alignable.  Additionally two other Rap 
proteins, Rap1b and Rap2b are, together with Ssp1 and Ssp2, encoded in the same locus 
within the T6SS gene cluster.  Structures of Rap1b and Rap2b have revealed a novel $-
helix fold and dimeric assembly (English et al., 2012), which was later observed in the 
Tai4 protein from E. cloacae (EcTai4) and S. Typhimurium (STTai4, Zhang et al., 
2013).  This fold is a template for some T6SS immunity proteins, called Tsi proteins, 
but not all.  For example, analysis of the Tse1-Tsi1 effector-immunity protein 
combination found in P. aeruginosa revealed Tsi1 as an all-# protein (Benz et al., 2012; 
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Ding et al., 2012; Shang et al., 2012), whereas Tsi2 in the same organism, the immunity 
protein associated with the cytoplasmic effector Tse2, has a helical fold distinct again 
(Li et al., 2012).  That effector immunity defense systems based on distinct folds have 
evolved is perhaps to be expected, given the strong evolutionary pressure applied by 
multifarious secreted effectors.  Indeed such pressure may even have contributed to the 
acquisition of effector-immunity pairs encoded outside of T6SS operons - for example 
all three Tse/Tsi pairs of P. aeruginosa. 
 
 
5.2  Aims - Part two 
 
Structures of Rap1a and Rap2a from S. marcescens were sought to gain insight into 
their fold and function, and to allow comparison with immunity proteins of known 
structure. 
! ,'!
 
Methods 
 
5.3  Rap1a and Rap2a - Crystallisation, molecular replacement and 
analysis 
 
Rap1a was dialysed against 150 mM sodium chloride, 25 mM Tris-HCl, pH 7.5, prior to 
crystallisation trials.  The sitting drop vapor diffusion method was used with 0.2 µL 
drops in a 1:1 ratio of protein at 9 mg mL-1 with reservoir at 20 °C.  A slender 
orthorhombic crystal of Rap1a, approximate dimensions 150 x 35 x 35 µm, grew within 
one month using a reservoir of 25% PEG 3350 and 100 mM Bis-Tris, pH 5.5.  
Monoclinic blocks of Rap2a were grown by combining protein at a concentration of 
13.5 mg mL-1 in 100 mM sodium phosphate, pH 6.4, with a reservoir of 25% PEG 1000 
and 0.1 M MES, pH 6.5.  These crystals attained a maximum dimension of 200 µm 
within five days.  Crystals were soaked briefly in mother liquor adjusted to contain 20 
% (v/v) glycerol as a cryo-protectant prior to being flash-cooled in liquid nitrogen then 
used for diffraction experiments. 
 Datasets for Rap1a and Rap2a were collected at Diamond Light Source, indexed 
and integrated in iMOSFLM (Battye et al., 2011) and scaled with SCALA (Evans, 2006).  
The structures were solved by molecular replacement in PHASER (McCoy et al., 2007).  
The starting model for Rap1a was taken from the structure of an Ssp1-Rap1a complex 
that had been solved by Dr. Velupillai Srikannathasan (PDB code: 4BI8; 
Srikannathasan et al., 2013); while that for Rap2a was a poly-alanine model prepared 
from the structure of the related Rap protein, Rap2b (PDB code: 4B6I; English et al., 
2012).  All non-protein atoms were removed from the models and initial B-factors were 
adjusted to match the Wilson B-values obtained during scaling.  Following successful 
molecular replacement the models were subject to several rounds of rigid-body 
refinement followed by real-space refinement in REFMAC5 (Murshudov et al., 2011), 
! ,(!
interspersed with inspection of the electron density maps and model improvement in 
COOT (Emsley et al., 2010).  Strict NCS restraints and van der Waals contact distance 
restraints were applied from the start of refinement.  NCS restraints were dropped at a 
late stage in the refinement following addition of water molecules to the models.  Side 
chains with more than one conformation visible in the density maps were modelled as 
rotamers with partial occupancies.  Model quality was validated using the MolProbity 
server (Chen et al., 2010) and the validation tools found in COOT.  Coordinates and 
structure factors for Rap1a and Rap2a have been deposited with the PDB, under codes 
3ZFI and 3ZIB respectively. 
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CHAPTER 6 
Rap1a and Rap2a –  
RESULTS AND DISCUSSION 
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6.1  Structure of Rap1a 
 
The structure of Rap1a was determined to 1.98 Å resolution and the amino acid 
sequence and assigned secondary structure is depicted in Figure 6.1.  Crystallographic 
statistics are presented in Table 6.1. 
!
Figure 6.1  Overall structure of Rap1a.  a)  The sequence of mature Rap1a.  The 26-residue N-
terminal signal sequence is not shown.  The assigned !-helical secondary structure is shown and 
numbered.  Residues involved in disulfide bond formation are coloured in yellow and those that 
contribute to the dimer interface are encased in blue. b)  Cartoon representation of the Rap1a dimer with 
labelled helices, Nt and Ct mark the N and C-terminal positions.  The disulfides formed between Cys78 
and Cys122 are shown as yellow sticks.  c) Residues and hydrogen bonds (dashed lines) at the dimer 
interface.  C atoms are grey and cyan to distinguish the subunits. 
 
 
 The Rap1a subunit displays a compact globular structure constructed from five 
$-helices that assemble to form the highly stable, symmetric dimer that constitutes the 
asymmetric unit (Figure 6.1).  This is consistent with the size-exclusion 
chromatography data, which identified that only a dimer was observed in solution (not 
shown).  The NCS is highly conserved with an RMSD for a least squares overlay of 96 
C$ positions of 0.6 Å.  A disulfide bond is formed between Cys78 on the $2-$3 loop 
and Cys122 at the C-terminal region.  This interaction appears crucial to stabilising the 
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subunit fold since it helps position $2, $3 and $5 close to each other and these segments 
of secondary structure provide the side chains that form the hydrophobic core of the 
subunit.  During initial recombinant expression tests it was noted that soluble protein 
was produced only in E. coli Rosetta-gami (DE3) cells; a strain that promotes the 
formation of disulfide bonds in the cytoplasm and so mimics what might occur in the 
oxidative environment of the periplasm.  This suggests the covalent bond is necessary 
for correct folding to occur, and for stability of the Rap1a fold and dimeric quaternary 
structure. 
 
Table 6.1  Crystallographic statistics for Rap1a and Rap2a 
 
Structure / PDB code Rap1a / 3ZFI Rap2a / 3ZIB 
Space group C2221 P21 
Unit cell dimensions 
a, b, c (Å) 
 
82.7, 93.0, 51.3 
 
39.7, 81.4, 58.5 
         # 91.5° 
Resolution range (Å) 46.50-1.98 (2.09-1.98) 40.67-1.90 (2.00-1.90) 
No. reflections 63106 (8849) 214423 (31351) 
Unique reflections 14089 (2003) 29067 (4190) 
Completeness (%) 99.9 (100.0) 99.4 (98.9) 
Rmerge 6.6 (48.6) 9.7 (51.6) 
Multiplicity 4.5 (4.4) 7.4 (7.5) 
< I/#(I)> 13.4 (2.7) 15.3 (4.0) 
Wilson B (Å2) 31.5 21.7 
Rwork/Rfree 19.2, 23.4 18.3, 23.4 
Number of residues / waters 185, 57 377, 137 
RMSD bond lengths (Å) /  
bond angles (º) 
0.018 
1.925 
0.019 
1.745 
Mean B-factors (Å2) 
Main chain, side chain 
 
 
 
Waters 
 
Chain A 34.3, 40.9 
Chain B 35.2, 40.0 
 
 
38.4 
 
Chain A 19.7, 23.7 
Chain B 23.0, 28.3 
Chain C 22.4, 27.5 
Chain D 18.9, 24.0 
30.6 
Ramachandran plot 
Favoured regions (%) 
Allowed regions (%) 
Outliers 
 
97.0 
3.0 
No outliers 
 
99.0 
1.0 
No outliers 
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Interactions involving residues on $2 make the major contribution to dimer 
formation.  Each subunit contributes a surface area of 1130 Å2 to the dimer interface, 
which is 20 % of the solvent accessible surface area (ASA, 5700 Å2) of a subunit.  Such 
a percentage of surface area is indicative of a stable association.  Nine residues from 
each subunit form a network of hydrogen bonds using both main chain and side chain 
functional groups (Ser36, Asn40, Leu41, Glu59, Tyr64, Asp70, Lys75, Arg107 and 
Glu113; Figure 6.1).  There are also indirect hydrogen bonding interactions via well-
ordered water molecules that link a number of side chains and main chains (not shown).  
Hydrophobic interactions that contribute to the stability of the dimer mainly involve the 
aliphatic side chains of Val39, Ile63, Leu66, Val68 and Ala71 but also Tyr80 (not 
shown). 
 Overlays were attempted with the structures of known immunity proteins, 
including Rap2a (Section 6.2), Rap1b, Rap2b from S. marcescens (English et al., 2012), 
and the Tai4 proteins (Zhang et al., 2013), however these proteins were all dissimilar 
from Rap1a.  Thus Rap1a adopts a unique fold for an immunity protein.  A search using 
the DALI server identified two proteins, YmgD and HdeA from E. coli, with some 
degree of structural similarity to Rap1a.  Both are acidic, !-helical periplasmic proteins, 
and overlays in COOT and PyMOL show that almost all secondary structural elements 
match.  YmgD and HdeA contain 89 and 90 amino acids respectively, discounting 
residues in periplasmic localisation sequences - for comparison, mature Rap1a contains 
101 residues. 
 YmgD (UniProt: P0AB46) shares 13% sequence identity with Rap1a and is a 
functionally uncharacterised homodimeric protein that becomes up regulated in 
response to alkaline-stress (pH > 8.0, Maurer et al., 2005).  The structure has been 
determined by NMR (PDB codes: 2LRV and 2LRM, Wang et al., unpublished) and 
aligns 81 C! positions to Rap1a with an RMSD of 3.4 Å (Figure 6.2). 
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 a)         b) 
 
Figure 6.2  Superimposition of YmgD and HdeA on Rap1a.  a)  Superimposition of 
YmgD on Rap1a.  Rap1a is coloured cyan and YmgD is coloured magenta.  b)  Superimposition of HdeA 
on Rap1a.  HdeA is coloured orange.  Disulfides are displayed as sticks in yellow, protein backbones are 
displayed as C! traces. 
 
 HdeA (UniProt: P0AES9), which has marginal sequence identity with Rap1a 
(~5%), is a periplasmic acid-stress chaperone.  HdeA forms a well-ordered, inactive 
homodimer at neutral pH, but under acidic conditions (pH < 3) it dissociates into 
partially unfolded monomers and binds to other periplasmic proteins; acting as a 
chaperone that prevents aggregation (Foit et al., 2013; Hong et al., 2005).  The crystal 
structure has been determined by two different groups (PDB codes: 1DJ8, Gajiwala & 
Burley, 2000; and 1BG8, Yang et al., 1998) and aligns 72 C! positions with Rap1a, 
with an RMSD of 2.9 Å (Figure 6.2).  Disulfide bonds are present at a similar position 
in both YmgD (Cys36-87) and HdeA (Cys39-87), but different from that in Rap1a 
(Cys78-122).  Such similarity between Rap1a and these periplasmic chaperones 
suggests the possibility of an evolutionary link from a common ancestor. 
 In the structure of the Ssp1-Rap1a complex (Srikannathasan et al., 2013) there 
are two molecules in the asymmetric unit, one Ssp1 and one Rap1a, and a 
crystallographic two-fold axis generates a heterotetramer (Figure 6.3).  The overall 
! -.!
dimensions of this assembly are approximately 90 x 50 x 50 Å.  The solvent accessible 
surface area of Ssp1 is 5840 Å2, and about 16% of this is occluded when the complex 
with Rap1a is formed (Srikannathasan et al., 2013). 
 
 
 
Figure 6.3  The heterotetrameric Ssp1-Rap1a complex.  Ssp1 is shown as van der Waals 
surface in orange, and the Rap1a subunits as grey and cyan ribbons.  A dashed line running through the 
centre of the figure indicates the position of the crystallographic axis of symmetry.  Disulfide bonds in 
Rap1a are displayed as yellows sticks.  An arrow indicates the location of the active site in Ssp1 subunit 
1.  Rap1a sterically blocks the Ssp1 active site; Rap1a $3 is highlighted.  This figure has been adapted 
from Srikannathasan et al., 2013. 
 
 Both !3 and the !3-!4 loop of Rap1a are directly positioned to block the Ssp1 
active site (Figure 6.3).  Gln84 of Rap1a forms a hydrogen bond with N0 of the catalytic 
Ssp1 His133 and is a clear marker of the steric block provided by the immunity protein.  
An overlay (not shown) of the two Rap1a structures, alone and in complex with Ssp1, 
gives an RMSD of 0.4 Å for 94 C! atoms indicating that the overall structure is highly 
similar with no major conformational differences.  Therefore, Rap1a is a pre-formed 
binding partner for Ssp1 under the right redox state.  However, there is a localised effect 
following complex formation.  In Rap1a, the segment linking !2 and !3, residues 74 to 
84 shows high average B-factors, 76.4 Å2, compared to the overall average B-factor, 
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31.5 Å2, and relatively diffuse electron density.  This region contributes to Ssp1-Rap1a 
complex formation and becomes well ordered with an average B-factor of 15.6 Å2 
compared to the overall B-factor of 22.6 Å2 for the Rap1a component of the complex 
(Srikannathasan et al., 2013). 
 
 
6.2  Structure of Rap2a 
 
Rap2a, like Rap1a, is predicted to be localised in the periplasm and could only be 
produced in soluble recombinant form using the E. coli Rosetta-gami (DE3) strain.  It is 
also a stable dimer in solution as shown by size-exclusion chromatography (English et 
al., 2012).  The structure was determined at 1.9 Å resolution with four molecules in the 
asymmetric unit arranged as two dimers (Table 6.1).  These four molecules, subunits 
A:B and C:D, are similar overall with RMSD values between superimposed C$ atoms 
ranging from 0.6 Å - 0.7 Å.  Minor deviations from NCS are present in a five-residue 
loop between $2 and $3, Gly67-Leu71, and indicate some conformational freedom in 
that part of the molecule.  The ASA of a Rap2a subunit averages out at approximately 
6110 Å2.  Each dimer covers an area that is approximately 20 % of the ASA. 
The Rap2a subunit displays a compact globular structure of five $-helices with 
an extended loop linking $3 to $4 (Figure 6.4).  A disulfide bond between Cys42 and 
Cys102 links $1 with $4 and interactions from these elements of secondary structure 
help to create the helical bundle fold and in particular to align $2.  Together $1, $2, the 
$2-$3 loop and $4 form the dimer interface, giving rise to a two-fold NCS axis, and 
here a combination of hydrogen bonding, salt bridge and van der Waals interactions 
serve to stabilise the association (not shown).  Main chain hydrogen-bonding 
contributions come from the amides of Ser48, Ala49, Met97, Thr98 and Met99 on both 
chains.  Side chain contributions come from the hydroxyl groups of Tyr28 and Tyr47, 
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and carboxylates of Glu51, Asp55 and Asp104.  There are in addition several solvent 
mediated contacts that serve to link functional groups on partner subunits (not shown).  
The side chains of Leu39, Ile43, Tyr47, Val52, Met99 and Ile103 are involved in van 
der Waals interactions with the partner subunit to stabilise the dimer. 
 
 
 
Figure 6.4  Overall structure of Rap2a. a) The amino acid sequence with assigned secondary 
structure and helices numbered.  Residues involved in disulfide bond formation are coloured in yellow 
and residues involved in subunit-subunit interactions are encased in blue.  b) Cartoon representation of 
the Rap1a dimer with subunits coloured brown and green.  The disulfides, N and C termini are labelled.  
c) Cartoon representation of Rap2b (magenta; English et al., 2012) and EcTai4 (grey; Zhang et al., 2013) 
superimposed on Rap2a (green).  Selected residues are displayed as sticks.  In EcTai4, Asp54 and Asp47 
contribute to the hydrogen-bonding network at the dimer interface and are absolutely conserved in Rap2b, 
while in Rap2a Asp47 is replaced by Ser48.  EcTai4 Arg40 and Glu74, conserved in Rap2b, have a major 
role in binding with the T6 effector EcTae4 (Zhang et al., 2013) - these residues are replaced by Val41 
and Thr75 in Rap2a. 
 
 Despite a low level of sequence conservation, the structural similarities of five 
T6SS immunity proteins (Rap1b, Rap2a, Rap2b, EcTai4 and STTai4) indicate an 
orthologous sub-set.  This structurally defined set is consistent with the designation of a 
‘Tai4’ family of immunity proteins cognate to Tae4 effectors (Russell et al., 2012).  
Pairwise comparisons indicate a range of sequence identities from 18 to 38%, and 
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matching between 90 and 92 C$ positions gives an RMSD range of 1.2 to 1.7 Å, 
indicative of a close structural similarity (Table 6.2).  Such similarity is exemplified by 
superimposition of Rap2a, Rap2b and EcTai4 (Figure 6.4).  Strikingly, the extended or 
protruding loop structure is structurally conserved between these species, despite high 
variability in the amino acid sequence (English et al., 2012; Zhang et al., 2013).  Parts 
of the EcTai4 subunit involved in interaction with an effector, identified by Val41 and 
Thr75 of Rap2a, are also well conserved in terms of three-dimensional structure (Figure 
6.4). 
 
Table 6.2  Structural similarity of Rap2a to known Tai4-family proteins. 
Structure  
(PDB code) 
STTai4 (4HFF) Rap2b (4B6I) EcTai4 (4HFK) Rap1b (4AX2) 
% sequence 
identity to Rap2a 
38 23 18 21 
No. C$ /  
RMSD (Å) 
92 
1.3 
92 
1.2 
90 
1.6 
91 
1.7 
 
 This sub-set of immunity proteins also displays similar dimer structures and the 
Cys42 - Cys102 disulfide bond in Rap2a is conserved in the other two S. marcescens 
proteins, Rap1b and Rab2b, highlighting the importance of this covalent interaction to 
the creation of the subunit fold and stable quaternary structure.  In the structure of 
EcTai4 and STTai4 there are conserved cysteines that match to the disulfide forming 
residues in the Rap proteins however they are in a reduced form.  In STTai4 for example 
the Cys48 SG Cys108 SG distance is 3.6 Å and the electron density unambiguously 
defines reduced cysteine residues.  This difference in the redox states may simply 
reflect distinct experimental conditions. 
! -(!
 
6.3  Structural basis of immunity to T6 effectors - Conclusions 
 
Rap2a has a similar fold to that seen previously for the Tai4 family of immunity 
proteins including Rap1b, Rap2b, EcTai4 and STTai4.  In contrast, Rap1a adopts a 
novel fold for an immunity protein.  These two structurally distinct families of Tai4 
immunity proteins are built upon similar underlying principles; namely stable, dimeric 
small !-helical bundles. S. marcescens Rap1a and Rap2a appear to rely on the 
formation of disulfide linkages for folding and activity.  Intriguingly, the unexpected 
structural similarity of Rap1a to the periplasmic chaperones HdeA and YmgD permits 
speculation that these proteins share a common evolutionary ancestor. 
 The Type VI associated endopeptidase effectors are highly basic proteins as 
exemplified by Ssp1 and Ssp2, with predicted pI values of 9.1 and 9.3 respectively.  
The immunity proteins are acidic; the pI values for the four Rap proteins fall in the 
range 5.1 to 6.3 after omitting the signal peptides.  Such complementarity of charge 
contributes to the high affinity interactions that support complex formation, despite 
distinctive structures and variation in sequence, and may generate long-range 
electrostatic attraction to assist correct binding. !
! -)!
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Lyase: Spatial Conservation of an Active Site Tyrosine
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Abstract
4-Amino-4-deoxychorismate lyase (PabC) catalyzes the formation of 4-aminobenzoate, and release of pyruvate, during
folate biosynthesis. This is an essential activity for the growth of Gram-negative bacteria, including important pathogens
such as Pseudomonas aeruginosa. A high-resolution (1.75 A˚) crystal structure of PabC from P. aeruginosa has been
determined, and sequence-structure comparisons with orthologous structures are reported. Residues around the pyridoxal
59-phosphate cofactor are highly conserved adding support to aspects of a mechanism generic for enzymes carrying that
cofactor. However, we suggest that PabC can be classified into two groups depending upon whether an active site and
structurally conserved tyrosine is provided from the polypeptide that mainly forms an active site or from the partner subunit
in the dimeric assembly. We considered that the conserved tyrosine might indicate a direct role in catalysis: that of
providing a proton to reduce the olefin moiety of substrate as pyruvate is released. A threonine had previously been
suggested to fulfill such a role prior to our observation of the structurally conserved tyrosine. We have been unable to
elucidate an experimentally determined structure of PabC in complex with ligands to inform on mechanism and substrate
specificity. Therefore we constructed a computational model of the catalytic intermediate docked into the enzyme active
site. The model suggests that the conserved tyrosine helps to create a hydrophobic wall on one side of the active site that
provides important interactions to bind the catalytic intermediate. However, this residue does not appear to participate in
interactions with the C atom that undergoes an sp2 to sp3 conversion as pyruvate is produced. The model and our
comparisons rather support the hypothesis that an active site threonine hydroxyl contributes a proton used in the reduction
of the substrate methylene to pyruvate methyl in the final stage of the mechanism.
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Introduction
Aminodeoxychorismate lyase catalyzes the formation of para-
aminobenzoate (PABA) from 4-amino-4-deoxychorismate (Figure 1)
as part of the biosynthetic route to folate [1][2]. The enzyme,
encoded by the pabC gene, is labeled as PabC.
In Escherichia coli and many other bacteria, PABA is synthesized
in two steps starting from chorismate [3]. The first step produces
4-amino-4-deoxychorismate [4] by transferring ammonia, derived
from glutamine, to chorismate. This reaction is performed by
PABA synthase, a heterodimer of proteins encoded by the pabA
and pabB genes [5]. 4-amino-4-deoxychorismate is then converted
to PABA with the loss of pyruvic acid (Figure 1). The pyridoxyl 59-
phosphate (PLP) - dependent PabC catalyzes this second step
[2][3][6][7]. In the Gram-positive Bacillus subtilis a third chemical
step is required for PABA biosynthesis. Chorismate is first
converted to 2-amino-2-deoxyisochorismate before production of
4-amino-4-deoxychorismate, which is then converted to PABA
and pyruvate by PabC [8].
PABA is required for the biosynthesis of folic acid and by
extension also of essential metabolites such as thymidylate and
methionine. In addition, PABA is required for biosynthesis of
antibiotics such as candicidin [9] and certain Streptomycetes even
possess additional copies of pabC, located in antibiotic production
operons [10].
The inhibition of PabC would reduce PABA levels and so
deplete the supply of folic acid available to the microorganism.
Provided that the microbe cannot obtain sufficient PABA from the
cellular environment or by other means these cells would be
expected to cease growth and die. This is what is observed in pabC
knockouts in E. coli [7], Pseudomonas aeruginosa [11], Helicobacter pylori
[12] and Acinetobacter baylyi [13]. A few anti-microbial agents exert
their effect through inhibition of folate biosynthesis. Sulphon-
amides for example deplete bacterial intracelluar folate levels by
inhibiting PABA synthase and dihydropteroate synthetase [14].
Combining novel PabC inhibitors with sulphonamides or with
other anti-folates such as the dihydrofolate reductase inhibitor
trimethoprim, could produce a synergistic anti-microbial effect
and new inhibitors of PabC would allow such a hypothesis to be
tested.
X-ray crystal structures of PabC from E. coli [15], Thermus
thermophilus [16] and Legionella pneumophila [Protein Data Bank
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24158
(PDB) code 3lul] have been determined. PabC displays a similar
overall fold to branched-chain amino acid transferases and D-
amino acid transferases [15][17][18]. These aminotransferases
have been investigated to identify potential inhibitors for example
in support of research for treatments of neurodegenerative disease
[19][20][21][22]. Moreover, since PLP-dependent enzymes pro-
vide opportunities for the design of mechanism-based suicide
inhibitors [17] this enzyme family appears an attractive one from
the perspective of structure and mechanism-based drug discovery.
The absence of the enzyme in humans and its essentiality in
various microbes suggests that inhibition of PabC offers the
possibility of new therapies targeting a range of microbial
infections and structural studies provide useful data to assess the
potential of this protein for such early stage drug discovery [23].
We have a particular interest in pathogens for which current
treatments are unsatisfactory, for example Gram-negative bacteria
such as P. aeruginosa, that are highly adaptable to their environment
and which possess efficient and varied drug-resistance mecha-
nisms. P. aeruginosa is often the cause of life-threatening infections
in people with cystic fibrosis, burns victims and immuno-
compromised individuals [24][25]. We describe the construction
of an efficient bacterial recombinant expression system, enzyme
purification and crystallization protocols, and report the high-
resolution crystal structure of PabC from P. aeruginosa (PaPabC).
Comparisons with previously determined PabC structures are
presented, concentrating on active site cofactor interactions. Our
structure-based comparisons identified the potential for a tyrosine
to participate in catalysis and suggested that a re-evaluation of a
published mechanism is warranted.
Materials and Methods
Cloning, protein purification and analytical
ultracentrifugation
The P. aeruginosa pabC gene (locus tag: PA2964) was amplified
from genomic DNA (American Type Culture Collection 47085,
strain PAO1) by PCR using the following primers:
PaPabC forward primer
59-CAT ATG CTG GAC TGG GTC GAC-39 (NdeI restriction
site in bold)
PaPabC reverse primer:
59-GGA TCC TCA GAA ATC CAG GTC G-39 (BamHI
restriction site in bold)
The PCR product was blunt-end ligated into a TOPO cloning
vector (Invitrogen) then ligated into a modified pET15b expression
vector (Novagen) that produces a hexahistidine-tag linked via a
tobacco-etch virus (TEV) protease cleavage site. The resulting
plasmid was heat-shock transformed into E. coli BL-21 (DE-3)
GOLD cells (Novagen). Cultures were grown at 37uC in 2 L of
Luria-Bertani medium supplemented with 100 mg mL21 carben-
icillin. Gene expression was induced, when the OD600 reached
0.6, by addition of 1 mM IPTG and growth continued for a
further 16 hours at 18uC. Cells were harvested by centrifugation
(30006 g at 4uC for 30 minutes), resuspended in 50 mM Tris-
HCl, 200 mM NaCl, pH 7.5, and lysed by passage through a
French pressure cell. Cell lysate was clarified by ultracentrifugation
(400006 g at 4(C for 30(minutes) and the supernatant was passed
through a 0.2 mm filter.
The lysate was loaded onto an immobilised metal ion affinity
chromatography column (5 mL HisTrap HP, GE Healthcare) with
the assistance of an FPLC system (A¨kta Explorer, GE Healthcare).
The hexahistidine-tagged protein was eluted from the column by a
linear concentration gradient of imidazole and fractions were
analysed by SDS-PAGE. Selected fractions were pooled and
dialysed into 100 mM HEPES, 500 mM NaCl pH 7.5. Attempts
to cleave the hexa-histidine tag by addition of TEV protease had
produced large amounts of precipitate so it was decided to leave
the purification tag in place. The protein was further purified by
size exclusion gel chromatography (Superdex 200 26/60, GE
Healthcare). This column had previously been calibrated with
molecular weight standards, blue dextran (.2,000 kDa), thyro-
globulin (669 kDa), ferritin (440 kDa), aldolase (158 kDa),
conalbumin (75 kDa), ovalbumin (43 kDa), carbonic anhydrase
(29.5 kDa), ribonuclease A (13.7 kDa) and aprotinin (6.5 kDa);
(GE Healthcare; data not shown). Protein purity was assessed by
SDS-PAGE, matrix assisted laser desorption/ionisation – time of
flight mass spectrometry (MALDI-TOF MS) and electrospray
ionisation mass spectrometry.
The protein concentration was determined spectrophotometri-
cally using a theoretical extinction coefficient of 33,460 M21 cm21
(ProtParam, [26]).
Crystallization, X-ray data collection, structure solution
and refinement
PaPabC was crystallized at 20uC by the hanging drop vapour
diffusion method. The enzyme was concentrated to 33 mg mL21
in 100 mM HEPES, 500 mM NaCl pH 7.5. Stock solutions of
PLP (100 mM in DMSO) and PABA (200 mM in deionized
water) were prepared and added to the PabC solution to give final
concentrations of 0.1 mM PLP and 10 mM PABA. The mixture
was left to incubate for 3 hrs then crystallization drops were
assembled by mixing 1 mL of the protein:ligand mixture with 1 mL
of reservoir containing 10% (w/v) PEG 400, 1.8 M ammonium
sulfate and 100 mM MES pH 6.5. Clumps of pale yellow,
Figure 1. PabC catalyzes the conversion of 4-amino-4-deoxychorismate to 4-aminobenzoate and pyruvate.
doi:10.1371/journal.pone.0024158.g001
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orthorhombic blocks grew over one week and a fragment of
approximate dimensions 0.3 mm60.2 mm60.1 mm was used for
data collection. Addition of cryoprotectant (25% v/v glycerol) was
required to allow crystals to be mounted in a gaseous nitrogen
cryostream at 2173uC for diffraction experiments. Crystals were
initially characterized using a copper anode X-ray generator
(Rigaku 007) and an image plate detector (RAXIS IV++). The
crystal was stored in liquid nitrogen for data collection at the
European Synchrotron Radiation Facility (ESRF, Grenoble,
France).
Diffraction data were collected on beamline ID29 at ESRF
using a Quantum4 CCD detector. It proved beneficial to use the
automated crystal annealing facility established on the station.
Data were indexed and integrated using MOSFLM [27], and
scaled with SCALA [28]. Crystallographic statistics are presented
in Table 1. The search model for molecular replacement was
prepared by generating a poly-alanine model of the E. coli PabC
structure (PDB code 1et0, [15]) from which all waters and non-
protein molecules had been removed. This model shares 35%
sequence identity with PaPabC. Molecular replacement calcula-
tions were performed using MOLREP [29].
Refinement was performed in REFMAC5 [30][31] and
the model was inspected and manipulated in COOT [32]. Strict
non-crystallographic symmetry restraints were employed in the
early stages of the refinement and then removed. The presence of
the PLP cofactor covalently bound to Lys140 was confirmed by
calculating an omit electron density map (Figure 2). The N-
terminal histidine tag was not visible in electron density maps. A
number of ligands (tetraethylene glycol, 1,2-ethanediol, di(hydrox-
ymethyl)ether, glycerol, chloride and sulfate ions) were assigned on
the basis of the difference density and chemical environment, and
refined satisfactorily. Both tetraethylene glycol and ethylene glycol
are likely decomposition products of PEG400 used in crystalliza-
tion, impurities or represent partially ordered molecules. MOL-
PROBITY [33] was used to assess model geometry, AREAIMOL
[31] and the Protein Interfaces, Surfaces and Assemblies, EMBL
server [http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html; [34]]
were used to calculate surface and interface areas. Figure 1 was
prepared with CHEMDRAW (Adept Scientific), Figure 5 with
ALINE [35] and the remainder using PyMOL [36] and
ILLUSTRATOR (Adobe Systems Inc.).
Amino acid sequence alignments and analysis
A search of the UniProt database with the Enzyme Commission
number for PabC (4-amino-4-deoxychorismate lyase; 4.1.3.38)
identified 368 entries. These were clustered such that sequences
Table 1. Crystallographic statistics.
Space group P 212121
Unit cell dimensions: a, b, c (A˚) 40.8, 66.8, 202.7
Resolution range (A˚) 30.00 - 1.75
Unique reflections 56255
Completeness (%) 98.9 (98.5)a
,I/s(I). 10.7 (2.5)
Multiplicity 3.7 (3.3)
Rmerge
b 7.8 (45.1)
No. of reflections 53372
Rcryst
c, Rfree
d 16.7, 21.5
Protein residues 538
Ligands 26 PLP, 3 Cl2, 2 SO4
22, 2 glycerol, 3 di(hydroxyethyl)ether, 5 tetraethyleneglycol, 3 1,2-ethanediol &
474 waters
r.m.s. deviations from ideal geometry
bond lengths (A˚) 0.025
bond angles (u) 2.1
B values (A˚2)
From Wilson Plot 18.4
Mean B values Chain A, main chain atoms: 15.1
Chain A, side chain atoms: 18.2
Chain B, main chain atoms: 18.5
Chain B, side chain atoms: 20.7
Waters: 30.8
PLP: Chain A 15.8 Chain B 21.5
Other ligands 36.3
Ramachandran favoured/allowed (%) 93.7/99.4 (3 outliers: Arg90, Chains A, B Leu89, Chain B)
aValues in parentheses refer to the highest resolution shell (1.8421.75 A˚).
bRmerge=ghklgi|Ii(hkl)2,I(hkl).|/ghklgi Ii(hkl); where Ii(hkl) is the intensity of the ith measurement of reflection hkl and ,I(hkl). is the mean value of Ii(hkl) for all i
measurements.
cRcryst=ghkl||Fo|2|Fc||/g|Fo|, where Fo is the observed structure factor and Fc is the calculated structure factor.
dRfree is the same as Rcryst except calculated with a subset, 5%, of data that are excluded from refinement calculations.
doi:10.1371/journal.pone.0024158.t001
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with a 90% or greater similarity to each other were grouped and a
representative sequence identified. This reduced the list to 197
entries. Sequences consisting of more than 400 amino acids were
removed and this further reduced the list to 181 entries. These
were aligned using MUSCLE [37] and then inspected following
pairwise alignment with PaPabC. A conservative group of 129
putative PabC sequences was then identified following the removal
of sequences that were fragmentary, labeled as other proteins or
which displayed a sequence identity of less than or equal to 20%.
Molecular modeling of the catalytic intermediate
A model of the substrate, 4-amino 4-deoxychorismate, was
prepared using PRODRG [38] and placed into the active site
using the molecular graphics program COOT [32] with the
position of the bound pyridoxyl 59 phosphate as a guide to allow
formation of the catalytic intermediate. The active site was
prepared for docking of this ligand using ICM pro (MolSoft L.L.C;
http://www.molsoft.com/index.html) with the centre of the
ligand-binding site defined by a cavity that contained the residues
within 5 A˚ of the 4-amino 4-deoxychorismate. The top ten
docking poses, as scored by ICM Pro software gave similar
orientations in the active site and one was selected for discussion
and display.
Results and Discussion
Overall structure
Size exclusion gel filtration, carried out during protein
purification, indicated a single species of approximate mass
50 kDa that is commensurate with a homodimeric species. In
the crystal structure two polypeptide chains, labelled A and chain
B together constitute the asymmetric unit in PaPabC (Figure 3),
and the crystals have an estimated bulk solvent content of 45%.
The polypeptide chains form a dimer (Figure 3) and, as described
below, such oligomerization is required to create the enzyme
active site. The presence of a PaPabC dimer is consistent with
previous studies since all PabC structures solved to date are
dimeric or in the case of T. thermophilus PabC, a dimer-of-dimers is
observed [16].
The PaPabC subunits display a high degree of non-crystallo-
graphic symmetry. The rmsd following a least-squares fit of 270
Ca positions is 0.4 A˚. It is therefore only necessary to detail one
subunit and one active site.
The PaPabC subunit is constructed from two domains (Figure 4).
The N-terminal domain (domain I) is smaller than the C-terminal
domain (domain II). Domain I comprises residues 1–107, which
Figure 2. The omit map for PLP and Lys140 from subunit A.
|(Fo)-(Fc)| difference density contoured at 3s (green chicken wire).
Selected hydrogen bonding associations between the protein, two
water molecules (red spheres) and PLP are depicted as dashed lines. A *
marks Tyr92 as contributed from subunit B. The side chain of Glu173
displays two rotamers with only one shown.
doi:10.1371/journal.pone.0024158.g002
Figure 3. The PaPabC dimer. Each subunit is depicted as a Ca trace
(yellow and purple) with the PLP shown as stick model in a similar
fashion to Figure 3. The N and C – terminal residue positions are
labelled.
doi:10.1371/journal.pone.0024158.g003
Figure 4. Ribbon diagram of the PaPabC monomer (b-sheet is
shown in purple, a-helix in yellow). Domain I is formed by a-helices
1–3 and the anti-parallel b-strands 1–4. Domain II is formed by a-helices
4–8 and b-strands 5–8.
doi:10.1371/journal.pone.0024158.g004
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contains three a-helices (a1-3) and a four-stranded anti-parallel b-
sheet in order b1-b4-b3-b2. Domain II comprises residues 112–
271 that form five a-helices (a4–8), one short two-stranded parallel
b-sheet (b5–b6) and one short two-stranded anti-parallel b-sheet
(b7–b8). Residues 108–111 link the two domains. The PLP
cofactor is covalently bound to Lys140 that is in domain II. The
active site is formed in a cleft formed between the two domains
(Figure 3).
Sixty residues from each subunit, provided by both domains,
contribute to dimer formation. These residues participate in
around 30 hydrogen-bonding associations and eight salt bridge
interactions to stabilize the quaternary structure. Most of the
residues that contribute to the dimer interface are found in two
patches; residues Ala10 to Gly25 centred on a1 and residues
Arg127 to Ala152 centered on a5.
The approximate dimensions of the dimer, which constitutes the
asymmetric unit, are 80 A˚640 A˚640 A˚ and this displays a solvent
accessible surface area of approximately 21,000 A˚2. The contact
area between the two subunits occupies approximately 2,050 A˚2,
about 15% of the surface of a subunit. These values are similar to
those observed for other PabC proteins, for example the interface
of the E. coli protein (PDB code 1et0) covers an area of 2,130 A˚2.
The structures of PabC from three organisms (E. coli, L.
pneumophila and T. thermophilus) display a high degree of structural
conservation with PaPabC. Least-squares fitting of the Ca
positions of single subunits results in RMSD values of between
1.27 and 1.95 A˚, with a coverage in the range of 81 to 92% of the
structures. The sequence identity shared with PaPabC, falls in the
range 26% to 35%.
The active site and mechanistic considerations
The active site of PaPabC is positioned between the two
domains of the monomer close to the dimer interface (Figure 3).
Here, the PLP cofactor is covalently linked to Lys140, bound and
oriented by interactions with key residues, a selection of which are
depicted in Figure 2. The PLP phosphate accepts hydrogen bonds
donated by a cluster of main chain amide groups from Val200,
Met201 and Ser237, and the side chain of Arg46. The side chain
of Arg46 is itself positioned by interactions with the side chain of
Glu28, which in turn accepts a hydrogen bond from His43 ND1.
Two well ordered water molecules mediate hydrogen bonding
networks linking the phosphate group to Asn178 OD1 and Arg202
N on one side, the main chain O and N groups of Thr29 on the
other. The cofactor ring is sandwiched between Val197 and the
main chain of a tripeptide segment comprising Val175-Phe176-
Ser177. A hydrogen bond between Asn236 ND2 and the carbonyl
of Phe176 in conjunction with hydrogen bonds formed between
the amide groups and the side chain of Glu161 helps to determine
the conformation of the tripeptide that forms a tight turn, between
b9 and b10, that covers part of the cofactor.
The PLP methyl group makes van der Waals interactions with
Gln147 CG and is positioned 3.2 A˚ distant from the carbonyl
oxygen of Val175. The geometry of this latter contact is
compatible with the presence of a C-HNNNO hydrogen bond [39].
The side chain of Gln147 is held in place by a hydrogen bond with
Arg144 NE. The arginine side chain is itself positioned by
hydrogen bonds formed with the carbonyl groups of Leu139 and
His141. There are also three water molecules (data not shown),
which form a complex network of hydrogen bonds linking the side
chain of Arg144 to other sections of the enzyme. In addition the
positive dipole from a6, the closest residue on this helix is Gly199,
provides an attractive force to interact with the PLP phosphate.
The side chain of Glu173 displays a degree of conformational
freedom with two rotamers being observed. One rotamer places
the side chain to accept a hydrogen bond donated from PLP N1
(Figure 2). The alternative rotamer places the carboxylate at a
distance of 3.7 A˚ from N1 (data not shown). Tyr92 from the
partner subunit forms a hydrogen bond to PLP O3. The cofactor
is also likely to posses an intra-molecular hydrogen bond involving
O3 and NZ of Lys140. The side chain of Phe27, Val197 and
aliphatic components of Arg46 and Arg144 surround the side
chain of Lys140.
No structures of PabC-ternary complexes have yet been
published to inform on aspects of substrate recognition and
enzyme activity. Given the importance of such complexes we
judged it important to get such data and attempted to determine
structures of PaPabC in complex with a number of compounds, for
example, the sample used for structure determination was
crystallized in the presence of 10 mM PABA. However, we have
been unable to identify electron density compatible with binding of
any such ligand in the substrate-binding pocket. We judged
therefore that the position of PLP and Lys140 NZ, together with
the conservation of amino acid sequence and structures give an
indication of where substrate binds and which residues are
important for substrate recognition and catalytic function.
Consideration of an amino acid sequence alignment and structural
overlay of PaPabC with three other structures in the PDB proved
particularly informative. To this we added molecular modelling
and docking of the covalent intermediate formed during catalysis.
The contributions of 24 residues, within about 5 A˚ of PLP, to
binding the cofactor and organising the active site are described
above and summarized in Figure 5. Seven of these residues are
strictly conserved in PabC of P. aeruginosa, E. coli, L. pneumophila and
T. thermophilus (Phe27, Thr29, His43, Arg46, Gly199, Lys140 and
Arg202 in PaPabC). With one exception these residues contribute
to the active site using the chemical properties of their side chains.
The exception is Gly199 where any alteration on Ca would result
in a steric clash with the phosphate group of PLP. Another seven
residues contribute to the active site primarily through the
hydrogen bonding capacity of the main chain (Val175, Phe176,
Ser177, Leu139, His141, Val200 and Met201). Phe176 is not
conserved in any of the three other sequences but the remainder
are conserved in at least one other orthologue. Ser237 interacts
with the PLP phosphate using main chain and side chain groups.
This residue is only different in the E. coli sequence where an
alanine is observed and an additional water molecule binds nearby
helping to satisfy hydrogen-bonding capacity (data not shown). A
similar observation is made when considering PaPabC Asn236.
The residue is conserved in EcPabC and LpPabC but changed to
glycine in TtPabC where a water molecule is observed to replace
the side chain (data not shown). Asn178 is strictly conserved in
EcPabC and LpPabC but changed to serine in TtPabC. The side
chain here simply helps to form one side of the cofactor-binding
site. Val197 is conserved in EcPabC and conservatively substituted
as leucine in the other two sequences. The residue at this position
in the active site forms van der Waals interactions with the
cofactor. In PaPabC Arg144 NE donates hydrogen bonds to
Gln147 OE1 and the carbonyl of His141; interactions that help to
create one side of the cofactor-binding site and to fix the position
of Val197. These residues and the interactions they form appear to
be conserved in EcPabC but not in LpPabC or TtPabC. Sequence
and structure alignments (not shown) indicate that PaPabC Arg144
is replaced by tyrosine in both LpPabC and TtPabC and PaPabC
Gln147 replaced by an alanine in LpPabC and a tyrosine in
TtPabC. This is an intriguing observation to be discussed below.
There are three glutamates amongst the 24 residues discussed
above, Glu28, Glu161 and Glu173. Glu28 helps to position Arg46
to bind the cofactor phosphate. Both residues are strictly
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conserved in LpPabC. A conservative substitution of the glutamate
to threonine occurs in both EcPabc and TtPabC and the hydrogen
bonding interactions to support the role of an arginine binding the
cofactor are preserved. Glu161 helps to configure a tripeptide
segment to cover part of the cofactor and this feature is conserved
since a glutamate is present in the other structures or, as in
LpPabC an aspartate occupies this position. The carboxylate side
chain of Glu173 can interact directly with the cofactor by
accepting a hydrogen bond donated from N1. In a similar fashion
to what is observed for Glu161, such interactions occur in the
orthologues with the residue either strictly conserved, or as in
TtPabC, replaced by aspartate.
A catalytic mechanism, based on previous studies of PLP-
dependent enzymes, was proposed for PabC prior to any structural
data being available [10]. Following structure determination of
EcPabC, a model of substrate binding was prepared to inform an
assessment of the mechanism [15]. The contribution of PLP was
considered the same, that is, following covalent linkage the
enzyme-cofactor adduct undergoes a nucleophilic attack by the
substrate amino group to produce a reactive external aldimine.
This species then undergoes a-proton elimination, at C4, to the e-
amino group of a lysine to yield a reaction intermediate. In
EcPabC Lys159 forms the covalent link to the cofactor and likely
responsible for a-proton abstraction. Nakai et al., [15] further
Figure 5. Structure-based alignment of PaPabC and LpPabC. Residues encased in black are strictly conserved. Red stars indicate the tyrosine
residues at Position I (PaPabC Y92) and Position II (LpPabC Y144). Triangles mark residues that are discussed in the text. Red triangles identify Lys140
and residues that interact directly with the Lys140-PLP adduct; yellow triangles mark residues that contribute to the organization of the active site or
that participate in solvent mediated interactions between the protein and the cofactor.
doi:10.1371/journal.pone.0024158.g005
Figure 6. Structural conservation of tyrosine in the PabC active site. PLP is shown in the same manner as Figure 2. Left panel. A structural
overlay of PaPabC (green C atoms) and EcPabC (blue C atoms). Here, Tyr92 and Tyr109, which represent position I, are contributed from the partner
subunit. Centre panel. LpPabC. Right panel. TtPabC. Residue Thr27 displays two rotamers. In the LpPabC and TtPabC structures, Tyr144 and Tyr130
respectively represent position II and belong to the same subunit that forms the PLP-binding site.
doi:10.1371/journal.pone.0024158.g006
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suggested that Thr28 of EcPabC supplies a proton to reduce the
olefin moiety of the substrate as pyruvate is released. To recover
the Schiff-base form of the enzyme, PABA is released and PLP
reacts with Lys159.
Three residues described as contributing to the mechanism of
action in EcPabC, Thr28, Lys97 and Lys159 [15], are strictly
conserved in PaPabC as Thr29, Lys80 and Lys140. They are also
conserved in LpPabC and TtPabC with the conservative change of
Lys80 to arginine in the thermophilic orthologue (Figure 5).
Lys140 of PaPabC is suitably placed to support a-proton
abstraction and although Thr29 may engage in the proposed
proton shuffling with both the olefin moiety of the substrate and
Lys80 we noted an alternative residue that might fulfil this role.
This residue may have been overlooked because Nakai et al., [15]
had access to only a single structure of PabC and alignments based
on sequences alone would not identify a tyrosine that is conserved
in three-dimensions.
In EcPabC and PaPabC tyrosine OH groups (Tyr109 and
Tyr92 respectively), from the partner subunit, donate a
hydrogen bond to PLP O3 (Figures 2, 6); an interaction that
influences the electronic structure of the cofactor [15]. The
sequence alignment of PabC orthologues suggests a degree of
variation in the identity of the amino acid that occupies the
position of this tyrosine (Figure 5). The structural overlays are
striking since they clearly identify a conserved tyrosine in
relation to the cofactor (Figure 6). In EcPabC and PaPabC,
Tyr109 and Tyr92 respectively, are contributed from the
partner subunit. We call this position I. However, in LpPabC
and TtPabC, Tyr144 and Tyr130 respectively, are contributed
from the same subunit, or position II.
We isolated 129 putative PabC sequences to investigate the
distribution of tyrosine at these two positions seeking to address the
hypothesis that if tyrosine is present at position I then it is likely
absent from position II and vice versa. This hypothesis holds true for
125 out of the 129 sequences (data not shown). Two sequences,
which share less than 30% sequence identity, have a tyrosine at
both positions. Analyses of the sequences suggests that PabC can
be classified into two groups depending on whether this active site
tyrosine is provided by the same subunit which primarily forms the
active site or from a partner subunit.
Furthermore the high degree of conservation of an active site
tyrosine in three-dimensional structures of PabC suggests a
functional role. One possibility is that this residue could act as a
proton donor for the methylene to methyl reduction that
completes the reaction. Such a reduction would have little
influence on the cleavage of the C-O bond of the substrate
since the driving force for that reaction would be production
of a conjugated aromatic six-carbon ring system. Our model
of the catalytic intermediate (Figure 7) was specifically created
to investigate the potential role of this active site tyrosine
and to re-evaluate the reduction process that completes the
reaction.
The model suggests that Tyr112 donates a hydrogen bond to
the C1 carboxylate whilst, with contributions from the partner
subunit, the main chain amide of Tyr92 and hydroxyl group of
Tyr22 donate hydrogen bonds to the other carboxylate of the
intermediate (Figure 7). Tyr92 contributes to the positioning and
electronic structure of the cofactor by virtue of the hydrogen bond
involving the hydroxyl group with the PLP carbonyl (Figure 2).
The bulk of the tyrosine side chain serves to create a hydrophobic
wall on one side of the active site. Although placed to interact with
the catalytic intermediate this residue does not appear to be
involved in donating a proton to convert methylene to methyl as
part of the catalytic cycle (Figure 7). Rather, Thr29, as first
postulated by Nakai et al., [15] appears to fulfil such a role with the
hydroxyl group placed about 3.5 A˚ from the olefin (Figure 7).
Lys80 NZ is around 4.3 A˚ distant from the sp2 hybridized C and it
is possible that an alternative rotamer could bring this functional
group into play with respect to either providing a proton itself or in
activating the Thr29 hydroxyl for proton donation. We note that
Thr29 is strictly conserved in 123 out of the 129 PabC sequences
and conservatively substituted by serine in another five sequences.
The single sequence in which we could not identify conservation in
terms of a threonine or serine corresponding to Thr29 is the
putative PabC from Pantoea vagans. This is a poorly conserved
sequence sharing approximately 30% identity.
To further investigate the structure-activity relationship of
PabC, and to assess the potential of this enzyme as a target for
structure-based drug discovery will require the powerful combi-
nation of steady-state kinetic analysis with site-directed mutagen-
esis studies, and to carry out screening of chemical libraries. It will
be imperative to extend from our work and to elucidate a means
whereby structural data on enzyme-ligand complexes can be
obtained.
Figure 7. A stereoview of the catalytic intermediate docked into the active site of PaPabC. The protein components are colored as in
Figure 2. The C atoms of the modelled intermediate are black. Black dashed lines represent potential hydrogen bonding interactions, with a
separation of 3.5 A˚ or less, and the red dashed line between Thr29 OG1 and the sp2 hybridized C indicates the proximity of functional groups likely
involved in catalysis.
doi:10.1371/journal.pone.0024158.g007
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Some Gram-negative bacteria target their competitors by
exploiting the type VI secretion system to extrude toxic
effector proteins. To prevent self-harm, these bacteria also
produce highly specific immunity proteins that neutralize
these antagonistic effectors. Here, the peptidoglycan endo-
peptidase specificity of two type VI secretion-system-
associated effectors from Serratia marcescens is characterized.
These small secreted proteins, Ssp1 and Ssp2, cleave between
!-d-glutamic acid and l-meso-diaminopimelic acid with
different specificities. Ssp2 degrades the acceptor part of
cross-linked tetratetrapeptides. Ssp1 displays greater promis-
cuity and cleaves monomeric tripeptides, tetrapeptides and
pentapeptides and dimeric tetratetra and tetrapenta muro-
peptides on both the acceptor and donor strands. Functional
assays confirm the identity of a catalytic cysteine in these
endopeptidases and crystal structures provide information on
the structure–activity relationships of Ssp1 and, by compar-
ison, of related effectors. Functional assays also reveal that
neutralization of these effectors by their cognate immunity
proteins, which are called resistance-associated proteins
(Raps), contributes an essential role to cell fitness. The
structures of two immunity proteins, Rap1a and Rap2a,
responsible for the neutralization of Ssp1 and Ssp2-like
endopeptidases, respectively, revealed two distinct folds, with
that of Rap1a not having previously been observed. The
structure of the Ssp1–Rap1a complex revealed a tightly bound
heteromeric assembly with two effector molecules flanking a
Rap1a dimer. A highly effective steric block of the Ssp1 active
site forms the basis of effector neutralization. Comparisons
with Ssp2–Rap2a orthologues suggest that the specificity of
these immunity proteins for neutralizing effectors is fold-
dependent and that in cases where the fold is conserved
sequence differences contribute to the specificity of effector–
immunity protein interactions.
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1. Introduction
Specialized secretion systems are key to bacterial fitness,
survival and pathogenesis. They perform a myriad of roles in
the processes that influence growth, colonization, attack and
defence as bacteria interact with each other and with
eukaryotic organisms (Filloux, 2011; Gerlach & Hensel, 2007).
The recently identified type VI secretion system (T6SS), which
is present in about 25% of Gram-negative bacteria for which
genome sequences are available (Boyer et al., 2009), can be
used to target bacterial and eukaryotic cells and is thus
important for both inter-bacterial competition and patho-
genesis (Burtnick et al., 2011; de Pace et al., 2010; Jani &
Cotter, 2010). Antibacterial T6SSs mediate the efficient killing
of competitors by direct injection of toxic antagonistic effector
proteins into target cells (Murdoch et al., 2011; Hood et al.,
2010; MacIntyre et al., 2010; Schwarz et al., 2010).
T6SS gene clusters encode the core components of a
secretion machine capable of membrane perforation. This is a
multi-protein needle-like assembly, resembling the contractile
bacteriophage tail, that delivers effectors across three
envelope layers in a single step (Bo¨nemann et al., 2010;
Cascales & Cambillau, 2012; Silverman et al., 2012). The
clusters also encode accessory and post-translational regula-
tory components. Some T6SS-secreted effector proteins are
also encoded within these large gene clusters. In the case of
antibacterial T6SSs, effectors are always encoded adjacent
to specific cognate immunity proteins. Immunity proteins
bear appropriate signals to direct their localization to the
compartment in which the toxic effectors act; for example, a
Sec signal sequence guides localization to the periplasm. The
provision of a cognate immunity protein provides protection
against attack from sister cells (Coulthurst, 2013).
Different catalytic activities are associated with T6SS
effectors. These include actin cross-linking and ADP-ribosyl-
ation, which disrupt the cytoskeletons of mammalian and
amoebal cells (Pukatzki et al., 2007; Rosales-Reyes et al.,
2012), and phospholipases, which degrade phosphatidyl-
ethanolamine, the major component of the bacterial
membrane (Russell et al., 2013). The best-characterized
effectors are peptidoglycan hydrolases, which exhibit potent
antibacterial activity (Russell et al., 2011, 2012). These
enzymes degrade peptidoglycan, the heteropolymer that
occupies the periplasmic space, imparts mechanical strength to
the cell wall and helps to maintain the shape of Gram-negative
bacteria.
Peptidoglycan hydrolases constitute a large enzyme family
which displays a rich diversity in terms of structure,
mechanism and specificity (Vollmer et al., 2008). There are
enzymes specific for every glycosidic and amide bond in
peptidoglycan. Such diversity is exploited to regulate bacterial
cell growth, division and daughter-cell separation and, of
particular interest here, to provide bactericidal properties that
can be exploited in niche competition. Several classes of
peptidoglycan hydrolases have been identified as T6SS
effector proteins. These are termed Tse proteins. Tse3 from
Pseudomonas aeruginosa is a muramidase, cleaving the glycan
backbone (Russell et al., 2011), and the C-terminal domain of
Vibrio cholerae VgrG-3 has been suggested to have lysozyme-
like muramidase activity (Brooks et al., 2013). A diverse group
of T6SS-secreted peptidoglycan amidases which cleave
peptide cross-links has been described (Russell et al., 2012).
Within this superfamily, four distantly related families with
distinct cleavage specificities were defined. Family 1 (Tae1),
which includes Tse1 from P. aeruginosa, hydrolyses peptide
cross-links at the !-d-glutamyl-meso-diaminopimelate dl-
bond, representatives of families 2 and 3 (Tae2 and Tae3)
hydrolyse dd-cross-links between d-mA2pm (meso-diamino-
pimelate) and d-alanine, and a representative of family 4, Tae4
from Salmonella enterica serovar Typhimurium, also hydro-
lyses the !-d-glutamyl-mA2pm dl-bond. Structures of Tse1
from P. aeruginosa and of Tae4 from Salmonella Typhimurium
and Enterobacter cloacae (Benz et al., 2012; Chou et al., 2012;
Ding et al., 2012; Zhang et al., 2013) place these T6-secreted
effectors in the NlpC/P60 family of endopeptidases, amidases
and acyltransferases (named after the new lipoprotein C from
Escherichia coli and a 60 kDa extracellular protein from
Listeria monocytogenes; Anantharaman & Aravind, 2003).
The opportunistic pathogen Serratia marcescens has recently
been shown to utilize T6-dependent secretion of two family 4
amidases, Ssp1 and Ssp2, to mediate antibacterial activity
(English et al., 2012).
Bacteria that secrete potent peptidoglycan hydrolase
effectors using the T6SS to attack competitors could generate
a deleterious effect on their own population. To cope with this
potential for friendly-fire damage, such bacteria also possess
cognate immunity or resistance proteins located in the peri-
plasm. These immunity proteins bind their cognate effectors
with low nanomolar affinity to neutralize them in a highly
specific manner (English et al., 2012). Four distinct families
of putative immunity proteins are associated with the four
Tae amidase families (Tai1–Tai4; Russell et al., 2012). In
S. marcescens, the resistance-associated proteins Rap1a and
Rap2a neutralize Ssp1 and Ssp2, respectively (English et al.,
2012). Additionally, two other Rap proteins, Rap1b and
Rap2b, are encoded together with Ssp1 and Ssp2 in the same
locus within the T6SS gene cluster. The structures of Rap1b
and Rap2b revealed a novel "-helix fold and a dimeric
assembly (English et al., 2012), which was later observed in
the Tai4 proteins from E. cloacae (EcTai4) and Salmonella
Typhimurium (STTai4; Zhang et al., 2013). This fold is a
template for some T6SS immunity proteins, called Tsi
proteins, but not all. For example, analysis of the Tse1/Tsi1
effector/immunity protein combination found in P. aeruginosa
revealed Tsi1 to be an all-# protein (Benz et al., 2012; Ding
et al., 2012; Shang et al., 2012), whereas Tsi2, the immunity
protein associated with the cytoplasmic effector Tse2, in the
same organism has a helical fold that is distinct again (Li et al.,
2012). That effector immunity defence systems based on
distinct folds have evolved is perhaps to be expected, given the
strong evolutionary pressure applied by multifarious secreted
effectors. Indeed, such pressure may even have contributed
to the acquisition of effector–immunity pairs encoded outside
T6SS operons (for example, all three Tse/Tsi pairs in
P. aeruginosa).
Here, we assess the peptidoglycan hydrolase specificity of
Ssp1 and Ssp2 and the protective role of cognate immunity
proteins. We define the specificity of the enzymes and confirm
using site-directed mutagenesis that an in vivo cell-killing
mechanism is directly attributable to their catalytic activity.
We report crystallographic analyses of S. marcescens Ssp1,
a disabled mutant (Ssp1-C50A), Rap1a, Rap2a and the
heterotetrameric Ssp1–Rap1a complex. Our data provide
information on the enzyme mechanism, aspects of substrate
specificity, the structural classification of Ssp1 and Rap
proteins, including the identification of a novel immunity
protein fold, and the molecular details of how an effector
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is neutralized by its cognate immunity protein, and suggest
generic features related to function that allow the classifica-
tion of these proteins into distinct groups. Finally, we consider
diversity within the Tae4 family of effectors and their immu-
nity proteins and how this may explain the presence of
multiple homologues within the same organism.
2. Materials and methods
2.1. Recombinant protein production and effector–immunity
protein complex formation
Recombinant Ssp1 and Ssp2 were expressed in E. coli
BL21 (DE3), and Rap1a and Rap2a, minus their N-terminal
periplasmic targeting sequences, were expressed in E. coli
Rosetta-gami (DE3) and purified in high yield using estab-
lished protocols (English et al., 2012). The predicted catalytic
cysteine of Ssp1 and Ssp2 (Cys50) was mutated to an alanine
using the QuikChange II Site-Directed Mutagenesis Kit
(Stratagene) and the altered proteins were purified as for the
wild-type samples. For co-expression of the Ssp1–Rap1a and
Ssp2–Rap2a complexes, full-length mature Rap1a (residues
25–127) and Rap2a (residues 25–131), without signal peptides,
were cloned using NdeI and XhoI restriction sites at the
second multiple-cloning site of the co-expression vector
pACYCDuet-1 (Novagen), and full-length Ssp1 (residues 1–
163) and Ssp2 (residues 1–158) were subsequently cloned
using NcoI and BamHI restriction sites at the first multiple-
cloning site. This introduces an N-terminal His6 tag into
the expressed product. Both the Ssp1–Rap1a and Ssp2–Rap2a
complexes were produced in E. coli Rosetta-gami (DE3) and
were purified by immobilized metal-ion affinity chromato-
graphy (English et al., 2012) and size-exclusion gel-filtration
chromatography with a Superdex 75 10/300 GL column (GE
Healthcare). The samples were concentrated to 13.5 mg ml"1
by centrifugation (10 000 molecular-weight cutoff, Amicon)
and dialyzed into 10 mM sodium phosphate pH 6.4. A high
level of purity of greater than 95% was confirmed by SDS–
PAGE. Size-exclusion chromatography was also used to
investigate the association of cognate Ssp-C50A mutant–Rap
combinations, with the proteins being mixed in equimolar
amounts prior to separation, as described by English et al.
(2012).
2.2. Peptidoglycan-cleavage assay
Purified peptidoglycan sacculi (300 mg) from E. coli D456,
consisting mainly of tetrapeptides with lower fractions of
tripeptides and pentapeptides (Chou et al., 2012), were incu-
bated with either Ssp1 or Ssp2 (100 mg ml"1) or, as a control,
no enzyme in 300 ml 20 mM sodium phosphate pH 4.8 for 4 h
at 310 K. The samples were incubated with 40 mg ml"1 of
the muramidase Cellosyl (kindly provided by Ho¨chst AG,
Frankfurt, Germany) for 16 h at 310 K to convert the residual
peptidoglycan and solubilized fragments into muropeptides.
The sample was boiled for 10 min and insoluble material was
removed by centrifugation. The muropeptides were reduced
with sodium borohydride and analyzed by high-pressure liquid
chromatography using established methods (Glauner, 1988;
Chou et al., 2012; Russell et al., 2012). The profile/retention
times were compared with previous samples for which mass-
spectrometric analyses with fragmentation had been carried
out and which had identified that the linear disaccharide
hexapeptide elutes before the disaccharide dipeptide, whereas
the branched disaccharide hexapeptide elutes after the
disaccharide dipeptide.
2.3. Phenotypic assays to characterize the C50A mutants of
Ssp1 and Ssp2
These assays were performed using the bacterial strains,
plasmids and protocols described previously (English et al.,
2012). The QuikChange II Site-Directed Mutagenesis Kit
(Stratagene) was used to generate C50A (Cys50 to Ala)
mutants of Ssp1 and Ssp2 in the existing plasmids pSC152 and
pSC138 (for periplasmic expression in E. coli) and pSC539 and
pSC541 (for complementation of the cognate mutation in
S. marcescens). Microscopic analysis, antibacterial co-culture
(competition) assays and immunodetection of secreted Ssp2
were performed as described in the previous study. In brief,
the format of the antibacterial co-culture assays was that the
attacker and target strains were mixed in a 1:1 ratio, co-
cultured on solid Luria–Bertani (LB) media for 7.5 h at 303 K
and the surviving target cells (in this case a streptomycin-
resistant version of the !rap2a, !clpV mutant) were
enumerated by serial dilution and viable counts on strepto-
mycin-containing media. ClpV is an ATPase that is essential
for the type VI secretion system to function and so deletion
provides an appropriate control. Statistical significance testing
was performed using ANOVA followed by Dunnett’s post-test
(GraphPad Prism software). For the detection of Ssp1 and
Ssp2 levels in solid-grown E. coli or S. marcescens, cells were
removed from the surface of agar plates, resuspended in liquid
media, boiled and the total cell extract was separated by SDS–
PAGE followed by anti-Ssp1 or anti-Ssp2 immunoblotting as
described previously (English et al., 2012).
2.4. Bioinformatic analyses
Multiple Ssp/Tae4 homologues were identified from public
databases as part of previous studies (English et al., 2012;
Russell et al., 2012). Multiple sequence alignments were
generated using MUSCLE (Edgar, 2004), and Jalview
(Waterhouse et al., 2009) was used to visualize the alignment
and to calculate the resulting tree (using neighbour-joining
construction and the BLOSUM62 distance matrix). Genomic
analyses using publicly available databases (http://
www.ncbi.nlm.nih.gov/ and http://www.sanger.ac.uk/resources)
allowed the identification of adjacently encoded candidate
immunity proteins, which were then used as bait to interrogate
the S. marcescens Db11 genome and determine the Rap
protein to which each was most closely related.
2.5. Crystallographic analyses
2.5.1. Crystal growth and data collection. For crystal-
lization trials, Rap1a was dialyzed against 25 mM Tris–HCl,
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150 mM sodium chloride pH 7.5 and all other samples were in
100 mM sodium phosphate pH 6.4. The sitting-drop vapour-
diffusion method was used with 0.2 ml drops with a 1:1 ratio
of protein solution to reservoir solution at 293 K. Several
commercially available screens were used in 96-well plates
with a Phoenix Liquid Handling System (Rigaku, Art Robbins
Instruments) to scout out initial conditions, which were then
optimized.
Crystals of Ssp1 were obtained by combining protein solu-
tion at a concentration of 10 mg ml"1 with reservoir solution
consisting of 0.2M potassium sulfate, 20% PEG 3350.
Orthorhombic block crystals grew to a maximum dimension
of approximately 350 mm over 5 d. The Ssp1-C50A mutant
(10 mg ml"1) gave isomorphous crystals (maximum dimension
of 250 mm) in 2 d using reservoir solution consisting of 0.1M
sodium citrate pH 5.5, 20% PEG 3000. The Ssp1–Rap1a
complex at 13.5 mg ml"1 formed clusters of plate-like crystals
using a reservoir solution consisting of 12.5% PEG 1000,
12.5% PEG 3350, 12.5% MPD. These crystals attained a
maximum size of 200 mm within 3 d. A single-crystal fragment
was removed from the cluster for
diffraction measurements. Mono-
clinic blocks of Rap2a were grown
by combining a protein concen-
tration of 13.5 mg ml"1 with a
reservoir solution consisting of
25% PEG 1000, 0.1M MES pH
6.5. These crystals attained a
maximum dimension of 200 mm
within 5 d. A slender ortho-
rhombic crystal of Rap1a with
approximate dimensions of 150 #
35 # 35 mm was observed after
about one month using a reservoir
solution consisting of 25% PEG
3350, 100 mM bis-tris pH 5.5. We
were unable to obtain crystals of
the Ssp2–Rap2a complex.
All crystals were soaked briefly
in mother liquor adjusted to
contain 20%(v/v) glycerol as a
cryoprotectant prior to flash-
cooling in liquid nitrogen and use
in diffraction experiments. Data
for Ssp1, the Ssp1-C50A mutant
and the Ssp1–Rap1a complex
were measured at 100 K using a
Rigaku MicroMax-007 rotating-
anode X-ray generator (Cu K")
coupled to a Saturn 944 CCD
detector and were processed
using XDS (Kabsch, 2010) or
HKL-3000 (Minor et al., 2006).
The Rap1a and Rap2a data were
collected on beamlines I04 and
I03 of the Diamond Light Source,
respectively, and were indexed
and integrated in iMosflm (Battye et al., 2011). Data sets were
analyzed and scaled with POINTLESS and SCALA (Evans,
2006) from the CCP4 program suite (Winn et al., 2011).
The isomorphous Ssp1 and Ssp1-C50A crystals contained
two polypeptides in the asymmetric unit with an estimated
solvent content of 50% and a VM of 2.46 A˚
3 Da"1. The Ssp1–
Rap1a complex crystal presented a heterodimer in the asym-
metric unit with an estimated solvent content of 40% and a VM
of 2.06 A˚3 Da"1. Rap2a crystallized with four molecules in the
asymmetric unit, an estimated solvent content of 40% and a
VM of 2.06 A˚
3 Da"1, whilst Rap1a displayed two molecules in
the asymmetric unit with an estimated solvent content of 45%
and a VM of 2.06 A˚
3 Da"1.
2.5.2. Structure determination and refinement. The Ssp1
structure was solved targeting the single-wavelength anom-
alous scattering properties of sulfur (Micossi et al., 2002).
Auto-Rickshaw, the EMBL Hamburg automated structure-
determination platform (Panjikar et al., 2005), was used. The
heavy-atom structure-factor contributions were estimated in
SHELXC (Sheldrick, 2010; Sheldrick et al., 2001) and the
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Table 1
Crystallographic statistics.
Values in parentheses are for the highest resolution shell.
Structure/PDB code Ssp1/4bi3 Ssp1-C50A/4bi4 Rap1a/3zfi Rap2a/3zib Ssp1–Rap1a/4bi8
Space group P212121 P212121 C2221 P21 P3221
Wavelength (A˚) 1.5418 1.5418 0.97950 0.96110 1.5418
Unit-cell parameters
a (A˚) 56.83 56.79 82.65 39.65 68.47
b (A˚) 65.26 64.59 93.00 81.35 68.47
c (A˚) 97.50 97.87 51.26 58.45 92.52
# ($) 91.54 90.00
Resolution range (A˚) 48.75–1.85
(1.95–1.85)
48.93–2.21
(2.26–2.21)
46.50–1.98
(2.09–1.98)
40.67–1.90
(2.00–1.90)
49.92–2.00
(2.05–2.00)
No. of reflections 503341 (41592) 139598 (9390) 63106 (8849) 214423 (31351) 493039 (32290)
Unique reflections 31504 (4357) 18726 (1331) 14089 (2003) 29067 (4190) 17462 (1279)
Completeness (%) 99.4 (100.0) 99.9 (98.5) 99.9 (100.0) 99.4 (98.9) 99.9 (99.1)
Rmerge† (%) 7.4 (23.9) 7.5 (26.3) 6.6 (48.6) 9.7 (51.6) 10.9 (58.7)
Multiplicity 16.0 (9.5) 7.5 (7.1) 4.5 (4.4) 7.4 (7.5) 28.2 (25.2)
hI/$(I)i 33.7 (10.2) 23.0 (8.1) 13.4 (2.7) 15.3 (4.0) 40.9 (11.4)
Wilson B (A˚2) 10.7 18.1 31.5 21.7 18.8
Rwork‡/Rfree§ (%) 20.4/24.0 19.2/24.6 19.2/23.4 18.3/23.4 17.9/22.7
No. of residues 326 326 185 377 256
No. of waters 300 372 57 137 192
No. of ligands 3 K+, 5 SO4
2" 1 glycerol
DPI} (A˚) 0.13 0.21 0.15 0.15 0.16
R.m.s.d. bond lengths†† (A˚) 0.006 0.008 0.018 0.019 0.006
R.m.s.d. angles†† ($) 0.967 1.301 1.925 1.745 1.020
Average B factors (A˚2)
Chain A 12.7 17.7 34.3 19.7 15.6
Chain B 11.2 17.9 35.2 23.0 22.6
Chain C 22.4
Chain D 18.9
Waters 15.2 25.1 34.8 30.6 27.0
K+ 22.0
SO4
2" 12.5
Glycerol 35.9
Ramachandran plot analysis
Favoured regions 97.1 97.0 97.0 99.0 96.4
Allowed regions 2.9 3.0 3.0 1.0 3.2
Outliers 0 0 0 0 0.4 [Lys125]
† Rmerge =
P
hkl
P
i jIiðhklÞ " hIðhklÞij=
P
hkl
P
i IiðhklÞ, where Ii(hkl) is the intensity of the ith measurement of reflection hkl and
hI(hkl)i is the mean value of Ii(hkl) for all i measurements. ‡ Rwork =
P
hkl
!!jFobsj" jFcalcj!!=Phkl jFobsj, where Fobs is the
observed structure factor and Fcalc is the calculated structure factor. § Rfree is the same as Rcryst except calculated with a subset
(5%) of data that were excluded from the refinement calculations. } Diffraction-component precision index (Cruickshank,
1999). †† Engh & Huber (1991).
maximum resolution for substructure determination and
initial phase calculation was set to 2.30 A˚. All 14 heavy atoms
(sulfurs) were found using SHELXD (Schneider & Sheldrick,
2002). The correct hand for the substructure was determined
using ABS (Hao, 2004) and SHELXE (Sheldrick, 2002) and
the initial phases produced a CC (correlation coefficient) of
0.32. The initial phases were improved by density modification
(Terwilliger, 2003) prior to phase extension to 1.85 A˚ resolu-
tion. The CC improved to 0.63, resulting in an electron-density
map with excellent quality. Almost 80% of the model was
constructed in ARP/wARP (Langer et al., 2008). The initial
model consisted of two polypeptides of 295 residues in total,
with Rwork and Rfree values of 29.7 and 31.4%, respectively.
Subsequent model building extended this to 326 residues,
with the Rwork and Rfree values improving to 20.7 and 24.1%,
respectively.
A molecule of Ssp1 was used to solve the structures of the
Ssp1–Rap1a complex and the Ssp1-C50A mutant by mole-
cular replacement (autoMR; Winn et al., 2011). The structures
of Rap1a and Rap2a were solved by molecular replacement
(Phaser; McCoy et al., 2007) using the structure of Rap1a from
the Ssp1–Rap1a complex and Rap2b (PDB entry 4b6i; English
et al., 2012), respectively. In the latter case the sequence
identity shared by the search model and the target structure is
only about 20%.
All structures were refined in an iterative process
combining REFMAC5 (Murshudov et al., 2011) with electron-
density and difference-density map inspections and model
manipulations in Coot (Emsley et al., 2010). For those struc-
tures with multiple copies in the asymmetric unit, tight
NCS (noncrystallographic symmetry) restraints were imposed
which were gradually released during refinement. Translation/
libration/screw analysis (TLS) refinements were applied with
the appropriate groups determined using the TLSMD server
(Painter & Merritt, 2006). Water molecules, and in the case of
the Ssp1 structure also potassium and sulfate ions, were added
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Figure 1
The specificity of Ssp1 and Ssp2. (a) Peptidoglycan from E. coli strain D456 was incubated with Ssp1, Ssp2 or no enzyme (control) followed by digestion
with the muramidase Cellosyl and analysis of the resulting muropeptides by HPLC. Both Ssp1 and Ssp2 cleaved non-cross-linked (tri, tetra and penta)
and cross-linked (tetratetra and tetrapenta) muropeptides between d-glutamate and meso-diaminopimelic acid (m-A2pm), resulting in the disaccharide
dipeptide (di) product. Ssp2 also produced a small amount of the disaccharide hexapeptide (hexa) product. (b) Proposed structures of the muropeptides
separated in (a). The arrows indicate the cleavage sites of d-iGlu-m-A2pm endopeptidases in peptidoglycan. GlcNAc,N-acetylglucosamine; MurNAc(r),
N-acetylmuramitol; m-A2pm, meso-diaminopimelic acid.
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Figure 2
The Ssp1 and Ssp2 C50A mutants are inactive. (a) Growth of E. coli MG1655 transformed with plasmids expressing OmpAsp-Ssp1 (sp-Ssp1; pSC152),
OmpAsp-Ssp1(C50A) [sp-Ssp1(C50A); pSC548], OmpAsp-Ssp2 (sp-Ssp2; pSC138) or OmpAsp-Ssp2(C50A) [sp-Ssp2(C50A); pSC549] from an
arabinose-inducible promoter, or with the empty vector (VC, pBAD18-Kn), on LB or M9 medium containing 0.2% arabinose. (b) Recovery of a
sensitive !rap2a mutant as the target strain following co-culture with the different attacking strains indicated, expressed relative to recovery of target
when co-cultured with the wild-type strain. Attacking strains are wild-type S. marcescensDb10 (WT), mutant lacking ClpV (!clpV), mutant lacking Ssp2
(!ssp2), each carrying either the vector control plasmid (+VC; pSUPROM) or a plasmid expressing wild-type Ssp2 (+Ssp2; pSC541) or the C50Amutant
of Ssp2 [+Ssp2(C50A); pSC1230]. (c) Phenotypes of wild-type S. marcescens Db10 and selected single and double mutants carrying plasmids expressing
variants of Ssp1 or Ssp2 following growth on solid medium. For each strain, representative images of the morphology of a culture spot (left; scale bar
1 mm), single colonies (middle; scale bar 1 mm) and individual cells [right; scale bar 2 mm in (i) or 5 mm in (ii)] are shown. Plasmids direct the expression
of wild-type Ssp1 (+Ssp1; pSC539), the C50A mutant of Ssp1 [+Ssp1(C50A); pSC1229], wild-type Ssp2 (+Ssp2; pSC541), the C50A mutant of Ssp2
[+Ssp2(C50A); pSC1230] or represent the vector control (+VC, pSUPROM). Growth was for 48 h onMM (i) or 24 h on LB (ii). (d) Immunoblot analysis
of levels of Ssp1 or Ssp2 proteins from E. coli MG1655 (top two panels) or S. marcescens (bottom two panels) grown on solid medium. Strains and
plasmids are as in (a)–(c), except that wild-type OmpAsp-Ssp1 and OmpAsp-Ssp2 were co-expressed with their cognate immunity proteins to allow the
strains to grow [sp-Ssp1(WT)Rap1a; pSC160 or sp-Ssp2(WT)Rap2a; pSC144].
during the refinement process. Where appropriate, dual
rotamer side-chain conformations were also included.
Refinements were terminated when there were no significant
changes in the Rwork and Rfree values and inspection of the
difference density maps suggested that no further corrections
or additions were justified.
MolProbity (Chen et al., 2010) was used to investigate the
model geometry. Secondary-structure and surface-interaction
analyses were performed using DSSP (Kabsch & Sander,
1983) and PISA (Krissinel & Henrick, 2007), respectively.
Figures were prepared using ALINE (Bond & Schu¨ttelkopf,
2009) and PyMOL (Schro¨dinger). The DALI server was used
to search the PDB for structural homologues, whilst super-
positions were calculated using DaliLite (Holm & Park, 2000).
Relevant crystallographic statistics and geometric details of
the refined models were extracted from the programs used in
the analyses and are reported in Table 1.
3. Results and discussion
3.1. Activity of Ssp1 and Ssp2 and neutralization by cognate
Rap partners
We previously identified S. marcescens Ssp1 and Ssp2 as
periplasmic acting antibacterial T6SS effectors (English et al.,
2012) and noted their membership, on the basis of sequence
similarity, of the family 4 amidases (Tae4 proteins) proposed
by Russell et al. (2012). We aimed to experimentally determine
the enzymatic activity of each protein. The incubation of
peptidoglycan sacculi with purified Ssp1 or Ssp2, followed by
muramidase digestion and high-pressure liquid-chromato-
graphy analysis, revealed the disaccharide dipeptide as the
single major product. This indicates that both enzymes cleave
the amide bond in peptidoglycan between isoglutamic acid
andmeso-diaminopimelic acid. Ssp1 quantitatively hydrolyzed
monomeric tripeptides, tetrapeptides and pentapeptides, as
well as dimeric tetratetrapeptides and tetrapentapeptides, on
both the acceptor and the donor side (Fig. 1). In the cross-
linked peptides, the "-amino group of the meso-diamino-
pimelic acid residue at position 3 on the acceptor side is
connected by an amide bond to the "-carboxylic group of
d-alanine at position 4 on the donor side. Although Ssp2 was
active against these muropeptides, the cleavage of monomeric
pentapeptide and dimeric tetratetrapeptide was less efficient
and the partially cleaved disaccharide hexapeptide product
was detected (Fig. 1a). This behaviour is similar to the family 4
amidase Tae4 from Salmonella Typhimurium (STTae4, also
known as Tae4TM; Russell et al., 2012). Hence, Ssp2 and
STTae4 preferentially cleave tetrapeptides in the acceptor
part of cross-linked peptides. This is distinct from P. aerugi-
nosa Tse1, which preferentially cleaves pentapeptides in the
donor part of cross-linked peptides (Chou et al., 2012; Russell
et al., 2012). These data indicate that Ssp1 and Ssp2 are
distinctive peptidoglycan dl-endopeptidases in terms of
specificity, with the former being more promiscuous regarding
the chemical structure that it is able to recognize and then
cleave.
Established functional assays
were utilized to examine the
effect of mutating the catalytic
cysteine (Cys50) of Ssp1 and
Ssp2. Heterologous expression
targeting Ssp1 and Ssp2 to the
periplasm of E. coli MG1655
prevents growth on M9 minimal
medium and, in the case of Ssp2,
also on LB medium. As shown in
Fig. 2(a), Ssp1-C50A and Ssp2-
C50A were no longer toxic to
E. coli. In S. marcescens itself,
a mutant lacking the immunity
protein, !rap2a, is susceptible to
self-killing by Ssp2 injected by the
wild-type strain. This is shown in
two ways. Firstly, co-culture of a
wild-type attacker strain with a
!rap2a target strain results in the
death of the latter. When the
attacker lacks a functional T6SS
(!clpV) or Ssp2 (!ssp2 mutant),
increased recovery of the target
strain is observed. Comple-
mentation of the !ssp2 mutant
attacker by expression of wild-
type Ssp2 from a plasmid restores
the killing activity, with the
recovery of the target reduced
below the levels observed with
the wild-type attacker. However,
the expression of Ssp2-C50A was
unable to complement the !ssp2
mutant and restore the killing
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Figure 3
Primary, secondary and tertiary structure of Ssp1. (a) The amino-acid sequence of Ssp1 with assigned
elements of secondary structure. Helices are depicted as cylinders and #-strands as arrows. An alignment of
Ssp1 and Ssp2 is also shown with strictly conserved residues shown on a black background. Residues
involved in disulfide-bond formation are coloured yellow. (b) Cartoon representation of Ssp1 with
secondary-structure elements labelled. The disulfide bond is shown in stick representation with C-atom
positions in yellow and S-atom positions in gold. His133 and Cys50 (sticks) mark the active site.
activity (Fig. 2b). Secondly, a single !rap2a mutant exhibits
fitness and morphological defects when grown on solid
medium and these defects are alleviated when ssp2 is also
deleted in a !rap2a!ssp2 mutant. Plasmid-mediated expres-
sion of Ssp2 in the!rap2a!ssp2mutant re-induced the fitness
and morphological defects caused by self-killing; however,
expression of the Ssp2-C50A mutant had no negative effect
(Fig. 2c). Similarly, expression of Ssp1, but not Ssp1-C50A, in
a !rap1a!ssp1 mutant induced mild morphological defects
(Fig. 2c). In each case, an equivalent level of stable expression
of Ssp1-C50A and Ssp2-C50A compared with wild-type Ssp1
and Ssp2 was confirmed by immunoblotting (Fig. 2d).
3.2. Catalytic inactivation of Ssp1 and Ssp2 does not affect
their secretion or immunity protein binding
It was necessary to confirm that the above observations
were not affected by any influence of the catalytic C50A
mutation on immunity protein binding or secretion of the
effectors. Each of the Ssp C50A mutants was mixed with an
equimolar amount of the cognate Rap protein, followed by
size-exclusion chromatography analysis to monitor complex
formation. In each case, a single species of apparent molecular
weight '55 kDa was observed (Supplementary Fig. S1a1).
This behaviour exactly matches that of the wild-type proteins
(English et al., 2012) and indicates that complexes consisting of
two Ssp and two Rap polypeptides are formed. It was also
demonstrated that the Ssp2-C50Amutant protein was secreted
by the T6SS of S. marcescens as efficiently as the wild-type
protein (Supplementary Fig. S1b). We conclude that mutation
of the catalytic cysteine in Ssp1 and Ssp2 abolishes their
bacteriolytic effect because the dl-endopeptidase activity is
compromised. Furthermore, we can conclude that the Ssp–
Rap interaction does not depend on the catalytic cysteine and
that recognition of the Ssp effectors by the T6SS machinery is
also independent of their enzymatic activity.
3.3. Structure of Ssp1
To gain a detailed insight into the structure and activity of
the peptidoglycan endopeptidase effector Ssp1, we applied
crystallographic methods. Isomorphous crystal structures of
Ssp1 (at 1.85 A˚ resolution) and the active-site Ssp1-C50A
mutant (at 2.2 A˚ resolution) reveal the overall enzyme struc-
ture and details of the active site. The protein is a monomer in
solution but crystallized with two molecules in the asymmetric
unit, each consisting of residues 1–163. The root-mean-square
deviations (r.m.s.d.s) between least-squares superimposed C"
atoms gives an average of 0.3 A˚ when comparing the four
polypeptides in the crystal structures. The copies in the
asymmetric unit are therefore judged to be essentially iden-
tical and neither mutagenesis of the catalytic Cys50 nor crystal
lattice packing interactions induces any major structural
changes.
The primary, secondary and tertiary structure of Ssp1
(Fig. 3) classifies it into the NlpC/P60 cysteine peptidase
superfamily (Anantharaman & Aravind, 2003). The overall
dimensions of the bilobal structure are about 35 # 40 # 50 A˚.
An N-terminal subdomain comprises residues 1–95 and is
formed by six "-helices ("1–"6) and, on the surface of the
protein, a #-hairpin-like loop (#1, turn, #2). A short peptide
segment links "6 to #3, which represents the start of the
C-terminal subdomain. This subdomain is dominated by a
four-stranded antiparallel #-sheet with order #3–#7–#4–#5,
which is flanked on one side by "7 and #6 and on the other
by "6. A disulfide bond is observed between Cys146 at the
C-terminal end of #6 and Cys150 located on the loop linking
#6 to #7. A cleft, the substrate-binding site, is created between
the subdomains by residues in the "1–"2 and "4–"5 links, the
C-terminal segment of #6 and the loop leading to #7. The
disulfide linkage appears important to create one side of the
active site and perhaps also contributes to the stability of the
C-terminal subdomain fold.
The family 4 amidase effectors hydrolyze the amide bond
between d-Glu and mA2pm. They are similar to CHAP
(cysteine, histidine-dependent amidohydrolases/peptidases)
family members, a subset of the NlpC/P60 superfamily with a
strictly conserved cysteine–histidine catalytic dyad (Fyfe et al.,
2008). In the case of Ssp1, Cys50 is located in the N-terminal
subdomain and His133 in the C-terminal subdomain (Fig. 3b).
Cys50 donates a hydrogen bond to a water molecule, which in
turn interacts with His133, Asn48 and Tyr129 (Fig. 4). Asp135
accepts a hydrogen bond from His133 and appears to
complete a catalytic triad reminiscent of that observed in
typical cysteine peptidases. The mechanism of such cysteine-
dependent proteases, especially papain, is well documented
(Alphey & Hunter, 2006 and references therein). The Cys–His
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Figure 4
The Ssp1 catalytic centre. The protein is shown as a semi-transparent van
der Waals surface coloured according to atom type (N, blue; O, red; S,
yellow; C, white). A water (blue sphere) participates in four hydrogen-
bonding interactions with Asn48, Cys50, Tyr129 and His133. Hydrogen
bonds are shown as dashed lines and selected residues are presented as
sticks with C-atom positions coloured orange, N blue, O red and S yellow.
1 Supplementary material has been deposited in the IUCr electronic archive
(Reference: BE5242). Services for accessing this material are described at the
back of the journal.
catalytic dyad forms a thiolate–imidazolium pair that is
oriented by a hydrogen bond between the histidine and an
acidic residue. In this case the residues are Cys50, His133 and
Asp135. The generation of a thiolate Cys50 following proton
abstraction by His133 would support nucleophilic attack at the
!-d-glutamyl-mA2pm amide bond to form an acyl thioester.
Hydrolysis of the thioester, exploiting an activated water
molecule, then releases the products. The main-chain amides
of the catalytic cysteine and Thr49 create an oxyanion hole
that may support thiolate attack on the amide linkage by
stabilizing the tetrahedral intermediate formed prior to the
formation of an acyl-enzyme complex. In this there are
striking parallels to the reaction catalyzed by nicotinamidase
(Fyfe et al., 2009).
Ssp1 shares about 20% sequence identity with Ssp2, but we
do not have a structure of Ssp2 for comparative purposes to
address the observation of distinct substrate specificities.
However, the closest structural relative of Ssp1 is the bacterio-
lytic effector Tae4 from E. cloacae and S. typhimurium (PDB
entries 4hfk and 4hff, respectively; Zhang et al., 2013), with
Z-scores of 17 and 16 and r.m.s.d.s of 2.2 and 2.1 A˚ for the
least-squares fit of 138 and 137 C" positions, respectively. Ssp1
shares about 15% sequence identity with these proteins but,
despite such a low sequence similarity, the r.m.s.d. values and
overlay confirm that these structures share the same fold
(Supplementary Fig. S2). On the basis that Ssp2 shares about
50% sequence identity with Tae4 and the same substrate
specificity, we suggest that it provides a suitable surrogate
structure for comparative purposes.
An overlay of the Ssp1 and Tae4 structures confirms simi-
larities in the protein fold and the relative positions of residues
linked to catalytic activity. However, the overlay also indicates
noteworthy differences (Supplementary Figs. S2 and S3). The
"1–"2 loop in Ssp1, consisting of about 15 amino acids, lines
one side of the active site then extends away from the catalytic
core. Adjacent to this loop is a turn carrying the Cys146 and
Cys150 disulfide. The turn and the polypeptide that follows,
which lead directly into #7, line the active site. In EcTae4, the
disulfide is conserved (Cys137 and Cys141), as is the structure
just after the turn. An eight-residue segment extends from the
turn and curls over to narrow the active-site cleft. In STTae4
the conserved residues Cys135 and Cys139 are in a reduced
form, for reasons that are not made clear, and the polypeptide
chain at the periphery of the active site is flexible and dis-
ordered, as shown by inflated thermal parameters and a lack
of electron density. Alignment of the Ssp1 and Ssp2 amino-
acid sequences (Fig. 3a) indicates that there is a truncation of
four residues in the region of the disulfide-containing loop and
this may reduce the size of the active-site cleft of Ssp2
compared with Ssp1. The alignment also suggests that Asp135
of Ssp1, assigned as a component of the catalytic triad, is not
conserved and corresponds to Thr133 in Ssp2. In STTae4 and
EcTAE4 a threonine is also
present at this position (Supple-
mentary Fig. S4). A superposition
of Ssp1 and EcTAE4 indicates a
difference of Ser148 replaced by
Asp139, with the carboxylic acid
side chain positioned to fulfil the
role of Asp135 of Ssp1 in the
catalytic triad (Supplementary
Fig. S3). The aspartate is
conserved in Ssp2, STTae4 and
EcTAE4 (Supplementary Fig.
S4).
The peptidoglycan hydrolase
assay data indicate that Ssp2
preferentially targets the acceptor
component of the peptidoglycan
tetratetra cross-link rather than
donor part and in this it is similar
to Tae4 (Russell et al., 2012). Ssp1
cleaves the acceptor and donor
stem of cross-linked and non-
cross-linked peptidoglycan. The
differences evident from struc-
tural comparisons suggest that a
distinctive and more open
substrate-binding surface in Ssp1
compared with those observed in
Tae4 structures or implied in Ssp2
might explain the promiscuous
endopeptidase activity of Ssp1.
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Figure 5
Primary, secondary and tertiary structure of Rap1a. (a) The sequence of mature Rap1a. The 26-residue
N-terminal signal sequence is not shown. These residues represent the cleaved N-terminal signal sequence
that was omitted from the analysis. The assigned "-helical secondary structure is shown and the helices are
numbered. Residues involved in disulfide-bond formation are coloured yellow and residues that contribute
to the dimer interface are shown on a blue background. (b) Cartoon representation of the Rap1a dimer
with labelled helices; Nt and Ct mark the N- and C-terminal positions. The disulfides formed between Cys78
and Cys122 are shown as yellow sticks. (c) The residues and hydrogen bonds (dashed lines) at the dimer
interface. C atoms are shown in grey and cyan to distinguish the subunits.
Structures of complexes with the appropriate ligands would be
required to further investigate this point.
3.4. Structure of Rap1a
Next, we sought to reveal molecular details of the immunity
proteins Rap1a and Rap2a, which neutralize Ssp1 and Ssp2
toxicity, respectively (English et al., 2012). The structure of
Rap1a was determined to about 2.0 A˚ resolution (Table 1) and
the amino-acid sequence with assigned secondary structure is
depicted in Fig. 5(a). A search for structural orthologues failed
to identify anything of relevance in the PDB. We therefore
conclude that the Rap1a fold has not been observed
previously, making it a unique member of the T6SS immunity
family of proteins. Several other candidate immunity proteins
identified in other organisms share significant sequence
identity with Rap1a (see below). Therefore, we propose that
this group of proteins be referred to as the ‘Tai4a’ immunity
proteins, to reflect the fact that whilst they are immunity
proteins to Tae4 effectors, they are distinct from the main
family of Tai4 proteins, which includes Rap1b, Rap2a and
Rap2b.
The Rap1a subunit displays a compact globular structure
constructed from five "-helices that assemble to form the
highly stable symmetric dimer that constitutes the asymmetric
unit (Fig. 5). This is consistent with the size-exclusion chro-
matography data, which identified that only a dimer was
observed in solution (Supplementary Fig. S1). The NCS is
highly conserved, with an r.m.s.d. of 0.6 A˚ for a least-squares
overlay of 96 C" positions. A disulfide bond is formed between
Cys78 (in the "2–"3 loop) and Cys122 in the C-terminal
region. This interaction appears to be crucial to stabilizing the
subunit fold since it helps position "2, "3 and "5 close to each
other and these segments of secondary structure provide the
side chains that form the hydrophobic core of the subunit.
During initial recombinant expression tests it was noted that
soluble protein was only produced in E. coli Rosetta-gami
(DE3) cells, a strain that promotes the formation of disulfide
bonds in the cytoplasm and so mimics what might occur in the
oxidative environment of the periplasm. This suggests that the
covalent bond is necessary for correct folding to occur and for
stability of the Rap1a fold and dimeric quaternary structure.
Interactions involving residues in "2 make the major
contribution to dimer formation. Each subunit contributes
a surface area of 1130 A˚2 to the dimer interface, which is 20%
of the solvent-accessible surface area (ASA) of the subunit
(5700 A˚2). Such a percentage of surface area is indicative of a
stable association (Krissinel & Henrick, 2007). Eight residues
from each subunit form a
network of hydrogen bonds using
both main-chain and side-chain
functional groups (Ser36, Asn40,
Leu41, Glu59, Tyr64, Asp70,
Lys75, Arg107 and Glu113,
Fig. 5c). There are also indirect
hydrogen-bonding interactions
via well ordered water molecules
that link a number of side chains
and main chains. Hydrophobic
interactions that contribute to the
stability of the dimer mainly
involve the aliphatic side chains
of Val39, Ile63, Leu66, Val68 and
Ala71, but also Tyr80.
3.5. Structure of Rap2a
Rap2a, like Rap1a, is predicted
to be localized in the periplasm
and could only be produced in
soluble recombinant form using
the E. coli Rosetta-gami (DE3)
strain. It is also a stable dimer in
solution as shown by size-exclu-
sion chromatography (English
et al., 2012). The structure was
determined at 1.9 A˚ resolution
with four molecules, arranged as
two dimers, in the asymmetric
unit. These four molecules, sub-
units A–B and C–D, are similar
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Figure 6
Primary, secondary and tertiary structure of Rap2a. (a) The amino-acid sequence with assigned secondary
structure and helices numbered. Residues involved in disulfide-bond formation are coloured yellow and
residues involved in subunit–subunit interactions are shown on a blue background. (b) Cartoon
representation of the Rap1a dimer with subunits coloured brown and green. The disulfides and the N- and
C-termini are labelled. (c) Cartoon representation of Rap2b (pink) and EcTai4 (grey) superimposed on
Rap2a (green). Asp54 and Asp47 are involved in the hydrogen-bond network in the interface in EcTai4 and
are absolutely conserved in Rap2b; in Rap2a, Asp47 is replaced by Ser48. Arg40 and Glu74 (replaced by
Val41 and Thr75, respectively, in Rap2a) have been shown to play a major role in binding to EcTae4; both
of these residues are also conserved in Rap2b but not in Rap2a.
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overall, with r.m.s.d.s between superimposed C" atoms ranging
from 0.6 A˚ (subunits A and B, residues Thr27–Gln123) to
0.7 A˚ (subunits C, residues 27–127, and D, residues 27–126).
Minor deviations from NCS are observed in a five-residue
loop between "2 and "3 (Gly67–Leu71) and indicate some
conformational freedom in this part of the molecule. The ASA
of a Rap2a subunit averages at approximately 6110 A˚2; the
range is from 6140 A˚2 for subunit C to 6090 A˚2 for subunit D.
Dimer formation occludes an area that is approximately 20%
of the ASA, which is indicative of a stable association (Kris-
sinel & Henrick, 2007).
The Rap2a subunit displays a compact globular structure of
five "-helices with an extended loop linking "3 to "4 (Figs. 6a
and 6b). A disulfide bond between Cys42 and Cys102 links
"1 to "4 and interactions of other side-chain groups on these
elements of secondary structure help to create the helical
bundle fold and in particular to align "2. Together, "1, "2, the
"2–"3 loop and "4 form the dimer interface, giving rise to a
twofold NCS axis, and a combination of hydrogen-bonding,
Figure 7
The Ssp1–Rap1a heterotetramer complex. (a) Ssp1 is shown as an orange van der Waals surface and the Rap1a subunits are shown as cyan and grey
ribbons. The disulfide bonds in Rap1a are presented as yellow sticks. Blue, red and purple circles mark the three distinct areas (I–III) of interaction
between the effector and immunity proteins. (b) Schematic diagram showing the hydrogen-bonding and salt-bridge interaction network involved in
complex formation. Black lines mark interacting residues. Residue positions in the protein structures are given by labelling the appropriate secondary
structure. The exceptions are Gln84 in Rap1a, which occurs just prior to "3 in this structure, and Asn48 and Asp130 in Ssp1, which are between "4 and "5
and at the C-terminal segment of #4, respectively. (c) Gln84 directly interacts with the catalytic His133 and blocks the active site. Grey, apo Ssp1; dark
orange, Ssp1 from the Ssp1–Rap1a complex; cyan, Rap1a from the Ssp1–Rap1a complex. Broken arrows indicate the adjustments of Asn48 and Tyr129
when comparing free and complexed Ssp1.
salt-bridge and van der Waals interactions serve to stabilize
the association. Main-chain hydrogen-bonding contributions
come from the amides of Ser48, Ala49, Met97, Thr98 and
Met99 on both chains. Side-chain contributions come from the
hydroxyl groups of Tyr28 and Tyr47 and the carboxylates of
Glu51, Asp55 and Asp104. Several solvent-mediated contacts
also serve to link functional groups on partner subunits (not
shown). The side chains of Leu39, Ile43, Tyr47, Val52, Met99
and Ile103 are involved in van der Waals interactions with the
partner subunit to stabilize the dimer.
Despite a low level of sequence conservation, the structural
similarity of five T6SS immunity proteins (Rap1b, Rap2a,
Rap2b, EcTai4 and STTai4) indicates an orthologous subset.
This structurally defined set is consistent with the designation
of a ‘Tai4’ family of immunity proteins cognate to the Tae4
effectors (Russell et al., 2012). Pairwise comparisons indicate
a range of sequence identities from 15 to 35%, and matching
between 93 and 124 C" positions gives an r.m.s.d. range of 1.2–
1.7 A˚ indicative of close structural similarity. The structural
overlay is exemplified by superposition of Rap2a, Rap2b and
EcTai4 (Fig. 6c). Of note is the conservation of an extended or
protruding loop structure which is highly variable in terms of
amino-acid sequence (see Fig. 7 in English et al., 2012). Parts
of the EcTai4 subunit involved in interaction with an effector,
identified by the positions of Val41 and Thr75 in Rap2a, are
also well conserved in terms of overall structure (Fig. 6c).
This subset of immunity proteins also display similar dimer
structures and the Cys42–Cys102 disulfide bond in Rap2a is
conserved in Rap1b and Rab2b. The covalent interaction
appears to be important for the creation of the subunit fold
and the stable quaternary structure. In the structures of
EcTai4 and STTai4 there are conserved cysteines that match
the disulfide-forming residues in the Rap proteins; however,
they are in a reduced form. In STTai4, for example, the
distance between the SG atoms of Cys48 and Cys108 is 3.6 A˚
and the electron density unambiguously defines reduced
cysteine residues. This difference in the redox states may
simply reflect distinct experimental conditions.
3.6. Inhibition of Ssp1 by Rap1a
We next sought to delineate the molecular basis of how
the S. marcescens Rap proteins neutralize their cognate Ssp
amidase/endopeptidase effectors and what features engen-
dered the exquisite specificity noted in the effector–resistance
protein combinations. We previously proposed that the
complexes exist as Ssp2–Rap2 heterotetramers based on
biochemical analyses (English et al., 2012), a conclusion that
was subsequently confirmed by the structures of related Tae4–
Tai4 complexes (Zhang et al., 2013). The similarities of Ssp2
and Rap2a to Tae4 and Tai4 in terms of peptidoglycan
hydrolase activity, sequence and structure suggested that the
mode of effector inhibition is similar and this will be discussed
below. In contrast, Ssp1 displays differences in activity and
structure from Tae4 and is biologically distinct from Ssp2. In
addition, the structure of Rap1a presents a new fold distinct
from the Tai4 proteins; hence, it was important to elucidate the
structure of an Ssp1–Rap1a complex.
Following purification using a co-expression strategy, we
determined the structure of the Ssp1–Rap1a complex at about
2.0 A˚ resolution. There are two molecules in the asymmetric
unit (one Ssp1 and one Rap1a) and a crystallographic twofold
axis given by the symmetry operation x " y, "y, "z + 2/3
generates a heterotetramer (Fig. 7a). The overall dimensions
of this heteromeric assembly are about 90 # 50 # 50 A˚ and
its molecular weight is approximately 60 kDa, consistent with
that observed by size-exclusion chromatography during puri-
fication of the complex (Supplementary Fig. S1). The model
contains residues 1–163 of Ssp1 and residues 30–123 of Rap1a.
The solvent-accessible surface area of Ssp1 is 5840 A˚2 and
about 16% of this (960 A˚2) is occluded when the complex with
Rap1a is formed.
Rap1a interacts with Ssp1 using residues in "1, "3, "4, "5
and the "4–"5 loop (Fig. 7). In particular, the "4–"5 loop and
"4 of Rap1a are directly positioned to block the Ssp1 active
site. An extensive network of hydrogen bonds, van der Waals
forces and water-mediated hydrogen bonds are present at the
Ssp1–Rap1a interface. These interactions occur primarily in
two areas (areas I and II in Fig. 7a). A total of 13 Ssp1 residues
(Asp16, Tyr17, Ser18, Tyr22, Ala25, Asp37, Ala47, Asn48,
Arg53, Asp130, His133, His149 and Tyr151) and 12 Rap1a
residues (Tyr50, Lys58, Arg62, Ser81, Gln82, Gln84, Thr85,
Val86, Thr87, Glu90, Glu94 and Arg119) contribute to the
network of interactions and the details are presented in a
schematic form in Fig. 7(b). Gln84 of Rap1a forms a hydrogen
bond to the N% atom of the catalytic His133 of Ssp1 and is a
clear marker of the steric block provided by the immunity
protein (Figs. 7b and 7c). Arg119, Arg66, Lys59, Glu94 and
Glu94 of Rap1a form salt-bridge interactions with Asp37,
Asp16, Glu140, Arg53 and Arg53 of Ssp1, respectively. Tyr50
in "1 of Rap1a interacts with Tyr17 from Ssp1 through a
hydrogen bond and &-stacking. A small interface (100 A˚2) is
created where Asp36 from Rap1a and His149 from Ssp1
interact (area III in Fig. 7).
An overlay (not shown) of the two Rap1a structures, alone
and in complex with Ssp1, gives an r.m.s.d. of 0.4 A˚ for 94 C"
atoms, indicating a high similarity in overall structure with no
major conformational differences. Rap1a therefore appears to
be a highly stable pre-formed binding partner for Ssp1 when in
the correct redox state. There is, however, a localized effect
following complex formation. In Rap1a, the segment linking
"2 and "3, residues 74–84, shows high average B factors
(temperature factors; 76.4 A˚2) compared with the overall
average B factor (31.5 A˚2) and relatively diffuse electron
density. This region contributes to Ssp1–Rap1a complex
formation and becomes well ordered, with an average B factor
of 15.6 A˚2 compared with the overall B factor of 22.6 A˚2 for
the Rap1a component of the complex. The overall structure of
Ssp1 is also well retained between the free and complexed
states, with an r.m.s.d. of 0.8 A˚ for the least-squares fit of 162
C" atoms. There are localized adjustments which appear to
support complex formation. In the "1–"2 loop of Ssp1, Tyr17
is relocated by about 7 A˚ to interact with Tyr50 and Arg62
of Rap1a. In addition, Asn48 and Tyr129 of Ssp1 move 1.8 and
3.5 A˚ outwards and away from the catalytic centre (Fig. 7c).
The Tae4–Tai4 complex from E. cloacae also forms a
heterotetrameric assembly, with the Tai4 dimer forming the
central segment and a Tae4 effector at either end (Zhang et al.,
2013). The complex is stabilized by extensive noncovalent
interactions formed between the effector and both Tai4
subunits. The protruding loop (Fig. 6c) of one Tai4 subunit
binds in the active site of the effector and helices "2 and "3 of
the other subunit are positioned to interact with residues in
the N-terminal subdomain. This Tae4–Tai4 complex is likely
to be a good model for the Ssp2–Rap2a complex. The close
structural relationship, in terms of fold, for both the effector
and the immunity proteins (see, for example, Fig. 6) would
suggest that Rap2a would interact with Ssp2 in a similar
fashion and that the selectivity of immunity proteins with the
Rap2a fold for or against other enzymes would be determined
by variation in the side chains. Such differences are likely to
involve residues in the loops linking "2 to "3 and "3 to "4 in
the immunity proteins, which interact with the "3–"4 section,
the #4–#5 loop and the N-terminal section of #7 in some Tae4
proteins. These parts of the proteins are poorly conserved in
terms of sequence identity (Supplementary Figs. S4 and S5).
However, the complex assembly that leads to inhibition is
completely distinct between Ssp1 and the other Tae4 systems.
Rap1a, which has a completely different fold to the conven-
tional Tai4 proteins, does not possess a protruding loop, but in
the complex a helix is positioned to block the effector active
site and the interactions that stabilize the complex involve
residues in the C-terminal subdomain of the effector rather
than the N-terminal subdomain (Supplementary Fig. S6).
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3.7. Co-evolved diversity within the Tae4/Ssp and Tai4/Rap
families
Finally, we considered the question of why S. marcescens
has two Tae4 homologues (Ssp1 and Ssp2) and four Rap-
family proteins rather than just one amidase effector–
immunity combination. Ssp1 and Ssp2 are not redundant since
they elicit different biological consequences in a target cell.
For example, as shown here and previously (Fig. 2; English et
al., 2012), an immunity mutant suffering Ssp2-mediated killing
is highly unfit and displays striking cell filamentation, whereas
an immunity mutant suffering Ssp1-mediated killing is less
disabled and shows round enlarged cells. The difference
between the Ssp1-mediated and Ssp2-mediated effects may be
related to the apparent modulation of substrate preference
observed in the in vitro enzyme assays, perhaps reflecting
differences in the extent or pattern of cell-wall damage (Fig. 1).
This study has unexpectedly revealed that the cognate
immunity protein for Ssp1, Rap1a, has a distinct structure
compared with the other Rap and Tai4 proteins studied to
date (Fig. 5).
A comparison of the amino-acid sequences of Ssp1, Ssp2
and Tae4 homologues showed that Ssp1 and several other
Tae4 homologues form a distinct grouping (Fig. 8). This is
consistent with several structural differences being observed
in Ssp1 compared with EcTae4 (Supplementary Fig. S2). When
the adjacently encoded known or putative immunity protein
was identified for all of these effectors and compared with the
four S. marcescens Rap proteins, a pattern became evident.
The Ssp1-like proteins all co-occur with immunity proteins of
the Rap1a type. The other Tae4 homologues are less separated
from each other, but there is a clustering of Tae4 proteins
sharing related immunity proteins. So, for example, the three
Tae4 proteins whose immunity proteins are most closely
related to Rap1b all cluster together (Fig. 8) and the Tae4
homologues most similar to Ssp2 all have associated Rap2a-
like immunity proteins (Fig. 8). Hence, effector and immunity
proteins appear to have co-evolved within the Tae4 and Tai4
family. In particular, the Ssp1-like proteins appear to form a
subgroup distinct enough to utilize a structurally unrelated
immunity protein (‘Tai4a’), exemplified by Rap1a. The reason
for this divergence is unclear, although it is consistent with the
distinct biological phenotypes associated with the two effec-
tors. Having both Ssp1 and Ssp2 is likely to confer an evolu-
tionary advantage on the secreting organism, perhaps with
each being more efficient against different target species or
under different growth conditions than the other. Addition-
ally, having Ssp1 may allow attack on a close relative with
Ssp2/Rap2a and vice versa, maximizing the ability to distin-
guish ‘self’ from competitors.
This analysis strongly suggests that Rap1b and Rap2b are
not ‘inactive’ immunity proteins; rather, they are likely to
provide protection against incoming Tae4 proteins from other
T6SS-elaborating bacterial species. Rap1b is most closely
related to immunity proteins associated with Tae4 proteins
(Fig. 8) and thus would be expected to bind an effector of this
type and not Ssp1- or Ssp2-like Tae4 proteins. Similarly, Rap2b
may neutralize Tae4 proteins related to EcTae4 (Fig. 8). This
idea would also predict that neither Rap1b nor Rap2b would
bind Ssp1 or Ssp2, and indeed we have shown previously that
they do not (English et al., 2012). Other bacteria can also be
observed to possess ‘extra’ Tai4 proteins compared with their
Tae4 complement (this study and Russell et al., 2012). For
example, Cronobacter sakazakii has ‘orphan’ Rap1a, Rap2a-
like and Rap2b-like proteins (ESA_03939, ESA_03933 and
ESA_03932) in addition to its Ssp1–Rap1a pairing. Thus, one
could envisage an ‘arms race’ in which attackers can gain an
advantage by acquiring a Tae4 protein of a different subgroup
whilst targets can counter by acquiring an immunity protein of
the matching type.
4. Concluding remarks
Our structural and activity data, and comparisons with related
systems, reveal that the T6SS family 4 endopeptidase effectors
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Figure 8
Subgroups of Tae4 family proteins and their associated immunity
proteins. Neighbour-joining tree calculated from a multiple sequence
alignment of Ssp1, Ssp2 and other Tae4 homologues from different
bacterial species (a full alignment is shown in Supplementary Fig. S6). For
each Tae4 protein, the adjacently encoded candidate immunity protein
was identified by genomic analysis and the S. marcescens Rap protein to
which it was most closely related was determined. Tae4 homologues with
associated immunity proteins similar to Rap1a (Tai4a) are shown by red
circles, whereas those with immunity proteins of the Rap1b/Rap2a/Rap2b
(Tai4) type are shown by squares (in light blue, green or dark blue for
most similarity to Rap1, Rap2a or Rap2b, respectively). Apart from Ssp1
and Ssp2 from S. marcescens, the Tae4 homologues are labelled by
organism and their identities are as follows (UniProt or genomic
identifiers): Acinetobacter baumannii, B0VVE3_ACIBS; Agrobacterium
tumefaciens, Atu4347; Burkholderia cenocepacia, Bcen_4030; Crono-
bacter sakazakii, ESA_03935; Enterobacter cloacae, ECL_01542; Entero-
bacter hormaechei, F5RYK9_9ENTR; Erwinia amylovora, EAMY_3018;
Erwinia tasmaniensis, ETA_06210; Escherichia coli, ECEG_03250;
Pantoea sp., S7A_11480; Pseudomonas syringae, Psyr_4040; Salmonella
enterica serovar Newport, SNSL254_A0303; S. enterica serovar Typhi-
murium, STM0277; S. enterica serovar Typhi, STY0307; Serratia
odorifera, D4E4R6_SEROD. Asterisks indicate the Tae4–Tai4 homo-
logues for which structures have previously been reported (Zhang et al.,
2013) and the open square indicates that this candidate immunity protein
showed only weak similarity to Rap2a. Details of the Tae4 homologues
and associated immunity proteins are given in Supplementary Table S1.
are likely to share the same enzyme mechanism but fall into
two functional categories in terms of overall structure and
substrate processing. One displays narrow specificity and one
is more promiscuous. Some of the immunity proteins encoded
within the T6SS gene clusters, those cognate to Tae4/family 4
effectors, can be placed in two protein-fold families which
we suggest be termed (i) Tai4, as described previously and
including Rap2a, EcTai4 and STTai4, and (ii) Tai4a, including
Rap1a and described for the first time here. Although distinct
in terms of structure, the two families are built upon similar
underlying principles, namely stable dimeric small "-helical
bundles. These T6SS-associated immunity proteins and indeed
the effectors in S. marcescens appear to rely on the formation
of disulfide linkages for folding and activity.
Although the mode of effector inhibition is conserved in
the two families, namely a steric block of the active site within
a heterotetrameric complex, our study reveals that a very
different structure can be used to accomplish effector
neutralization. The inhibitory action of immunity proteins is
therefore highly specific for effector proteins, even though
some effectors have closely related enzyme activities. The type
VI-associated endopeptidase effectors are highly basic
proteins, as exemplified by Ssp1 and Ssp2, with predicted pI
values of 9.1 and 9.3, respectively. These enzymes act on
peptidoglycan and process a substrate in the vicinity of two
acidic carboxylates, the d-Glu residues. The immunity proteins
are acidic; the pI values for the four Rap proteins fall in
the range 5.1–6.3 after omitting the signal peptides. Such
complementarity of charge contributes to the high-affinity
interactions that support complex formation, despite distinc-
tive structures and variation in sequence, and may generate
long-range electrostatic attraction to assist correct binding.
The exact mechanism by which the effector proteins are
secreted using the T6SS is not yet known. One model suggests
a needle comprising a channel formed by haemolysin-
coregulated protein (Hcp) oligomers with an internal
diameter reported as about 40 A˚ (Mougous et al., 2006). How
this value was estimated is not detailed. We would suggest that
from measurements across the pore and taking van der Waals
radii into consideration, 40 A˚ might be a generous estimate of
the pore size. We analyzed the globular dimensions of the
family 4 endopeptidase effectors and the largest, by a small
margin, is Ssp1, with approximate dimensions of 35 # 40 #
50 A˚, taking into consideration the van der Waals radii. Such
effector proteins, when folded, are therefore comparable in
size with or smaller than the pore of the Hcp oligomer. Some
effectors may be translocated out of the cell in an intact folded
and functional state (Benz et al., 2012) and some may be only
partially folded when they are the substrate for the T6SS
(Chou et al., 2012). It is possible that Ssp1, Ssp2 and related
effectors may utilize disulfide bonds to ‘lock’ their final
structure once translocated away from the reducing environ-
ment of the cytoplasm, either in the extracellular environment
or within the periplasm of a target cell. In this sense, the T6SS
may have evolved to exploit redox status in the periplasm both
for arming effector warheads when engaged in attack or for
generating a protective armour when in defensive mode.
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Supplementary Table S1. Ssp/Tae4 family proteins and corresponding adjacently-encoded 
immunity proteins. 
O rganism Ssp/Tae4 protein Adjacent Immunity Protein 
 UNIPR O T 
identifier or name 
Genomic 
identifier 
UNIPR O T 
identifier or name 
Genomic 
identifier C losest Rap
 
Agrobacterium 
tumefaciens  C58 
Q7CUP8_AGRT5 Atu4347 A9CGG9_AGRT5 Atu4346 Rap1a 
(SMA2260) 
Burkholderia 
cenocepacia AU1054 
Q1BN86_BURCA Bcen_4030 Q1BN87_BURCA Bcen_4029 Rap1b 
(SMA2262) 
Cronobacter sakazakii 
ATCC BAA-894 
A7MQ14_CROS8 ESA_03935 A7MQ15_CROS81 ESA_03936 Rap1a 
(SMA2260) 
Enterobacter cloacae 
ATCC 13047 
D5C6F6_ENTCC ECL_01542 D5C6F7_ENTCC ECL_01543 Rap2b 
(SMA2266) 
Enterobacter 
hormaechei ATCC 
49162 
F5RYK9_9ENTR  F5RYK8_9ENTR  Rap2b 
(SMA2266) 
Erwinia amylovora 
CFBP1430 
D4I0Q7_ERWAC EAMY_3018 D4I0Q6_ERWAC EAMY_3017 Rap2a 
(SMA2265) 
Erwinia tasmaniensis 
Et1/99 
B2VH84_ERWT9 ETA_06210 B2VJE3_ERWT9 ETA_06220 Rap2a 
(SMA2265) 
Escherichia coli B354 D6J6Z7_ECOLX ECEG_03250 D6J6Z8_ECOLX ECEG_03251 Rap2a 
(SMA2265) 
Pantoea sp. Sc1 
 
H8DNR2_9ENTR S7A_11480 H8DNR1_9ENTR S7A_11475 Rap2b 
(SMA2266) 
Pseudomonas syringae 
pv. syringae B728a 
Q4ZP52_PSEU2 Psyr_4040 Q4ZP51_PSEU2 Psyr_4041 Rap1b 
(SMA2262) 
Salmonella Newport 
SL254 
B4SV53_SALNS SNSL254_A0303 B4SV54_SALN SNSL254_A0304 Rap2a 
(SMA2265) 
Salmonella Typhi CT18 Q8Z963_SALTI STY0307 Q8Z964_SALTI STY0306 Rap1a2 
(SMA2260) 
Salmonella 
Typhimurium LT2 
Q93IS4_SALTY STM0277 Q8ZRL5_SALTY STM0278 Rap2a 
(SMA2265) 
Serratia odorifera  
DSM 4582 
D4E4R6_SEROD  D4E4R5_SEROD  Rap1b 
(SMA2262) 
Acinetobacter 
baumannii SDF 
B0VVE3_ACIBS p2ABSDF0033 B0VVE4_ACIBS p2ABSDF0034 (Rap2a)3 
(SMA2265) 
Serratia marcescens 
Db10 
Ssp1 SMA2261 Rap1a SMA2260  
Serratia marcescens 
Db10 
Ssp2 SMA2264 Rap2a SMA2265  
1 Note that this is not the same protein as the one identified as a Tai4 protein in this organism by 
Russell et al., 2012; that protein, ESA_03932, is an orphan Tai4 protein of the Rap2b type not 
immediately adjacent to Tae4 
2 STY0306 (SciQ) is approximately twice the size of other Rap proteins, resembling a fusion of two 
adjacent Rap1a proteins 
3 p2ABSDF0034 is shows only very weak sequence similarity with Rap2a 
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Supplementary F igure S1. Immunity protein binding and secretion is not impaired in 
Ssp1 and Ssp2 C50A mutants. (A) Size exclusion chromatography analysis of complex 
formation between Ssp1 (C50A) and Rap1a, top, or Ssp2 (C50A) and Rap2a, bottom. 10 
nmol of the protein indicated, or of each protein in the case of the mixtures, was separated on 
a calibrated Superdex 75 10/300 GL column. (B) Immunoblot detection of Ssp2 in the 
secreted fraction of the strains indicated: wild type S. marcescens Db10 [WT]; mutant lacking 
Ssp2 [ ssp2]; ssp2 mutant carrying plasmids expressing wild type Ssp2 [+Ssp2(WT); 
pSC541] or the C50A mutant of Ssp2 [+Ssp2(C50A); pSC1230]; and a Type VI secretion 
system mutant [ T6SS] expressing wild type Ssp2. 
 
 
 
 
 3 
 
 
Supplementary F igure S2. Super imposition of Ssp1 (orange ribbon) and EcTae4 (green 
ribbon). The catalytic triads (histidine, cysteine and aspartate) are shown as sticks and 
divergent regions are shown in the boxes. 
 
Supplementary F igure S3. Super imposition of the catalytic residues of Ssp1, PaTse1 and 
EcTae4. The color code is N blue, O red, S yellow then C positions for Ssp1 orange, PaTse1 
grey and EcTae4 green. 
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Supplementary F igure S4. Sequence alignment of Ssp1 and selected homologues. A. 
Structure-based sequence alignment highlights the conserved secondary-structure content 
(orange cylinders and sheets) in this group of four endopeptidase effectors. Residues involved 
in disulfide bond formation are coloured yellow. The catalytic histidine and cysteine residues 
are marked in cyan. The alignment was generated using ClustalW and the figure was prepared 
using ALINE (Bond & Schüttelkopf, 2009). B. An alignment of S. marcescens Rap2a with 
Tai4 from E . cloacae and S. Typhimurium. Sequence numbering and secondary structure has 
been drawn based on the Rap2a crystal structure (without signal peptide - brown).  Strictly 
conserved residues in all four sequences are encased in black, conserved in two or three in 
shades of grey with the conserved cysteines involved in disulfide bond formation highlighted 
in yellow. 
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Supplementary F igure S5. Multiple sequence alignment of Ssp1 and Ssp2 with other 
Tae4 proteins. Alignment was generated using MUSCLE (Edgar, 2004) and visualised using 
Jalview (Waterhouse et al., 2009). Red arrows show the amino acid residues forming the 
catalytic triad. The Ssp1-like proteins associated with Rap1a-type immunity proteins are also 
indicated. The Tae4 homologues are labelled by organism and their identities are as follows 
(UNIPROT identifier, genomic identifier): Acinetobacter baumannii (B0VVE3_ACIBS, 
p2ABSDF0033), Agrobacterium tumefaciens (Q7CUP8_AGRT5, Atu4347), Burkholderia 
cenocepacia (Q1BN86_BURCA, Bcen_4030), Cronobacter sakazakii (A7MQ14_CROS8, 
ESA_03935), Enterobacter cloacae (D5C6F6_ENTCC, ECL_01542), Enterobacter 
hormaechei (F5RYK9_9ENTR), Erwinia amylovora (D4I0Q7_ERWAC, EAMY_3018), 
Erwinia tasmaniensis (B2VH84_ERWT9, ETA_06210), Escherichia coli (D6J6Z7_ECOLX, 
ECEG_03250), Pantoea sp. (H8DNR2_9ENTR, S7A_11480), Pseudomonas syringae 
(Q4ZP52_PSEU2, Psyr_4040), Salmonella enterica serovar Newport (B4SV53_SALNS, 
SNSL254_A0303), Salmonella enterica serovar Typhimurium (Q93IS4_SALTY, STM0277) 
Salmonella enterica serovar Typhi (Q8Z963_SALTI, STY0307), Serratia odorifera 
(D4E4R6_SEROD). See also Supplementary Table S1. 
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Supplementary F igure S6. Distinct placement of the immunity proteins inhibits different 
peptidoglycan endopeptidases. Four polypeptides are shown in ribbon style; Ssp1 is colored 
orange, EcTae4 is green, one subunit of EcTai4 is grey and one subunit of Rap1a is cyan. A 
least-squares overly of Ssp1 and Tae4 was carried out and this then highlights the different 
positions that the immunity proteins occupy when they bind and inhibit their cognate effector. 
	  
